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Heterocyclic compounds represent almost two-thirds of all the known organic 
compounds: they are widely distributed in nature and play a key role in a huge number of 
biologically important molecules including some of the most significant for human beings. 
The use of natural and synthetic heterocyclic compounds in many commercially important 
spheres is enormous. It is not surprising, therefore, that this class of compounds has 
received special attention by chemists of different origin to provide selective synthetic 
access to the huge variety of structural features typical of this class. Furthermore, in the 
21st century an imperative factor in the organic synthesis is the control of the absolute 
stereochemistry of all the relevant chiral centers. Experimental and theoretical 
investigations on the reaction mechanisms become thus important not only from an 
academic point of view, but also in optimizing reactions’ pathways: knowledge of detailed 
reaction mechanism in fact is usually the basis for development of new transformation and 
improvements of existing procedures, improvements that often mean enhancement of 
diastereomeric and enantiomeric excesses.  
Synthetic methodology employing azadienes represents a straightforward and 
efficient approach to the synthesis of nitrogen-containing heterocycles, which have a range 
of potential biological activities and are building blocks for many therapeutically useful 
materials1,2. The use of 3-trialkylsilyloxy-2-aza-1,3-dienes has been demonstrated 
particularly attractive in this context. In fact, these compounds are easily accessible by 
synthesis and show a wide range of chemical-physical properties and a varying reactivity 
depending on their substitution patterns. 
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Chapter 1                                                      
 
 
 
Azadienes in organic synthesis 
 
 
 
The azadienes, or iminodienes, are among the most used heterodienes in organic 
chemistry. These are interesting intermediates in the synthesis of heterocyclic compounds 
and specifically nitrogen compounds, because their typical reactivity foresees their 
participation in the electrocyclization reactions, particularly, Diels Alder reactions.1-3 The 
advance of the azadiene imino Diels-Alder reaction to the status of general synthetic 
method owes much to the development of methods to activate the azadiene system. In 
fact, a limitation to the application of azadienes relative to the more commonly used 
oxodienes is that azadienes generally require some form of activation to achieve general 
synthetic utility. Anyway, with appropriate substitution pattern, 1-aza-1,3-butadienes and 2-
aza-1,3-butadienes are reactive as either electron rich or electron deficient Diels-Alder 
dienes. Reviews featuring the general synthetic utility of azadienes and their utility in the 
Diels-Alder reaction specifically have appeared in recent years. 1,4-10 
 
 
1.1  1- and 2-Azabuta-1,3-dienes 
 
1-Azadienes, or enimine dienes, react with ketenes through [2+2] cycloadditions 
giving rise to the formation of 4-vinyl-β-lactams.11 They give also rise to five-membered 
rings through carbenes addition or 1,3 dipolar cycloaddition.12 1-Azadiene complexes of 
the early-transition metals have been reported and are precursors of metallacyclic 
alkylidene complexes.13 Anyway their main application is in the field of six-membered rings 
formation via Diels-Alder reaction (Chapter 3). Owing to their electron deficient character 
simple 1-azadienes are less reactive toward standard electron deficient dienophiles. They 
therefore tend to undergo inverse electron demand Diels-Alder reactions when they do 
react. These reactions usually do not reach high yields because of the unfavourable s-
 8 
trans/s-cis equilibrium and the electrophilicity of nitrogen atom: self-condensations, 
dimerizations, imine additions, tautomerization of the imine to enamine become 
competitive reactions.3,14 The introduction of electron-donor groups in the diene makes 
them electron-rich and allows their participation to normal electron demand Diels Alder 
reactions, by raising their HOMO energy. 
 
2-Azadienes are key intermediates in the preparation both of heterocyclic and open-
chain polyfunctionalised compounds. While generally more reactive, their electronic 
properties mirror the 1-azadienes’ ones: depending on the electronic features of their 
substituents, they can be electron deficient (electron-withdrawing substituents), electron 
rich (electron donating substituents) or electronically neutral. Their chemistry consists, 
most of all, of [4+2] cycloaddition reactions with alkenes, alkynes and heterodienophiles 
such as enamines, carbonylic compounds, nitrogen and nitroso compounds. The main 
difference between 1- and 2-aza-1,3-dienes is the efficacy of Lewis acid catalysis in the 2-
azadienes cycloadditions. The success of Lewis acid mediated catalysis depends on the 
identification of a Lewis acid which, by complexing an appropriate functional group, 
activates the dienophiles and does not irreversibly complex the azadiene nitrogen. 
Among the electron-rich azadienes, this study takes into account the preparation 
and reactivity of  3-trialkylsilyloxy-2-aza-1,3-dienes A (Fig. 1.1). 
 
N
H
R1
R2O
H
SiAlk3
A
Fig 1.1: 3-Trialkylsilyloxy-2-aza-1,3-dienes  
 
 
1.2  3-Trialkylsilyloxy-2-aza-1,3-dienes 
 
2-Aza-1,3-dienes bearing in position 3 a trialkylsilyloxy- group (A, Fig. 1.1) firstly 
appeared in literature in the 1980’s,15 authored by Prof. Léon Ghosez research group. 
Since then, their chemistry has been mainly developed by Prof. Ghosez and Prof. Bongini-
Prof. Panunzio’s research groups. 
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3-Trialkylsilyloxy-2-aza-1,3-dienes’ structure was designed in order to obtain 
azadienes reactive toward the hetero Diels-Alder reaction with electron-deficient 
dienophiles. The unsubstituted azadienes’ reactivity depends on conformational factors: 
the reactive conformation is the s-cis one, whereas often the most stable is the s-trans. 
The introduction of a substituent in the position 3 of an azadiene enhances the reactivity of 
the π system by increasing the population of the s-cis conformer. In the mean time, the 
electron donating nature of the trialkylsilyloxy- substituent raises up the HOMO energy 
and, in the HOMO, the C-4 coefficient, thus favouring the electron-deficient dienophile’s 
attack in this position.16 The hetero Diels-Alder reaction will be discussed in detail in the 
Chap. 3. 
 
- Structure analysis and properties 
 
A careful analysis of the structure of these azadienes (Fig. 1.2) shows that they are 
highly functionalised and thus potentially highly reactive: first, their dienic nature allows 
them to take part to a series of reactions (electrocyclic reactions) which occur, in principle, 
without any charge development. The C-1 atom is an iminic ones and therefore 
electrophilic; the C-3 atom is carboxylic, being so the precursor of an amidic or an acidic 
function. The C3-C4 framework is a silylenolether, thus conferring nucleophilic character to 
the C-4 atom. The C-1 and C-4 atoms can be variously functionalised both with satured or 
unsatured carbo- or hetero-groups, and with aromatic or non aromatic carbo- or hetero-
cycles. By changing the silicon substituents (Alk) it is possible to obtain azadienes with 
varying stability. The most utilised groups are the trimethylsilyloxy- and the tert-
butyldimethylsilyloxy groups, the latter conferring higher stability. 
 
N
H
R1
R2Alk3SiO
H
A
Fig 1.2: 3-Trialkylsilyloxy-2-aza-1,3-dienes' structure analysis
1
3
4
Carbon 4 nucleophilic
Carbon 1 electrophilic
Carbon 3 carboxilic
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NOMENCLATURE: Obviously, by varying the substituents on the diene, the carbon 
atoms’ priority will change and thus the carbon atoms’ enumeration. However, for the sake 
of the semplicity, along this thesis, the carbon skeleton enumeration reported in Fig. 1.2 
will be adopted, regardless the substituents’ nature. 
 
In Fig. 1.3 the azadienes more frequently utilized by the Prof. Ghosez’s group are 
reported. These azadienes are colourless oils. They are purified by distillation and they are 
sufficiently stable to be stored for several months at –20°C. With respect to their 
substitution pattern, the substituents at C-1 and C-4 can be alkylic bearing or not one or 
two oxygenated substituent at C-1. This characteristic increases their reactivity as 
enophiles. 
 
N R1R3Me2SiO
R2
N R1TBDMSO
R2
OR3
N OR1TBDMSO
R2
OR
N
TBDMSO
OTBDMS
R1= Ph, -C(Me3)=CHPh, CH=CH2, CH2Ph(OMe)m,p
R2= H, Me,Ph
R3= Me, t-Bu
R1= H, Me
R2= H, Me, Cl, F, Ph, CH2Ph, Bu
R3= t-BuMe3Si, i-Pr, Et
R= i-Pr, Et
R1, R2= H, Me
Fig. 1.3: Ghosez's azadienes  
 
In previous works, the azadienes reported in Fig. 1.4 have been synthesised by 
Prof. Panunzio’s group: they belong to different series which mainly differ in the C-4 
substituent: hydrogen (no substituent), amidic groups, chlorine, bromine, iodine, thioaryl 
and benzyloxy groups have been placed in this position, whereas at carbon C-1 several 
aliphatic and aromatic substituents, more or less substituted, are present. 
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N RTMSO
H H
R= Ph,
OTIPS
N RTMSO
N H
R= Me, t-Bu, Ph, -CH=CHPh,
OTIPS OTIPS
Ph
OTIPS
, ,
O
O
N RTMSO
N H
O
Ph
O
R= Ph,
R2
OR1
R1= TIPS, TES, TBDMS
R2= Me, i-Pr, Ph
N RTMSO
X H
X= Br, Cl, I, ArS, BzO
R= Ph, p-Cl-Ph, p-NO2-Ph, p-MeO-Ph,
OTIPS
OTIPS
Ph
OTIPS
,
,
OTBDMS
,
OTBDMS
,
OTIPS
, Ph
OTBDMS
Fig. 1.4: Panunzio's azadienes  
 
Their synthesis and their reactivity will be discussed in the next chapters. They 
contain several functional groups and are sufficiently stable to be analysed and sometimes 
stored at –20°C for some days. They are colourless or pale yellow oils and are used after 
their synthesis as such without any further purification. The only exception is the azadiene 
B reported in Fig. 1.5, which is sufficiently stable to be purified by flash chromatography in 
silica gel (cyclohexan/ethyl acetate 80/20), thanks to the tert-butyldimethylsilyl- group.17 
NTBDMSO
N H
O
O
OTIPS
H
B  
Yield= 85%; [α]D20= -26 (c=1.0, CHCl3); IR (CHCl3): 1735 cm-1; 
1H NMR (200 MHz, CDCl3): 7.96 (d, 1H, J=6.4Hz), 7.82 (m, 2H), 7.68 (m, 2H), 5.47 (s, 
1H), 4.48 (m, 1H), 1.32 (d, 3H, J=6.5 Hz), 1.02 (m, 21H), 0.75 (s, 9H), 0.02 (s, 
6H) ppm; 
13C NMR (50 MHz, CDCl3): 168.1, 166.6, 155.7, 133.9, 132.3, 123.2, 90.5, 70.4, 25.5, 
21.7, 17.9, 17.6, 12.2, -4.1, -4.2 ppm. 
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Fig.1.5:(5S)-2-(tert-Butyldimethylsilyloxy)-1-phtalimido-5-(triisopropilsilyloxy)-3-aza-esa-1,3-diene and its 
spectral properties.              
 
 
- Stereochemistry 
 
The comprension of the stereochemistry of this compounds is essential in order to 
elucidate the mechanisms of their formation reaction and their further reactivity. The two 
double bonds configurations are responsible for the dienes themselves configuration, 
whereas the dihedral angle between the two double bonds’ planes determine the 
azadienes’ conformation. Configuration and conformation have been deduced from 1H, 
13C, 15N NMR spectra (Fig. 1.6, 1.7), from theoretical study of stability for a representative 
diene (Fig. 1.8) and, a posteriori, from the careful analysis of the products arising from 
azadienes themselves. 
The double bond C=N’s configuration has been assigned18 from the geminal 
coupling constant 2JNH value in the 15N NMR spectrum: it is small and positive, thus 
demonstrating that the lone pair on the nitrogen is trans with respect to the iminic 
hydrogen and so that the C=N double bond is E. 
The vicinal coupling constant 3J(N-H) through the enaminic π bond has been used as a 
parameter to determine the double bond C=C’s configuration: its value is small and 
positive, thus showing the cis relation between the nitrogen and the enaminic hydrogen 
and so the (Z) configuration of the double bond C=C. Concerning the conformation, the 
existence of long range coupling constants 4J(C-H4) e 5J(C-H5) in the 13C NMR spectrum 
demonstrates the presence of the s-trans conformation (Fig. 1.6). 
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N
R3
R1(R
2)3SiO
H
H
N
R3
R1(R
2)3SiO
H
H
N
C
H
R1(R
2)3SiO
H
H
H
N
R3
R1(R
2)3SiO
H
H
2JNH=+2 to +5 Hz 3JNH< 3Hz
4JCH
5JCH
(E)
(Z)
s-trans s-trans
CONFIGURATION
Figure1.6: 13C, 15N-NMR results upon 3-trialkylsilyloxy-2-aza-1,3-dienes
CONFORMATION
 
 
Despite this, as it was already noted, the presence of a substituent in the position 3 
of the azadiene increases the population of the s-cis conformer. In fact, 1H NMR NOE 
experiments have been reported, which demonstrate the proximity of C1-H and C4-H (HB 
and HA respectively) (Fig. 1.7).17,19 
 
Figure 1.7: NOE Experiment representative example
HA HB      7.0%
HB HA      1.4%
HB HC      2.1%
Me HB      1.6 %
Me HC      4.0%
NOE 
effects
irradiations
NTMSO
N HA
O
O
OTIPS
HB
HC
NTMSO
N HA
O
O
OTIPS
HB
HCPh
HA HB       3.1%
HB HA       3%
HB HC       2.0%
NOE 
effects
irradiations
NTMSO
PhS HA
OTIPS
HB
HC
HA HB      1.13%
HB HA      1.78%
HB HC      2.32%
HC HB      2.50 %
NOE 
effects
irradiations
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Furthermore, ab initio quantomechanical calculations upon the simple azadiene 
reported in Figure 1.8 show the existence of a long range interaction of the silicon with the 
nitrogen atom (0.084 e-) responsible for the stabilization of a twisted (46°) s-cis 
conformation. This form is the absolute minimum of all possible conformers7, thus 
explaining the reactivity of these dienes in Diels-Alder reactions. 
 
twist (46°) s-cis
N
O
SiH3
H
H H
H
0.084 e
-
46°
Figure 1.8: MP2/6-31G* calculations' results  
 
In conclusion, the configuration of 3-trimethylsililoxy-2-aza-1,3-dienes is, without 
doubt, EZ. The most stable conformations are the s-cis and the s-trans ones. By the use of 
different approaches both of them have been identified in the NMR spectra. Anyway the 
conformation reactive toward electrocyclizations  is the s-cis one. 
 
 
1.3   3-Trialkylsilyloxy-2-aza-1,3-dienes synthesis 
 
All the several synthetic methods to 3-trialkylsilyloxy-2-aza-1,3-dienes can be 
represented as in the retrosynthetic sketch of Fig. 1.9: convergent synthesis which 
combines a carboxylic acid synthon and an iminic synthon. 
N
R3
R1
(R2)3SiO
R3
O
X
R1
H
NH+ + (R
2)3SiX
Figure 1.9: Retrosynthetic approach to 3-trialkylsilyloxy-2-aza-1,3-dienes  
 
Four different synthetic strategies have been used18 which differ in the iminic 
synthon: synthesis from iminoethers, from imides, from imines and from aldehydes. Except 
for the second one, the acidic synthon is always represented by an acyl chloride. 
A brief overview about the literature-reported syntheses of 3-trialkylsilyloxy-1,3-
azadienes is presented. 
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- Synthesis from iminoethers  
 
1,3-Diactivated 2-aza-1,3-dienes C can be prepared via the acylation of an 
iminoether hydrochloride, followed by silylation of the resulting acyl-imidate (Scheme 1.1). 
The imino-ethers can be obtained by the Pinner procedure20 or by reaction of an amide 
with an alcohol in the presence of benzylic chloride.21This synthesis presents some 
limitation about the substituents R1 and R2, because of the tendency of the iminoethers 
toward trimerization. 
OR1
t-BuMe2SiO
R3
NR2
R4R1O
R2
NH.HCl
R2
R1O
N
C
O
CHR3R4
R1= i-C3H7, C2H5, CH3; 
R2= H, CH3, Ph; 
R3= H, CH3, n-C4H9, Ph, C6H4CH2, C(CH3)3, CH=CH2, F, Cl, CO2Me
R4= H, CH3
Scheme 1.1: Synthesis from iminoethers
i ii
imino-ether acyl-imidate
i): R3R4CHCOCl 3; ii): t-BuMe2SiOTf, TEA, Et2O.
C
 
 
Sometimes it can be helpful to invert the reaction sequence, by silylating the 
iminoether before and then acylating the resulting N-silyl-imino-ether (Scheme 1.2).18 
i-PrO
H
NH.HCl
i-PrO
H
N SiMe2t-Bu
t-BuMe2SiO
R
N
Oi-Pr
Scheme 1.2: Synthesis from iminoethers
i): t-BuMe2SiOTf, TEA (22eq), CH2Cl2,  -40°C; ii): RCH2COCl, TEA, Et2O, r.t
i ii
R= H, Me, n-Bu, Ph, PhCH2, t-Bu, CH=CH2, F, Cl, CO2Me.
imino-ether
C
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- Synthesis from imides  
 
The cyclic dienes D represented in the Scheme 1.3 has been obtained by silylation 
of both the glutaryl imide’s oxygens with trialkylsilyl-triflates in the presence of 
triethylamine (Scheme 1.3).22 
HN
O
O
N
RMe2SiO
OSiMe2R
RMe2SiOTf, Et3N
Et2O, rt
Scheme 1.3: Synthesis from imides
imide D
R= Me, Y=48%
R=t-Bu, Y=91%
 
 
 
- Synthesis from N-silyl-imines 
 
N-Silylimines, prepared and, if possible, purified  following the literature procedure, 
have been acylated with acyl chloride in the presence of an excess of triethylamine, 
obtaining azadienes. This method is quite general, but can not be applied to the synthesis 
of azadienes bearing a strong electron withdrawing group at C-1 (Scheme 1.4).18 
 
R1
H
N
SiMe2R
2
R1 N
R3
OSiMe2R
2
1.1-10 eq Et3N
R3CH2COCl, 25°C, 2h
Scheme 1.4: Synthesis from N-silyl-imines
N-Silylimine E
 
 
 
- Synthesis from aldehydes 
 
The same authors have tempted to carry out the azadienes’ synthesis avoiding the 
silylimines’ isolation and thus to obtain azadienes from aldehydes in just one step. N-
Trimethylsilylimines have been obtained by treating the aldehydes with LiHMDS and 
acylated with acyl chloride in the presence of triethylamine. This method gives the same 
results than the previous and is more practical when applied to non-enolisable aldehydes. 
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R1
H
O
R1 N
R3
OSiMe2R
2
LiHMDS, 0°C, 1h
Et3N, R
3CH2COCl, (0-25)°C, 2h
Scheme 1.5: Synthesis from aldehydes
E
Aldehyde
 
 
 
 
1.4   3-Trialkylsilyloxy-2-aza-1,3-dienes synthesis: our protocol 
 
In our research group 3-trialkylsilyloxy-2-aza-1,3-dienes A have been synthesized 
starting from aldehydes 1 through the corresponding N-trialkylsilylimines 2 and 
acylchloride 3, as represented in the Scheme 1.6. 
 
O
R2
hexane, 0°C, 1h N
SiAlk3
R2
Me3Si
N
+ Me3SiOLi
 TMSCl 
1h, r.t.
+ LiCl + Me3SiOSiMe3
Scheme 1.6: Synthesis of azadienes A
1 2
R1= Ph, Me, t-Bu, PhCH=CH-, p-Cl-Ph, p-NO2-Ph, p-MeO-Ph,
OTIPS OTIPS
Ph
OTIPS
, ,
OTBDMS
,
OTBDMS
,
OTBDMS
,
Ph
OTBDMS
R1CH2COCl (3), TEA 
2h r.t.
R2= N
O
O
O
N
O
Ph
, , Br, Cl, ArS, PhCOO-,  H. N
H
R1
R2O
H
SiAlk3
A
SiAlk3
Li
N
SiAlk3
R2
2
Alk3= Me3, t-BuMe2
H H H
 
 
The reaction has been carried out on a wide variety of reagents, the conditions 
depending on the substituents, on the aldehydes 1 and on the acylchlorides 3. The general 
reaction procedure for the preparation of the most used azadiens is herein reported: 
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Aldehyde 1 (1 mmol) was added to a solution of LiHMDS 1M in THF (1.1 mmol) and 
hexane (5 mL) at 0°C under inert atmosphere. The reaction mixture was stirred at 0°C for 
1 h. Trimethylchlorosilane (1 mmol) was added in one portion and after stirring 10 min at 
0°C the mixture was allowed to stir for 1 h at room temperature. A white precipitate 
formed. The mixture was cooled at 0°C, triethylamine (2 mmol) was added in one portion 
and after 5 min a solution of acylchloride 3 (1 mmol) in 5 mL of hexane was added. Stirring 
was mantained for 2 h and a conspicuous precipitate formed. The mixture was filtered 
through Celite® under inert atmosphere and the solvent was removed in vacuo to afford 
the azadiene A as an oil, which could be analyzed by 1H NMR spectroscopy. 
 
Some general consideration can be taken into account: 
1) The starting aldehydes 1 are aliphatic, aromatic and heteroaromatic. Enolizable and 
non-enolizable type may be used as well. The corresponding N-trialkylsilylimines 2 
are obtained adding a lithium N-bis-trialkylsilylamide solution to the aldehydes 1, 
upon inert atmosphere, at 0°C.23 As solvent hexane, heptane or tetrahydrofuran 
have been used. In the reaction with lithium hexamethyldisilyl amide, N-
trimethylsilylimines are obtained. The use of lithium trimethyl-triisopropyl-
disilylamide24 or tert-butylpentamethyl-disilylamide gave rise to the formation of N- 
(triisopropylsilyl) imines and N-(tert-butyldimethylsilyl) imines, with elimination, 
regardless to the other trialkylsilylgroups linked to the nitrogen atom, of lithium 
trimethylsilanoate.25,26 The reaction is quantitative and can be controlled by IR 
spectroscopy: the stretching of the C=NSiR3 bond relies between 1650 and 1680 
cm-1. Moreover the formed trialkylsilylimines have (E)-geometry, as deducted from 
1H NMR through NOE measurements. 
2) The lithium trimethylsilanoate, by-product of the reaction, is eliminated by adding 
trimethylsilylchloride to the reaction mixture, with precipitation of lithium chloride and 
formation of hexamethyl-disiloxane. The two by-products are subsequently 
eliminated by filtration and distillation respectively. The elimination of the lithium 
trimethylsilanoate from the reaction mixture has been demonstrated necessary to 
avoid its addition to the azadiene A, with the formation of the amidic product 4 
(Scheme 1.7). 
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Me3SiOLi
Scheme 1.7: Trimethylsilanoate addition to azadiene 1
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3) Despite the fact that this reaction can be described as a base-mediated acylation of 
the N-silylimine,27 it is thought that the ketene 5 (Scheme 1.8) is formed in situ in 
the reaction pot, adding triethylamine and acylchoride 3. In fact, its formation in the 
reaction mixture has been demonstrated by a low temperature FTIR study of the 
reaction of acylchloride with imines in presence of a base.28 The acylchloride 3 may 
be substituted in the α position by hydrogen,29 alkyl, halogen,30 amidic7,17,31 or 
ethereal32 groups. Thus, the reaction proceeds through a nucleophilic attack of the 
imine’s nitrogen lone pair to the ketene (Scheme 1.8) with concomitant migration of 
the trialkylsilyl group from nitrogen to oxygen. This process is known as 
“silyltropism”; its significance in determining the reaction pathway will be discussed 
in the next paragraphs (Chapter 5). 
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Scheme 1.8: Imine's nucleophilic attack upon ketene
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4) The 3-trialkylsilyloxy-2-aza-1,3-dienes A with various substitution patterns are 
obtained in variable yields. Their stability largely depends on their substitution 
pattern. The substituents R2 present in the aldehydes 1 (Scheme 1.6) seem not to 
have effects, whereas the ketenic substituents R1 have a greater influence: it is 
possible to isolate and characterize by spectroscopy the azadienes deriving from 
ketenes carrying in the α-position two hydrogens, an amido groups, a halogen 
(chlorine or bromine) or a thioaryl group. The stability is mostly conferred by the 
nature of the silylimines 2 utilised. The most stable 3-trialkylsilyoxy-2-aza-1,3-
dienes are the triisopropyl- and the tert-butyl-dimethyl-silyloxy ones because the 
triisopropyl- and tert-butyl-dimethylsilyl groups are not easily hydrolizable. It has 
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been even possible to purify by flash chromatography on a short silica gel-column 
the azadienes B carrying an amidic substituent in position 4 and a tert-butyl-
dimethylsilyl group on the oxygen (Fig. 1.5).7,33,34 The configuration of the isolated 
and purified azadienes has been determined by a serie of NOE experiments. In the 
Figure 1.7, the results obtained for some azadienes have been reported as 
example. Observing the increment values obtained, it can be deducted that the 
configuration of these azadienes is s-cis-EZ.7,17 
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Chapter 2                                                      
 
 
 
Azadienes in elettrociclic [4+2] reaction 
 
 
 
 
The Diels-Alder (DA) reaction is a powerful tool for organic synthesis, since ring 
structures are a common feature in many target molecules and dienes are required motifs 
within precursor molecules. The DA reaction can simplify certain synthetic problems and 
help shortcut synthetic pathways, allowing sometimes complicated ring structures to be 
built in a single step. 
Although for many years the reaction has been limited to the all-carbon DA reaction, 
in the last twenty years, hetero DA (HDA) reactions involving heterodienes and/or 
heterodienophiles have become pivotal steps in the preparative synthesis of a huge range 
of products. 
 
 
2.1 Diels-Alder reactions 
 
Under suitable conditions, conjugated dienes undergo a cycloaddition reaction with 
multiple bonds to form unsaturated six-membered rings (Fig. 2.1). In conventional 
terminology, this is a 1,4-addition of a diene and a dienophile. It occurs thermally and it is 
called [4+2]-cycloaddition reaction because four π electrons from the diene and two π 
electrons from the dienophiles are directly involved in bonding change. This reaction has a 
great synthetic importance and Otto Diels and Kurt Alder received the 1950 Nobel Prize in 
Chemistry "for their discovery and development of the diene synthesis". 
The simplest DA reaction is the reaction of a 1,3-butadiene and ethylene to yield 
cyclohexene. 
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Figure 2.1: The Diels-Alder reaction of ethylene and butadiene  
 
There is not a single mechanism for all DA reactions.35 At first approximation, we 
can divide them into two classes: 
1) Synchronous and symmetrical (concerted) mechanisms when the two new bonds 
formed simultaneously. In the transition state, the two forming bonds have the same 
lengths. The combination of ethylene and butadiene is one example. 
2) Multistage (non-concerted) and asynchronous mechanisms. The transition state is a 
di-radical, one bond being formed, the other not. 
 
 
Figure 2.2: Possible mechanisms for DA reactions.  
 
Concerted mechanism leads to a stereospecific and completely syn (suprafacial) 
addition with respect to both the alkene and the diene. Non-concerted asynchronous 
processes pass through open chain intermediate in which there can be a rotation at the 
unbound termini, leading to loss of stereospecificity. Real mechanisms are a mixture of 
these two extremes, one bond being more properly formed and thus shorter than the 
other. 
When both the diene and the dienophile are suitably substituted, a stereochemical 
feature arises because the reactants may approach each other in two distinct orientations 
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(Figure 2.3). The substituent on the dienophile may be directed toward the diene (endo 
approach) or away from the diene (exo approach). 
R
R
X
R
R
H
H
X
endo addition
R
R
X
R
R
H
H
X
exo addition
Figure 2.3: Endo/exo approaches of the dienophile to the diene  
 
In most DA reactions, when the product distribution is under kinetic control, the 
endo adduct is preferentially, sometimes exclusively, formed. Several hypotheses have 
been made to explain this selectivity.36-38  
According to the FMO (Frontier Molecular Orbital) theory39 the DA reaction is 
controlled by the energy gap between HOMO (Highest Occupied Molecular Orbital) and 
LUMO (Lower Unoccupied Molecular Orbital). For the most common case, which involves 
dienophiles with electron-withdrawing substituents, the frontier orbital are Ψ2 of the diene 
(which is the HOMO) and π* of the dienophiles (which is the LUMO). These reactions are 
called normal electron demand DA reactions: they are particularly efficient and rapid when 
the dienophiles contains one or more electron-attracting groups and still more if the diene 
also contains electron-releasing groups. There are also examples where the substituents 
are reversed so that the dienophile is electron-rich and the diene is electron-deficient, 
these are called inverse electron demand DA reactions and involve HOMO(dienophile) 
and LUMO(diene) (Figure 2.4). 
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Fig 2.4: Normal/Inverse electron demand DA reactions  
 
The regiochemistry of the reaction is sentive to the nature of the substituents and 
can be predicted on the basis of the generalization that the strongest interactions will be 
between the centres on the frontier orbitals having the largest orbital coefficients. 
By swapping carbon atoms on the diene and/or the dienophile component with 
heteroatoms, the so-called hetero-Diels-Alder (HDA) takes place. It is a very useful 
method for constructing heterocyclic rings and is widely used as a key step in the 
synthesis of natural products.3,40-47 Compared to the numerous theoretical calculations on 
the normal DA reactions, only very few theoretical studies of HDA reactions have been 
performed.48,49 It has been pointed out that the reaction can change from a concerted non-
syncronous mechanism to a stepwise mechanism depending on the substituents on the 
reacting species and on the reaction conditions. 
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2.2 3-Trimethylsilyloxy-2-aza-1,3-dienes in HDA 
 
Conjugated systems containing nitrogen, typified by the 1- and 2-azabutadienes 
systems, show diminished reactivity toward representative electron-deficient dienophiles, 
meaning that the introduction of a nitrogen atom into conjugated systems will confer 
electrophilic character to the system.1,2 Actually this recognition led to the investigation, 
demonstration, and, subsequent development of the inverse electron demand (LUMOdiene 
controlled) DA reactions. Obviously the introduction of complementary electron-
withdrawing groups accentuates the electron-deficient nature of the azadiene, thus 
permitting the use of electron-rich, strained, or even simple olefins as dienophiles. 
Alternatively, the complemetary addition of strong electron-donating substituents to the 
azadienic system increases nucleophilic character of the azadiene system and permits the 
use of conventional electron-deficient dienophiles in DA reactions. In such instances, the 
introduction of the electron-donor group raises the HOMOazadiene energy, thus diminishing 
the magnitude of the HOMOazadiene -LUMOdienophile energy separation: these energetic 
variations result in the participation of the diene in normal (HOMOdiene controlled) DA 
reactions (Fig. 2.5). 
N
N
TMSO
E
DIENES
LUMO
HOMO
Fig. 2.5: Energetic effect of the substituents  on the diene  
 
3-trialkylsilyloxy-1,3-azadienes A, subject of this thesis, are electron-rich dienes, 
due to the strong electron-donating properties of trialkysilyloxy-subtituent. Therefore, they 
partecipate to normal electron demand HDA reactions with electron-deficient dienophiles. 
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The presence of the trialkylsilyloxy group at C-3 also decreases the energy barrier 
between the cisoid and transoid conformation of the diene, thus favouring the 
cycloaddition over reactions on the nitrogen atom.50,51  
3-Trialkylsilyloxy-2-aza-1,3-dienes A have been used in HDA reactions with a 
variety of dienophiles furnishing pyridones, isoquinolones, tetrahydropyridones, 
piperidones, pyrimidones, tetrahydrooxazinones with various substitution patterns.23 This 
chemistry has been mainly developed by Prof. Ghosez' and Prof. Bongini- Prof. 
Panunzio's groups. 
 
 
2.3 Dienophiles in HDA 
  
 
- Carbonyl compounds 
 
Cycloaddition reactions of a 1,3-diene with a carbonyl compound provides a 5,6-
dihydro-2H-pyran derivative (Scheme 2.1). 
 
R R'
O O
R
R'
1
2
3
4
5
6
Scheme 2.1: Carbonylic compounds as dienophiles in HDA
+
 
 
The transition state of the HDA reaction is generally found to be unsymmetrical. For 
the reaction of formaldehyde with 1,3-butadiene, Houk et al. have calculated the C-C and 
the C-O bond lenghts to be different in the transition state 
represented in Fig. 2.6.48 Unsymmetrical exo or endo 
transition states have been calculated also investigating 
the reaction of BH3-coordinated formaldehyde with 1,3-
butadiene. This coordination confers polar character to the 
transition state and lowers the activation energy of the 
reaction considerably. In fact, generally reactions of this 
type involving aliphatic or aromatic aldehydes or ketones 
proceed poorly unless highly reactive diene and/or catalysts are used: simple aldehydes 
Figure 2.6: The transition
state (ab initio calculations) 
of the HDA reaction of
formaldehyde with 1,3-
butadiene.
2.133 Å
1.998 Å
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react readily with many electron-rich oxygenated dienes under Lewis acid catalysis (Fig. 
2.7). 
N
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Fig. 2.7: Energetic effect of the substituents  on the diene and dienophile  
 
A pioneering work in this field has been done by Prof. Danishefsky group: the 1-
methoxy-3-trimethylsilyloxy-1,3-butadiene, which is known as Danishefsky diene, reacts 
with a wide range of unactivated aldehydes under Lewis acid (zinc chloride, boron 
trifluoride etherate, Eu(fod)3) catalysis to directly afford 2,3-dihydro-δ-pyrone (Scheme 
2.2). 
R H
O
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H
R
O
H
R
Me3SiO
OCH3
O
Danishefsky diene
Lewis
 acid+
Scheme 2.2: HDA reaction between Danishefsky diene and carbonylic compounds
H3CO
OSiMe3
 
 
The mechanism, the stereochemistry and the applicability of the reaction have been full 
described. Two mechanicistic pathways have generally been taken into account for these 
LA mediated HDA reactions: 1) the traditional DA pathway or 2) the formation of the HDA 
adduct by Mukaiyama-aldol reaction pathway. Depending on the catalyst and/or the 
solvent used and on the reaction substrates, pericyclic and/or Mukaiyama aldol-like 
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pathways may be invoked.52 Similar remarks will be drawn for reaction of 3-
trimethylsilyloxy-2-aza-1,3-dienes A and carbonilic compounds (Fig. 3.1, Fig. 3.2). 
 
 
- Electron deficient olefins 
 
Several examples of Diels Alder reactions between electron-rich 2-azadienes and 
olefinic dienophiles have been reported in literature. 
Cycloaddition of 3-trialkylsilyloxy-2-azadienes F with cyclic electron-deficient olefins 6 
took place with endo-selectivity (product 7), whereas acyclic dienophiles 8 gave an 
unexpected high kinetic exo-selectivity (product 9), (Scheme 2.3). This stereochemical 
dichotomy has been assigned to different reacting conformations by authors.51  
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Scheme 2.3: Electron deficient olefins as dienophiles
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Highly selective asymmetric cycloadditions to the azadiene D have been observed with 
unsatured amides derived from C2 symmetric pyrrolidines 10a, whereas less satisfactory 
results have been achieved by using Evans’, and Oppolzer’s dienophiles, 10b and 10c 
respectively (Scheme 2.4).51  
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Otherwise an asymmetric version of the HDA reaction upon 3-trialkylsilyloxy-2-azadienes 
G has been obtained by using as chiral catalyst the Evans’ mild Lewis acid 14 derived 
from copper (II) triflate and a C2-symmetric bis (oxazoline) ligand. This catalyst is tolerated 
by the azadiene G by binding selectively the bidentate imide group of the dienophile 15 
(Scheme 2.5)50 and works well between –45°C and room temperature. 
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Scheme 2.5: Enantioselective HDA reaction
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The enhanced exo-selectivity has been imputed to the large size of the copper complex 
bound to the imide dienophile. 
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2-Azadienes H cycloadd also to quinones 16a,b giving the corresponding 
aromatised cycloadducts 17, 18 (Scheme 2.6).50 It is possible to carry out the reaction with 
a one-pot multicomponent procedure, which combines the N-t-butyldimethylsilyl 
iminoether, an acetyl chloride derivatives (precursors of the 2-azadiene H) and a 
dienophile in the presence of triethylamine without isolation of any intermediate. In general 
the one-pot procedure gave higher yields than the  two-step process involving the 
synthesis and isolation of 2-azadienes. 
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Polisubstituted 2-azaantraquinon-3-ones 20 a, b of biological interest have been 
regiospe-cifically and in high yields obtained by cycloaddition of the 2-azadiene I to 
bromonaphtoquinones 19 a, b (Scheme 2.7).53,54 The presence of the bromine improves 
regiocontrol and yields of the reaction respect to unbrominated quinones. The acidic 
hydrolysis of the 3-silyloxy group is not necessary, because of the in situ formation of HBr. 
 
 
- Acetylenes as dienophiles 
 
Azadienes cycloadd also to electron-deficient acetylenic dienophiles 21 yielding 
pyridones 22 (Scheme 2.8). Also in this case it is possible to carry out the reaction in a 
one-pot multicomponent way, obtaining higher yields than the two-step process. 
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Scheme 2.8: Acetylenic compounds as dienophiles
C
R3= H, Me, CO2Me; 
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- Nitroso compounds as dienophiles. Aminoacids synthesis 
 
The addition of nitroso compounds, 23a-c, to 2-azadienes E is the route for obtaining 
α-aminoacids, 25a-c.55 In detail arylnitroso compounds 23a react with azadiene E to give 
the adducts [1,2,5]oxadiazinan-4-one 24a that are potential precursors of α-N-arylamino 
acids 25a; α-cyanonitroso and acylnitroso compounds, 23b and 23c, lead to 
[1,2,5]oxadiazinan-4-ones 24b and 24c that are converted into α-amino acid derivatives 
25b and 25c (Scheme 2.9). 
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Scheme 2.9: Nitroso compounds as dienophiles
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- Activated nitriles as dienophiles 
 
2-Azadienes C cycloadd also to activated nitriles 26 yielding polisubstituted 
pyrimidones 27 (Scheme 2.10).50 In this case too, the one-pot multicomponent reaction 
gives better results respect to the two-step procedure. 
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Scheme 2.10: Nitriles as dienophiles
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- Particular  dienophiles 
 
The HDA reaction of the electron rich 1,3-bis(silyloxy)-2-aza-1,3-diene L with low 
LUMO-lying C60 28 proceeds smoothly at room temperature to give 2-piperidone-fused 
C60 29 after hydrolysis (Scheme 2.11).56  
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Barluenga in a recent paper regarding the cycloaddition reactions of Fisher carbene 
complexes to 2-aza-1,3-butadienes has reported some HDA reaction examples.57 The 
[(trimethylsilyl) ethylnyl] carbene 30a gives rise to metal-containing and metal-free [4+2] 
cycloadducts, 31 and 32 respectively, whereas the (phenylethynyl) carbene 30b furnishes 
azafluorenones 33 by a tandem [4+2] cycloaddition/pentaannulation process (Scheme 
2.12). 
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Chapter 3                                                      
 
 
 
3-Trimethylsilyloxy-2-Azadienes in elettrociclic 
[4+2] reaction. Part two. Our experience. 
 
 
 
Earlier studies7,8,17,29-31 from this laboratory have shown that a wide variety of 3-
trimethylsilyloxy-2–aza-1,3-butadienes could be prepared in an easy way starting from 
silylimines and ketene. The different reactivity of these compounds is due to the 
functionalities present on the skeleton of the azadiene.  
For these reasons, 3-trialkylsilyloxy-2–aza-1,3-butadienes A may be considered 
precursors of a wide range of nitrogen containing biologically activity compounds. Herein is 
reported a summarizing scheme of the compounds whose synthesis have been elaborated 
from our research group. 
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Scheme 3.1: Reactivity of 3-trialkylsilyloxy-2-azadienes in our reaserch group
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- β-Lactams: elettrociclic [2+2] reaction 
 
Our reaserch reported the synthesis of several β-lactams obtained starting from 2-
azadiene through a formal two-step Staudinger reaction. The 3-trimethylsilyloxy-2–aza-
1,3-butadienes may be considered a neutral equivalent to the classical zwitterionic 
intermediate invoked in the Staudinger reaction ([2+2] cycloaddition of an imine and a 
ketene). Both neutral and zwitterionic intermediates undergo conrotatory electrocyclization. 
Recently, in a series of papers, we have proved that the ring closure could be activated in 
several ways: traditional heating (reflux in toluene for several hours), microwave irradiation  
or catalyzing with Lewis acid (BF3). 
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- γ-Lactams: C-iminic addition 
 
Stereoselective Lewis acid catalyzed addition of a cyano group to the azadiene, 
followed by intramolecular ring closure, in a four-step one-pot synthesis, results in the 
formation of γ-lactams in satisfactory yields.58 The 1,5-dihydropyrrol-2-ones so obtained 
are key compounds for the preparation of tetramic acid analogues. 
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- δ-Lactams: elettrociclic [4+2] reaction 
 
The dienic nature of azadienes makes those intermediates interesting starting 
materials for elettrocyclic [4+2] reactions. The application of hetero Diels-Alder (HDA) 
strategy to heterocycles and natural products synthesis has been well known for long 
time.3 An important part of this strategy takes into account the use of imino Diels-Alder 
reaction which provide a rapid stream to the construction of functionalized six-membered 
nitrogen-containing heterocyclic structures2, with regio-, diastereo- and enantioselectivity 
control.59  
The HDA adducts thus obtained, in turn,  have been used as such for the synthesis of 
more complex cyclic structure, or have been easily converted into new heterocycles or into 
open-chain compounds. 
 Recent years have witnessed the usefulness of azadiene of type A in the preparation 
of important intermediates in organic synthesis.1,7,9,60 
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Our reaserch group have been reported the application of our methodology in the 
synthesis of perhydrooxazin-2-ones, using 3-trimethylsilyloxy-2–aza-1,3-butadienes A and 
a wide range of aliphatic, aromatic and heteroaromatic carbonyl compounds as 
dienophiles, with particular emphasis on the diastereoselectivity of the reaction.  
Recently we reported the extension of our protocol to different type of dienophile to 
obtain piperidin-2-ones to convert in new class of biologically active  compounds. 
 The formation of six-membered nitrogen-containing heterocyclic structures is the 
mainly argument of this PhD thesis and will be well discussed in the next paragraphs. 
 
 
 
3.1 Synthesis of Perhydroxazinan-4-ones 
 
 
 
- Uncatalyzed reactions 
 
The highly activated azadiene E and G, prepared by Ghosez and described in Par. 1.3, 
are sufficiently reactive to cycloadd to various aldehydes without Lewis acid catalysis 
(Scheme 3.4).61,62 The cycloaddition works well both with aromatic and aliphatic 
aldehydes; a wide variety of substituents at C-4 of the diene are allowed; endo-selectivity 
is observed in most cases. Ethanolysis of 1,3-oxazinones 34 stereoselectively yields the 
corresponding β-hydroxyamides 35. 
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Scheme 3.4: Carbonylic compounds as dienophiles, uncatalysed reactions
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- Lewis acid mediated reactions 
 
In our research group, the Lewis acid mediated reactions between 4-substituted-3-
trialkylsilyloxy-2-aza-1,3-dienes A and aldehydes leading to perhydro-1,3-oxazin-4-ones 
have been reported (Scheme 3.5).19,63,64  
Scheme 3.5: Carbonylic compounds as dienophiles, LA mediated reactions
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A Perhydroxazinan-4-ones
 
 
As already anticipated in Chapter 2, the formation of the six-membered rings via LA 
catalized HAD reaction takes place through and asynchronous concerted mechanism or 
an aldolic two-step one-pot.3b,c The competitive existence of both reaction pathways has 
been demonstrated by the stereochemical analysis of the three new stereogenic centers 
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(C-2, C-5, C-6) formed in the products. The degree of diastereoselection in  both 
mechanism appears to be dependent upon the steric and electronic nature of the 
dienophile and the diene used.  
Diastereoselection in pericyclic reactions has been explained in terms of exo-/endo-
transition states depending on the Lewis acid and the steric demand of the substituents on 
the dienophile. When the Lewis acid coordinate the aldehyde oxygen syn to the hydrogen 
force the R group into an endo-position in the transition state TS-1 leading to the C5-H/C6-
H-cis-product P-1 characterized by a basket conformation of C2-H, C5-H and C6-H (Fig. 
3.1). Aldehydes having R group larger than the coordinating LA can react via a pericyclic 
exo-mode TS-2 affording the C5-H/C6-H-trans-product P-2 (Fig. 3.1). 
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Fig. 3.1:concerted HDA mechanism. 
 
The HAD reaction was expected to produce endo- or exo-products in which a cis-
relationship is established between C2-H and C5-H. However, analysis of the reaction 
mixture, in some cases, shows the presence of diastereoisomers with a trans-relationship 
between C2-H and C5-H. There are two possible explanation for the formation of C2-
H/C5-H trans-products: the first involves epimerization of the C2-H and/or C5-H 
stereogenic centers during the reaction; alternatively, a stepwise Mukaiyama mechanism 
may be occurring. Formulation in terms of the Mukaiyama silylenol-ether aldol process 
leads to the intermediates I-3 and I-4 which, upon ring closure, give rise to the product P-1 
and/or P-3 (Fig. 3.2) and P-2 and/or P-3 (Fig. 3.1). Once again, the substituents play a 
decisive role for the mechanism and therefore for the stereochemistry of the final products. 
 
 41 
N R1R3SiO
R2
R
O
N R1R3SiO
R2 OLA
-
R HH
N R1R3SiO
R2 OLA
-
R HH
N
H
O
O
R2
R
R1
H
H
H
N
H
O
O
R2
R
R1
H
H
H+
N
H
O
O
R2
R
R1
H
H
H
N
H
O
O
R2
R
R1
H
H
H+
+
+TS-3
I-3
I-4
P-3
P-4P-2
P-1
c
d
 
Fig. 3.2: Aldolic Mukaiyama type mechanism. 
 
 
- Stereoselection 
 
The HAD reaction between a 2-azadiene and aldehyde as dienophile, provides the 
formation of three new stereogenic centers (C-2, C-5, C-6) in the perhydroxazinonic ring. 
Its diastereoselectivity has been deeply investigated by the use of various combination of 
achiral and chiral azadienes and aliphatic, aromatic or heteroaromatic aldehydes (Scheme 
3.6).8 Herein we report the first synthesis optimized by our research group using 
azadienes with an amido group in position 4. The results are illustrated in Scheme 3.6. A 
complete study regarding the configuration of the products obtained is reported and it’s 
also important for the determination of the configurations of the perhydroxazinones with 
different substituents. 
Treatment of the azadiene 36 - 42 with an aldehyde in the presence of a 
stoichiometric amount of boron trifluoride etherate (CH2Cl2, -78°C to 20°C for 8 h), followed 
by aqueous work-up, gives rise to the formation of the perhydrooxazinones 37 - 43 
(Scheme 3.6). 
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Relative configuration of the products has been attributed by NOE measurements and 
on the basis of the coupling constant J(H5-H6) and J(H2-H2’) at 1H NMR spectra. In Table 
3.1 the typical coupling constants values and the observable NOE effects for the generic 
compounds a-f are reported. It is well known that in cyclic systems a small coupling 
constant is observed between two vicinal protons when their relative configuration is cis, a 
large one is obtained when they are in a trans relationship. 
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Products J5-6 (Hz) J2-2' (Hz) NOE 
N
H
O
O
H
H
H
R
1
R
2
R
3
2
5
6
a - rac
 
3.7 – 5.9 --- 2 6; 5 6 
N
H
O
O
H
H
H
R
1
R
2
R
3
2
5
6 b - rac
 
9.6 – 10.5 --- --- 
N
H
O
O
H
H
H
R
1
R
2
R
3
2
5
6
c - rac
 
3.7 – 5.9 --- 5 6 
N
H
O
O
H
H
H
R
1
R
2
OTIPS
2
5
6 d
 
3.7 – 5.9 7.7 2 6; 5 6 
N
H
O
O
H
H
H
R
1
R
2
OTIPS
2
5
6 e
 
3.7 – 5.9 3.2 – 4.7 2 6; 5 6 
N
H
O
O
H
H
H
R
1
R
2
OTIPS
2
5
6 f
 
9.6 – 10.5 3.2 – 4.7  
 
Tab. 3.1: Coupling constants and NOE results for perhydroxazinones 
 
These observations have been confirmed by the existence of NOE effects between 
H5 and H6 for a, c, d, e type products (Table 3.1). Further, the existence of NOE effects 
between H2 and H6 shows that these protons are in a cis orientation in a, d, e type 
products. 
Moreover, it has been demonstrated by calculations that it is possible to assign the 
relative configuration between H2 and H2’ on the basis of their coupling constants: a small 
value indicating a syn relatioship, a large value an anti one (Table 3.1, products d-f). In 
fact, a full AM1 conformational analysis (Hypercube, Inc. Hyperchem; Rel. 5.11 ed.: 
Waterloo, Ontario, Canada) of the model diastereoisomers (RS) and (SS) (Fig. 3.3) shows 
that in both isomers the system is best described by the two conformations (RS)3 and 
(SS)1 in which a bonding interaction between the silyloxy oxygen and the amino group is 
operating. The coupling constant of the conformer (SS)1, with the two hydrogens anti to 
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each other, was expected to be greater than that of the (RS)3-conformer, in which the two 
hydrogens have a gauche-relationship. The experimentally observed coupling constants of 
about 7 and 4 Hz, respectively (Table 3.1), allow the absolute configuration of the C-(2) 
stereocentres to be established. 
By combining all these informations, the absolute configuration of a-f type compounds 
has been assigned. 
Figure 3.3: AM1 calculated percentage population of the (R,S)- and (S,S)-conformers
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3.2 Novel Synthesis of Perhydroxazinan-4-ones 
  
 
In continuation of our studies on the use of hetero Diels-Alder strategy in the 
synthesis of heterocyclic compounds with different substitution pattern and their use for the 
preparation of acyclic derivatives we would like to present here our recent results on the 
synthesis of  new perhydrooxazinan-4-ones. The aim of our researches is the synthesis of 
5-substituted oxazinan-4-ones with the position five of the heterocyclic adduct substituted 
by an easy removable group (alogen, tiophenyl) for further elaborations. We have been 
also investigating to find new synthetic protocols which allow the preparation of 
perhydrooxazinan-4-ones with milder conditions: the use of microwaves as non 
conventional heating source and the use of Lewis acid in catalytic amount. 
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- From 4-halo-3-Me3SiO-2-azadienes to 5-halo-1,3-oxazinan-4-ones  
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Scheme 3.7: Synthesis of 5-halo-2-phenyl-1,3-oxazinan-4-ones
X= Cl, Br, I
R= Me, n-Propyl, i-Propyl, t-Butyl, n-Heptyl, Ph, p-NO2Ph
 
 
The azadiene 47 was prepared from he corrisponding acid halides 46 and N-trimethylsilyl 
imines 45 following the procedure describe (Paragraph 1.4). Table 3.2 summarize the 
results of the cicloaddition reactions of 47 with aldehyde 48, activated with boron trifluride 
etherate, to give the six-membered ring adducts 49 e 50.  
 
 
Entry X R1 Products Ratio Yield(%) 
1 Cl Me 49a/50a >98 40 
2 Br Me 49b/50b >98 45 
3 I Me 49c/50c 92/8 48 
4 Br Propyl 49d/50d 94/6 56 
5 Br n-Heptyl 49e/50e >98 50 
6 Br n-Heptyl _ _ 0 
7 Br i-Propyl 49g/50g 9/91 52 
8 Br i-Propyl 49g/50g 9/91 45 
9 Br t-Butyl 49h/50h 30/70 40 
10 Br Ph 49i/50ib 61/39 40 
11 Br p-NO2-Ph 49j/50j 80/20 41 
 
Tab. 3.2: Cycloaddition of azadienes 47 with aldehydes 48 
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The relative configurations of C2-H, C5-H and C6-H in the product 49 and 50 were 
established on the basis of 1H NMR chemical shifts, coupling costants and NOE values 
according to the results of Tab. 3.1. The basket configuration of the protons (H2-H5-H6), in 
the series of compounds 49, has been demonstrated by the values of coupling constant 
(H5-H6) and by a positive NOE effect between the H2 and H6. The absence of this effect for 
the compounds 50 allow the configurations to be assigned (Tab. 3.1). 
 
Examination of Table 3.2 leads to the following remarks:  
 
1) Diastereomeric ratio was evalueted by 1H NMR analysis of the crude reaction 
mixture. No changes were observed after silica gel column purification. 
2) Yields were calculated on the basis of mmol of benzaldehyde 44 used for the 
preparation of azadiene 47 and refer to chromatographically isolated products. 
3) Irrespective of the nature of R in the dienophilic aldehyde 48, the cycloaddition 
takes place with a complete (H5-H6)-cis diastereoselectivity. 
4) The HDA cycloaddition works well with linear aliphatic aldehyde with an almost 
complete (H2-H5-H6) relative diastereoselectivity (entries 1-5). Accordingly, the final 
cycloaddition adducts 49 resulted from an endo approach of the reactants. 
5) The reaction takes place al low/ambient temperature under BF3 mediated 
cycloaddition, whereas no cycloadduct products were obtained under Ghosez 
conditions (acetonitrile/reflux/no LA added, entry 6). 
6) Using aliphatic aldehydes with branched side chains (entries 7-9) or aromatic 
aldehydes (entries 10-11) mixtures of cycloadducts 49 and 50 in variable ratio are 
obtained. The products of series 50 show a complete cis-diastereoselectivity 
between C5-H and C6-H but a trans relationship between C2-H and C5-H.  
7) The formation of isomer 50 could be assigned to the epimerization of the 
stereocenter 2 in the product 49. As already known, an equilibrium between the 
cyclic perhydrooxazinan-4-ones and the open-chain derivatives may exist (Schema 
3.8). An extra experiment (entry 8), quenching the reaction mixture at low 
temperature (-78°C) after 90 min makes this hypothesis likely. 
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The 5-halo-oxazinan-2-ones obtained with the reported procedure have been 
converted, mainly, in cis epoxides via N-Boc protection as illustrated in Chapet 4. 
 
 
 
- From 4-PhS-3-Me3SiO-2-azadienes to 5-PhS-1,3-oxazinan-4-ones  
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Scheme 3.9: Synthesis of 5-phenylthio-1,3-oxazinan-4-ones
 
5-Phenylthio-1,3-oxazinan-4-ones 56 and 57 with various sobstituent patterns at the C2 
and the C6 atoms, have been obtained from the easily available 1,3-azadienes 54, 
prepared from silylimines 52 and acylchloride 53, in presence of triethylamine, and using 
aldehydes 55 as dienophiles (Scheme 3.9, Table 3.3). In the present study, the starting 
azadiene 54 is a neutral 3-trimethylsilyloxy-4-thioaryl-2-aza-1,3-diene, already used in a 
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previous study for the preparation of a β-lactam ring by a 4π-conrotatory 
electrocyclization.60 
 
Entry R R1 Products Ratio Yield(%) 
1 Ph Ph 56a/57a 90/10 35 
2 Ph Ph 56a/57a 74/24 35 
3 Ph 
S
 
56b/57b 40/60 38 
4 p-MeO-Ph Ph 56c/57c 80/20 55 
5 o-TIPSO-Ph Ph 56d/57d 85/15 48 
6 Ph Me 56e/57e 50/50 51 
7 Ph 
N
BOC
 
      56f/57f 40/60 41 
 
Tab. 3.3: Cycloaddition of azadienes 54 with aldehydes 55 
 
The results shown in Table 3.3 warrant some comments: 
1) Diastereomeric ratio was evalueted by 1H NMR analysis of the crude reaction 
mixture. No changes were observed after silica gel column purification. 
2) Yields were calculated on the dienophilic aldehyde 51 and refer to 
chromatographically isolated products. 
3) No traces of azetidinones, arising from a 4π-conrotatory electrocyclization, have 
been detected in the crude reaction mixture. 
4) All the reactions are completely regioselective. 
5) Irrespective of the nature of R1 in the dienophilic aldehyde 55, the cycloaddition 
takes place with a complete (H5-H6)-cis diastereoselectivity. 
6) Two groups of cycloadducts are present: one (compounds 56) presenting the three 
ring protons in a basket conformation and an other group (compounds 57) 
presenting the same cis –configuration between C5-H and C6-H but a trans-
relationship between C2-H and C5-H as pointed out by the combined analysis of 
coupling constants and NOEs. 
7) In order to ascertain if this stereo-difference is originate from a different cyclization 
mechanism (HDA vs Mukaiyama) or from the presence of the equilibrium reported 
in Scheme 3.8, we added an excess of BF3 etherate to pure 56a in methylene 
chloride for 4 h at room temperature. A mixture of 56a and 57a in 90/10 
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diastereomeric ratio was obtained. This is a clear evidence that some degree of 
isomerization could take place after the formation of the Diels-Alder adducts. 
 
In order to develop  a chiral version of the HDA reaction, a stereocenter was introduced 
in the structure of the starting azadiene 59 using enantiopure lactic aldehyde 58 in its 
synthesis. 
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Scheme 3.10: Synthesis of enantio-pure 5-phenylthio-1,3-oxazinan-4-ones
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Entry R Products Ratio Yield(%) 
1 Ph 62a/63a 50/50 81 
2 
S
 
62b/63b 60/40 90 
3 Me 62c/63c 50/50 32 
4 
 
62d/63d 50/50 41 
7 
N
BOC
 
      62e/63e 63/37 55 
 
Tab. 3.4: Cycloaddition of azadienes 60 with aldehydes 61 
 
Also for the results of Tab 3.4 is possible to do some comments: 
1) Diastereomeric ratio was evalueted by 1H NMR analysis of the crude reaction 
mixture. No changes were observed after silica gel column purification. 
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2) Yields were calculated on the dienophilic aldehyde 61 and refer to 
chromatographically isolated products. 
3) The two diastereoisomer 62 and 63 present the same basket configuration for the 
protons on the heterocyclic ring but an opposite absolute configuration on the C2, 
C5 and C6 stereocenters. 
4) The stereochemistry of the obtained products 62 and 63 is a further confirmation of 
the presence of the equilibrium between the cyclic perhydrooxazinan-4-one and the 
open-chain derivates (Scheme 3.8). The hydroxy-alkyl group on the C2 
stereocenter doesn’t favor the formation of a positive charge; in fact, we obtained 
only the HDA adducts arising from a concerted mechanism. 
 
The cycloadducts thus prepared have been shown to be useful intermediates for the 
synthesis of 1,3 aminoalcohols, valuable intermediates in the preparation of biologically 
significant molecules (Chapter 4). 
 
 
- Lanthanides Lewis acids in the synthesis of 1,3-oxazinan-4-ones  
 
A target of our researches is the formation of the six-member heterocycles in the 
presence of a catalyst. This has been possible using lanthanides Lewis acid and the highly 
efficient MAOS (Microwave Assisted Organic Synthesis) technique.. This has been 
possible using lanthanides Lewis acid and the highly efficient MAOS (microwave assisted 
organic synthesis). The starting 4-unsubstitued-azadienes 65 used in this study have been 
prepared according reported procedure starting from the silylimine  45 and acetyl chloride 
64 in the presence of triethylamine.  
 
 51 
N
H
O
O
Ph
PhN
H
H
PhO
H
+
SiMe3
ii
N
H
O
O
Ph
Ph
H Ph
O
iiiH Ph
N
TMS
i
Reagent and conditions. i) LiHMDS, TMSCl; ii) CH3COCl 64, TEA; iii)                 66
44 45 65 67rac
cis
68rac
trans
Scheme 3.11: Lanthanides Lewis acids in HDA reactions
LA= EuFOD, EuCl3, Eu(Tf)3x10H2O, YbFOD, Sc(Tf)3
HPh
O
LA
 
 
Several different lanthanides Lewis acids have been tested using the azadienes 65 (2 
mmol) and benzaldehydes 66 (1 mmol) in the presence of a catalyst [catalyst LA (0.1 
mmol, 5%)] in chlorobenzene (5mL).  The mixture were placed in a flask and submitted to 
MW-irradiation in a Prolabo oven for the time reported in Table 3.5. Afterwards, the solvent 
was evaporated under vacuum and the reaction mixture was filtered on silica gel eluting 
with a mixture of hexane and ethyl acetate (3:2) to give the cyclic adducts in the yields and 
diastereomeric ratio reported in Table 3.5. 
 
Entry LA Temp °C Time Yield% Cis/Trans Method 
1 EuFOD (5%) r.t. 7 gg 5 n.d. CH 
2 EuFOD (5%) reflux 60 min 59 78/22 CH 
3 EuCl3 (5%)  30 min Traces n.d. DH 
4 Eu(Tf)3x 10H2O (5%)  40 min Traces n.d. DH 
5 EuFOD (5%)  5 min 84 78/22 DH 
6 EuFOD (5%)  30 min 5 n.d. DH 
7 YbFOD (5%)  40 min  47 86/14 DH 
8 Sc(Tf)3 (5%)  30 min 20 69/31 DH 
 
Table 3.5: Lanthanides LA catalyst in HDA 
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The results shown in Table 3.5 warrants some comments: 
1) Diastereomeric ratio was evalueted by 1H NMR analysis of the crude reaction 
mixture. No changes were observed after silica gel column purification. 
2) Yields were calculated on the dienophilic aldehyde 66 and refer to 
chromatographically isolated products. 
3) The best results in term of yields and reaction time have been achieved using 
EuFod as catalyst, MAOS technique and a ratio diene:dienophile:catalyst 2:1:0.05. 
4) Comparison between dielectric heating (DH Table 3.5) and conventional heating 
(CH, Table 3.5) not surprisingly demonstrates the advantages of MAOS, in term of 
higher yields of the cycloadduct and shorter reaction time, on the conventional 
heating. 
5) No difference has been noted in the diastereomeric ratio between the two 
procedure. 
 
The versatility of the methodology was tested using different substituents on the diene  
and on the dienophile (Scheme 3.12). Exploiting EuFOD (5%) as catalyst satisfactory, 
from the total yields point of view, results are obtained (Table 3.6). 
 
N
H
O
O
R1
RN
H
H
RO
H
+
SiMe3
ii
N
H
O
O
R1
R
H R
O
iiiH R
N
TMS
i
Reagent and conditions. i) LiHMDS, TMSCl; ii) CH3COCl 64, TEA; iii) R
1CHO 70, EuFOD (5%)
51 52 69 71rac
cis
72rac
trans
Scheme 3.12: EuFOD in HDA reactions  
 
 
 
 
 
 
 
 
 53 
Entry R R1 LA Time Yield% Cis/Trans Method 
a 
OTIPS 
Ph EuFOD (5%) 8 min 49 54/46 DH 
b 
OMe 
Ph EuFOD (5%) 30 min 49 80/20 DH 
c 
OMe
 
Ph EuFOD (5%) 40 min 45 100 DH 
d Ph 
OMe
 
EuFOD (5%) 40 min 35 50/50 DH 
e 
OMe OMe 
EuFOD (5%) 30 min 50 75/25 DH 
f 
OMe OMe 
YbFOD (5%) 30 min 43 79/21 DH 
g 
NO2
 
Ph EuFOD (5%) 40 min 10 26/74 DH 
 
Table 3.6: EuFOD in HDA reactions 
 
The above reported procedure must be considered efficient and valuable in view of 
the possibility to build up a small library of oxazinan-2-ones, which may in turn, be 
elaborated to a 1,3-aminols according to protocols illustrate in Chaper 4. 
 
 
3.3 Synthesis of Piperidones via HDA 
  
 
The Diels-Alder reaction is one of the most versatile routes for the construction of 
carbocycles.1-3 Appropriate selection of diene and dienophiles allows for a wide range of 
structural and functional variations in the adducts. The syntheses till now reported, show 
the reaction of an azadiene with carbonylic compounds as dienophiles. In order to expand 
the versatility of the HDA reaction we started to investigate the use of olefinic dienophiles 
for the preparation of piperidinones. 
 3-Trimethylsilyloxy-2-aza-1,3-dienes A are electron-rich dienes able to undergo 
[4+2] cycloadditions with electron-poor dienophiles. Ghosez65 had reported the reaction 
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between the 3-t-butyl dimethylsilyloxy-2-aza-1,3-diene H and methyl acrylate for direct 
synthesis of functionalized piperidines. 
 
CO2Me
HN
CO2Me
O
2)  HF
1)
N OSiMe2t-BuO
t-BuMe2Si
Yield=65%H
Scheme 3.13: Ghosez piperidines' synthesis  
 
More recently the same group obtained enantiomerically pure piperidinones 12 and 
13 starting from highly nucleophilic azadienes G and 3-alkenoyl-1,3-oxazolidin-2-ones 15 
activated by Evans mild Lewis acid 14 derived from copper(II)triflate and a C2-symmetric 
bis(oxazoline) ligand (Scheme 2.5).50 
 
The main theme of our research has always been the formation of cycloadducts 
cointaining several functional groups in order to generate more complex cyclic structure, 
new heterocycles or new class of biologically active  compounds. For these reasons we 
have selected phenyl vinylsulfone 73, one of the most useful functionalities in organic 
synthesis66, as oleifinic dienophile on the HDA reaction with 2-aza-1,3-dienes.  
Several examples of cycloaddition with phenyl vinylsulphone have been reported in 
literature.66,67 Herein we reported the addition of phenyl vinylsulphone to Danishefsky 
diene to obtain a sulfonyl functionalized adduct in high yield after a direct ketalization 
(Scheme 3.14).68 
 
N
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Schema 3.14: Cycloaddition of phenyl vinylsulphone to the Danishefsky diene.
Yield = 88%
73
 
 
Now we report our result obtained from cycloaddition of azadienes and phenyl 
vinylsulphone. In a preliminary study, a simple 3-trimethylsilyloxy-2-azadiene 65, without 
substituent in position 4, has been used in order to evaluate the best reaction conditions. 
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Scheme 3.15: Synthesis of piperidinones  
 
Several different reaction conditions have been tested and the results are reported 
in Table 3.7. 
 
Entry 
  
Solvent MW Temp °C Time Yields % 
1 1 eq 1 eq ClBn √ 132 5' 38 
2 1 eq 1.5 eq ClBn √ 132 10' 32 
3 1 eq 1 eq Toluene   110 20 h 40 
 
Table 3.7: HAD ractions with phenyl vinylsulphone 
 
The results shown in Table 3.7 warrant some comments: 
1) Yields were calculated on the aldehyde 44 used for the formation of the 
silylimine and refer to chromatographically isolated or crystallize products. 
2) The reaction is completely regioselective and diasteroselective: we have 
obtained only one racemic product with cis relationship between C5-H and C6-
H.  
3) Also in this case the methodology MAOS has been furnished the best reaction 
conditions: the same yield obtained with conventional heating (CH, Table 3.7) 
but a very short time (5 min instead 20h).  
 
The same reaction applied to 5-halo-oxazinan-4-one 47a gives rise to a competitive 
reaction between a [4+2] cyclization, with the formation of the six-membered cycloadduct 
75, and an intramolecular reaction to give trans 4-halo-azetidinone 76 (Scheme 3.16). 
Every effort to change the reaction condition resulted in unsatisfactory results. 
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Scheme 3.16: Synthesis of  rac-5-halo-piperidinones
toluene
Y= 15% Y= 40%
 
 
However, the major interest of our research is the synthesis of enantiomerically 
pure piperidinones. Thus adducts have been obtain introducing a stereocenter in the 
structure of the azadiene (Scheme 3.17). Also in this case several different reaction 
condition have been tried and the results are reported in Table 3.8. 
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Scheme 3.17: Synthesis of enantiopure piperidinones
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Entry 
  
Solvent MW Watt Temp °C Time Yields % Ratio 78/79 
1 1 1 ClBn √ 300 132 30’ 46 60/40 
2 1 1 ClBn √ 300  20' 37 64/40 
3 1 1 diglyme √ 300 162 30’ 25 70/30 
4 2 1 toluene   110 20 h 35 65/35 
 
Table 3.8: enantiopure HAD with phenyl vinylsulphone. 
 
The results shown in Table 3.8 warrants some comments: 
1) Yields were calculated on the aldehyde 58 used for the formation of the 
silylimine and refer to chromatographically isolated or crystallize products. 
2) Strictly reaction conditions furnished a mixture of HDA-adduct 78 and 79 and a 
diastereomeric mixture of azetidinones 80 and 81 in some 1/1 ratio and 80/20 
diastereomeric mixture in β-lactams (Scheme 3.18). 
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Scheme 3.18: Azetidinones formation
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3) Use of diglyme as solvent (bp 162°C), entry 3, Table 3.8,  furnished the same 
results, apart from a lowering (5%). of yield. 
4) Once again, the methodology MAOS has been furnished the best reaction 
conditions. Entry 4, Table 3.8, reports the azadiene derived from (S)-lactic 
aldehyde OTBDMS protected. With conventional heating, the reaction time is 
much longer than using dielectric heating. 
 
Activation with Lewis acids doesn’t produce satisfactory results for the poor 
nucleophilicity of the oxygen atom of the sulfonyl group. Better results obtained by  the use 
of a bis-sulfonyl ethylene 82 due to the increasing of the electron-withdrawing ability of the 
dienophile. As a matter of fact, this class of compounds are characterized by a high 
dienophiles reactivity and by the fact that the activating groups can be readily removed. 
The use of 1,1-bis(phenylsulfonyl)ethylene as dienophile in HDA reaction with 3-
trimethylsilyloxy-2-aza-1,3-dienes has been given excellent results with all the substrates 
utilized (Scheme 3.19) . 
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Scheme 3.19: Synthesis of  piperidinones with bis-sulfonyl olefin via HDA
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Scheme 3.19 reports the high yields obtained in a very short time using mild 
reaction conditions. Also in the example with 4-halo-azadiene 47a, with great satisfaction, 
only the six-membered cycloadduct was obtained. 
All these compounds are particulary interesting for further elaboration to biologically 
active compounds. 
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Chapter 4                                                      
 
 
 
 
3-Trimethylsilyloxy-2-Azadienes for the synthesis 
of biologically active compounds. 
 
 
 
Hetero Diels-Alder cycloaddition is a versatile strategy for the synthesis of natural 
compounds containing six-membered heterocyclic rings.2,3,6,41 Moreover, this strategy has 
found important applications through the elaboration of the cyclic adducts thus obtained to 
acyclic compounds with a well-defined stereo- and regio-control of the present 
functionalities. 
Our reaserch group have already reported on the possibility of synthesizing 
biologically active compounds starting from perhydroxazinan-4-ones I, a useful 
intermediate obtained with an HDA reaction of 3-trialkysilyloxy-2-aza-1,3-dienes and 
aldehyde or ketone as dienophile (Chapter 3). The synthesis of a large amount of 
biologically active compounds is due to the high degree of functionalization of these 
cycloadducts as illustrated in Fig 4.1. 
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Fig. 4.1: Perhydroxazinones' functionality
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Analyzing the structure of the perhydroxazinones I it’s possible to deduct some 
informations about its reactivity: 
- three new stereocenters can be introduced during the course of [4+2] cycloaddition 
and their configurations controlled to a large extent.  
- An aminalic carbon is present in position 2. The ring can be opened by a simple 
hydrolysis in acid or basic conditions 
- The carboxyl of the amidic function can be reduced or can be attack by 
nucleophiles 
- R1, R2, R3 can be variously functionalized with satured or unsatured carbo- or 
hetero-groups, and with aromatic or non aromatic carbo- or hetero-cycles 
- The position 5 can be substituted by an easily removable group. 
 
 
 
4.1 Perhydroxazinones precursors of biologically active 
compounds. Part one. 
 
  
- Threonine synthesis  
 
In the past few years we have reported on the possibility of synthesizing 5-amido-
perhydroxazinan-4-ones as useful precursors of β-hydroxy-α-amino acids: D-threonine 90 
and D-allo-threonine 92 have been obtained starting from (2R,5R,6R)-2-[(S)-1-
[triisopropyl)oxy]ethyl]-5-[(benzyloxycarbonyl)amino]-6-methylperhydro-1,3-oxazinan-4-one 
43a (Schema 4.1).19  
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Reagents and conditions:  i) MeCHO, BF3
.Et2O, -78°C, CH2Cl2; ii) Li/NH3, -78°C, THF; 
                                          iii) CbzCl, acetone/ H2O, NH4Cl; iv) HCl/ MeOH; v) DBU/DMF, 80°C.
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Scheme 4.1: Threonine synthesis
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The reaction between N-trimethylsilylimine 87 of (S)-lactic aldehyde 58 and acid 
chloride 88, in presence of triethylamine, gave the azadiene 42. Compounds 43 were 
obtained via a hetero Diels-Alder reaction between the azadiene 42, and acetaldehyde in 
the presence of BF3 etherate in dichloromethane at –78°C. After chromatographic 
purification, one-pot-two-step removal of the Evans’ oxazolidinone in 43a and in situ 
formation of the corresponding N-Cbz derivative, the oxazin-4-one 89 was obtained. Ring 
opening of this product by methanolic HCl furnished the (D)-N-Cbz-threonine methyl ester 
90 in 39% overall yield calculated on starting (S)-lactaldehyde. Epimerization of the C-5H 
stereocenter of 89 with DBU in DMF and treatment with methanolic HCl furnished the (L)-
N-Cbz-threonine methyl ester 92. 
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- Serine synthesis  
 
Interest in the field of stereoselective synthesis of β-hydroxy-α-amino acids is in 
continuous growth because of their presence in nature as metabolites or components of 
biologically active compounds. Moreover, due their high degree of functionalization, they 
find wide use as chiral starting materials in asymmetric synthesis.  
In order to demonstrate the utility of our approach in the synthesis of non-
proteinogenic amino acids, we have also reported the enantioselective synthesis of (+)-D-
serine 95 protected as N-Cbz- methyl ester obtained with 24% overall yield calculated on 
starting (S)-lactaldehyde.69 
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                                          iii) CbzCl, acetone/ H2O, NH4Cl; iv) HCl/ MeOH.
D-Serine
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Scheme 4.2: Serine synthesis
 
 
 
 
- Polyoxamic acid synthesis  
 
The same reaction sequence upon the cycloadduct 96, obtained by the use of (D)-
gliceraldehyde acetonide as dienophile, gives rise, after acidic work-up, to the cyclic form 
of scalemic 2,4-di-epi-polyoxamic acid 98 in 54% overall yield calculated on starting (S)-
lactaldehyde.63 
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- β-hydroxy acids synthesis 
 
On the other hand, the use of ketones as dienophiles has permitted the synthesis of 
6,6-disubstituted perhydroxazinones as useful precursors of 3,3-disubstituted-β-hydroxy 
acids.29 The possibility of preparing optically pure β-hydroxy perhydroxazinones and, 
therefore, β-hydroxy acids has been tested using optically pure starting material as diene 
or dienophiles. The use of the azadiene 65 and the optically pure (-)menthone 99 as 
dienophile achieved the synthesis of oxazinones 100 and 101 with a very high selectivity. 
(ratio 91/9 respectively). Trasformation of 100 and 101  into Boc derivatives 102 and 103 
and treatment of such compounds with LiOH in EtOH/H2O solution, afforded the  β-
hydroxy acids 104 and 105 in almost quantitative yields. 
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Scheme 4.4: !-Hydroxyacids synthesis  
 
 
4.2 Perhydroxazinones precursors of biologically active 
compounds. Part two. New synthesis. 
 
Recent studies on the synthesis of perhydroxazinones with an easy removable 
group (halogen, thioaryl) in position five of the heterocyclic adducts allow us to achieve 
new classes of biologically active compounds.  
 
 
- α ,β-Epoxy acids synthesis  
 
The preparation of the 5-halo-1,3-oxazinan-4-ones 49 and 50 have been illustrated 
in chapter 3.2. We now describe the results of our study on the synthesis of α,β-epoxy-
carboxylic acids by the above reported HDA strategy. Carboxylic acids bearing in 
α,β−position an oxirane ring functionality are, in fact, useful intermediates in the synthesis 
of biologically active compounds. They have recently found application in the synthesis of 
Taxol and Taxotere derivatives and the carboxy-acid functionality presents several 
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advantages over the corrisponding carboxy-ester in the coupling  reaction of Bacchatin 10 
and side chains,70 adding extra value to their synthesis. 
The HAD adducts, obtained from 4-halo-3-trimethylsilyloxy-2-aza-1-phenyl-1,3-
butadiene 47 and aldehydes 48 activated with BF3 etherate (Tab 3.2), were processed to 
the final oxirane 108 and 109by the sequential reactions shown in Scheme 4.5. In order to 
facilitate the lactamic ring opening the corrisponding t-Boc-derivatives 106 and 107  were 
prepared.71 
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Scheme 4.5: !,"-Epoxy acids synthesis
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It is well know that a facile opening of lactamic ring takes place when a t-Boc group 
is directly linked to the lactamic nitrogen.72 Final ring closure to the expected oxirane was 
studied in detail. Among the methods tested, in order to achieve one-spot two-step 
perhydroxazionone ring opening and nucleophilic substitution of alogen atom with the 
formation of the final oxirane ring, the best conditions have been proved to be those 
reported in the Scheme 4.5 as Method A and Method B. The two methods differ each 
other in the presence of hydrogen peroxide (Method B). The basis for the use of method B 
is to allow the use of oxygen nucleophiles that have positive deviation from the Bronsted-
type nucleophilicity plot. These molecolues are said to exhibit an α-effect, a term 
describing a nucleophile alpha to an atom having a lone pair of electrons.73,74 The most 
extensive class of α-nucleophiles are peroxy anions, which include peroxide salts. Our 
objective was to take advantage of this increased nucleophilicity for a faster ring opening 
of the perhydroxazinones, in the hope of lowering the rate of isomerization and side 
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product formation. Unfortunately (entry 1  and 2, Table 4.1) a better yield corresponds with 
a decreasing diastereomeric ratio (diasteromeric ratio was evalueted by 1H NMR of the 
crude reaction mixture). In fact, partial isomerization at the C5-H stereocenter, presumibly 
due to the basic condition used, is observed with both methods. This side reaction takes 
place at the perhydroxazinone stage because of the high lability of the C5-H proton under 
the basic condition used. A direct isomerization of the epoxy acid lithium salts is 
unreasonable. Indeed, such isomerization are known to require drastic condition on the 
corrisponding epoxy esters.75 Most important are the results reported in entries 5, 6 and 7 
(Table 4.1). Using as starting perhydroxazinones the compounds of series 106 and 107, 
the expected oxiranes were obtained in almost the same diastereomeric ratio compared to 
that obtained starting from single pure isomer. For this reason a mixture of the 
diastereomeric perhydroxazinones has been used as starting material for the final step of 
our strategic plane. 
 
Entry Compound R Yield (%) Method Products Ratio Hrs 
1 106b Me 55 A 108b/109b 90/10 8 
2 106b Me 90 B 108b/109b 70/30 3 
3 106d Propyl 60 A 108d/109d 75/25 3 
4 106e n-Heptyl 80 A 108e/109e 80/20 3 
5 106g i-Propyl  60 A 108g/109g 95/5 3 
6 106g i-Propyl  80 A 108g/109g 80/20 3 
7 106g+107g (10/90) i-Propyl  78 A 108g/109g 88/12 3 
8 106h+107h (30/70) t-Butyl 70 B 108h/109h 48/52 48 
9 106i+107i (61/39) Ph 85 A 108i/109i >98/2 8 
10 106j+107j (47/53) p-NO2-Ph 75 B  108j/109j 45/55 3 
 
Table 4.1: Epoxy acids from t-BOC perhydroxazinones derivatives 
 
The synthetic protocol for the synthesis of cis a,b-epoxy oxiranes, here described, 
may be considered a convergent synthesis of cis-epoxydes in good to high stereochemical 
fashion, due to the strict control of the stereoselectivity during the formation of the C5-C6 
stereocenters. The lack of high stereocontrol in the formation of the C2 stereocenter is not 
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crucial for our strategy, since this stereocenter is destroyed during the final step of the 
oxirane formation.  
 
 
 
- Optically active 1,3-aminols:(R)- and (S)-Fluoxetine synthesis  
 
In continuation of our studies on the use of HDA strategy in the synthesis of 
heterocyclic compounds with different substitution pattern and their use for the preparation 
of acyclic derivatives, we report the synthesis and use of the 5-phenylthio-substituted 
oxazinan-4-ones. Its importance is due to an easily removable group, as the thiophenyl 
one, in the position five of the heterocyclic adduct. 
 
Reported in this section are our recent results on the synthesis of Fluoxetine 
(Prozac®)76,77 and Duloxetine (Cymbalta®),78-80 two potent and highly selective inhiborts of 
neutral serotonin-reuptake and among the most important drugs for the treatment of 
psychiatric disorders and metabolic problems. 
Using our experience on the synthesis of optically active perhydroxazinones via 
HDA, we have been formed the cycloadduct 62 and 63 starting from the azadiene 60, in 
turn derived from the trimethylsilylimine of the (S)-lactic aldehyde 58 and the 2-
phenylthioacetylchloride 59 as source of the ketene, and benzaldehyde activated with BF3 
etherate in DCM  at –78°C.(Scheme 3.10, Table 3.4). Perhydroxazinones 62a and 63a 
(Scheme 4.6) were obtained in 50/50 diastereomeric ratio and 81% overall yield (and the 
two diastereoisomers were separated by flash chromatography eluiting with 
cyclohexane/ethylacetate 7/3. 
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Compounds 62a and 63a  were easily desulfurated by the use of Nickel-Raney in a 
novel microwave-mediated81-85 desulfurization reaction.86-90 Thus treatment of such 
compounds with Nickel-Raney under MAOS conditions have been allowed to obtain, in a 
very short time (2 min) and high yields (90% and 98% respectively) the corresponding 
desulfurated derivatives 110 and 111. These compounds were treated with LiHMDSA and 
methyl iodide in order to get the corresponding N-metyl derivatives 112 and 113 in 
quantitative yields. Reduction of carboxy functionality occurred with diphenyl silane in the 
presence of catalytic amount of tris(triphenylphosphine)rhodium(I) carbonyl hydride to give 
the perhydroxazinones 114 and 115 in yields up to 98%. Due to their relative instability, 
the crude reaction mixture of 114 and 115 was used as such in the subsequent step of our 
process. Accordingly, final mild ring opening of these compounds by means of diluted HCl 
furnished the enantiomerically pure (1R)- and (1S)-aminoalcohols 116 and 117b in 60% 
and 67% respectively overall yields based on the desulfurated products 110 and 111. Final 
conversion of intermediates 116 and 117 to the title compounds was achieved according 
to literature procedures.81 
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- Optically active 1,3-aminols: (R)- and (S)-Duloxetine synthesis  
 
 
Using the same optically active azadiene 60 above  reported but 2-thiophene-
carboxaldehyde as dienophile we obtained the proper perhydrossazinones required for the 
synthesis of enantiomerically pure (R)- and (S)-Duloxetine (Scheme 3.10, Table 3.4).  
The 3-silyloxy-2-aza-1,3-diene 60, prepared from the trimethylsilylimine of the (S)-lactic 
aldehyde 58 and the 2-phenylthioacetylchloride 59 as source of the ketene, and 2-
thiophenecarboxaldehyde activated with BF3 etherate reacted in DCM  at –78°C to give 
perhydroxazinones 62b and 63b in 60/40 diastereomeric ratio and 90% overall yield after 
purification by flash chromatography eluiting with cyclohexane/ethylacetate 8/2 (Scheme 
4.8). 
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Desulfuration of oxazinan-4-ones 62b and 63b by the above reported microwave-
mediated Nickel-Raney methodology partially failed when applied to this compounds 
giving rise to low yields of the desired 5-unsubstituted derivatives 118 and 119, probably 
due to side reactions on the thienyl ring. We have found that desulfuration with aluminum 
amalgam91 was the method of choice. The crude reaction mixture was used for the next 
step without any purification. Methylation by LiHMDS and methyl iodide gave rise to the N-
methyl intermediates 120 and 121 in quantitative yields. Reduction of the amide 
functionality by means of Ph2SiH2 in the presence of 1 mol % RhH(CO)(PPh3)392 in THF, 
resulted in the production of the partially unstable intermediates 122 and 123. Ring 
opening by aqueous hydrochloridric acid furnished the corrisponding aminol 124 and 125. 
(R)-and (S)-Duloxetine were obtained by means of arylation of 12 and 125 according to a 
literature procedure.93 
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Scheme 4.9: (R)- and (S)-Duloxetine synthesis
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- Optically active 1,3-aminols: (R/S)-Venlafaxine synthesis  
 
In continuation of our studies on the use of hetero Diels-Alder strategy in the 
synthesis of heterocyclic adducts and their use for the preparation of acyclic optically 
active compounds, 5-(4-methoxy-phenyl)-2-phenyl-1-oxa-3-aza-spiro[5,5]undecan-4-one 
128, precursor of the Venlafaxine,94 an important drug for the treatment of psychiatric 
disorders, has been prepared.  
The reaction of N-trimethylsilylimine of benzaldehyde 45 and the p-
methoxyacetylchloride 126  in presence of triethylamine gave rise the azadiene 127. The 
subsequence cyclization with ciclohexanone activated by BF3 etherate in DCM  at –78°C 
produced the racemic perhydroxazinones 128 in 66%  overall yield after purification by 
flash chromatography eluiting with cyclohexane/ethylacetate 8/2 (Scheme 4.10). A novel 
microwave81-85-mediated transketalization reaction has been developed in our laboratories. 
Compound 128 in presence of formic acid and formic aldehyde, in MW oven for 3 min 
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gave rise to compound 130 through the intermediate 129.  A simple reduction with lithium 
aluminum hydride furnished the desidered aminol 131.  
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                                       iii) HCOOH, HCHO, MW; iv) LiAlH4.
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Chapter 5                                                      
 
 
 
Theoretical calculations 
 
 
 
 
This part has been added for the sake of a complete overview on the reactivity of 
the azadiene from a theoretical point of view. Further studies are currently under 
developments and a full paper is in preparation and will be published in due course.95 
The HAD reaction of carbonyl compounds with dienes is a convenient synthetic 
procedure for the preparation of six-membered heterocyclic compounds. In recent years 
an intensitive effort has been performed to achieve asymmetric HDA reactions. According 
to previous calculations performed on a similar substrate the cyclization reaction is 
considered to happen by a concerted HDA mechanism through the formation of an 
oxazinic ring, but, in analogy with what is known for similar reaction, a stepwise 
mechanism with the formation of an aldol-type intermediate cannot be ruled out (Fig. 3.1, 
Fig. 3.2). 
The stereochemical outcome of the reaction depends on the structure of the imine, 
on the ketene precursor, on the substituents of reagents and on the LA utilized. 
With the aim of gaining a deeper insight into this subject we performed a DFT 
computational study on both the uncatalyzed and Lewis acid catalyzed reaction. 
 
 
 
5.1  Azadiene geometry 
 
 
The formation of the azadiene consist in the coupling reaction of the N-
trimethylsilylimine 2 with the ketene n obtained in situ from the parent acyl chloride 3 and 
TEA (Scheme 1.6). 
According to the proposed  mechanism,96-98 ketene formation takes place at the first 
step, followed by nucleophilic attack of the imine nitrogen atom on the ketene sp carbon 
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atom. To test if the presence of the N-silyl group is compatible with this mechanism, an ab 
initio study (MP2/6-31G* level using the Gaussian 94 series of program) was performed, 
using as model compounds ketene K and N-silylformaldimine S; the results are shown in 
Scheme 5.1.  
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H H
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H
SiH3
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C N
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H H
H
O SiH3
C N
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H H
H
O
SiH3
K S EC TS I
Scheme 5.1: nucleophilic attack of the imine nitrogen atom on the ketene
 
 
The calculations show the preliminary formation of a stabilizing electrostatic 
complex EC followed by the generation of a polar-type transition state TS. The length and 
the bond order of the C-N bond being formed (1.792 Å, 0.44 bond order) and the angle 
between the planes of the two subunits (44°) are in agreement with the transition state 
already calculated for a (non-silyl)imine.98 The presence of the silyl atom, however, 
stabilized TS in a syn form due to a weak bonding interaction between the oxygen atom 
and the silicon itself. Next, the simultaneous formation of the C-N and Si-O bonds takes 
place, resulting in the formation of the neutral silyloxyazadiene I, in which the long range 
interaction of the silicon with the nitrogen atom (0.084e-) is responsible for the stabilization 
of a twisted (46°) s-cis conformation.  
In addition, when substituents are present on C1 and C4 of the azadiene, we have 
been able to assign sperimentally the E,Z configuration of the azadienes. In our case, 
due to the high stability of the neutral silyloxyazadiene, the stereoselectivity is already 
established at the moment of the azadiene formation. In fact we have been able to isolate 
azadiene as a unique compound which has been determined by NOE experiments (Fig. 
1.7).17,19   
A more difficult aspect to explain is how such an azadiene geometry arises, 
because silylimines are reported to adopt the anti configuration99 and the attack of an anti 
imine to the less hindered side of a ketene should lead to a (Z,Z)-azadiene.  
If we examine the geometry of TS we note that the chelating effect of the silicon 
atom on the ketene oxygen atom constrains the structure in a syn forming which the two 
methylene groups on the ketene and the imine are close together. This fact enhances the 
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steric repulsive effect of the substituents, especially when they are bulky as in our cases, 
and forces the attack to give the less-crowded E,Z form. To obtain this result the imine 
must easily change its configuration. The change of configuration in imine takes place by 
pyramidal inversion at the nitrogen atom. Alkylimines have a high inversion barrier (27 kcal 
mol-1)100 but it is known that such a barrier is significantly lowered by higher row atoms 
belonging to group IVa (germanium) directly linked to the inversion center. In this context 
we determined the inversion barrier of N-silylformaldimine by ab initio calculations. The 
barrier is taken as the energy difference between the bent form and a linear transition 
state. The calculated value is 9.3 kcal mol-1. For the sake of comparison these calculations 
were also performed on N-methyl- and N-germylformaldimine; the results are reported in 
Table 5.1. The value of the N-silylimine is predictably lower than that for N-alkylimines and 
allows for the facile inversion at the nitrogen atom as requested from the steric 
requirements. 
 
N
H H
H3M
N
H H
MH3
N
H H
MH3
M
C
Si
Ge
calc
32.5
9.3
14.9
Table 5.1: MP2/6-31G* inversion barrier energies (kcal mol-1)  
 
NOE studies and ab initio calculations show that the azadiene intermediate prefers 
two s-cis conformations (Scheme 5.2): a twisted conformation with a C=N-C=C dihedral 
angle of about 45° (rotamer P) and the corresponding counter clockwise conformation 
(rotamer M). 
H
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Scheme 5.2: Azadiene conformation  
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5.2  Uncatalyzed cyclization 
 
 
In order to determine the preferred pathways for the cyclization reaction, the 
calculations were performed using the unsubstitued 3-silyloxy-2-azadiene and 
formaldehyde as model starting compounds.101 
The calculations show the preliminary formation of a stabilizing electrostatic 
complex EC1 with a mean distance of a 3 Å between the two molecules (Scheme 5.3). 
The subsequent transition state TS-1 has an energy 12.6 kcal mol-1 higher than that of the 
electrostatic complex and has the same sign of the two dihedral angles C1-N2-C3-C4 and 
N2-C3-C4-C5 of 10° and 53° respectively. The strong planarization of the azadiene 
skeleton in the transition state (10° against 41° in the EC1), the neat pyramidalization of 
C1, C4 and C5 (150-160°), the equality of the lengths of the two forming bonds C4-C5 and 
C1-O6 (2.14 and 2.15 Å) and the values of their bond orders (0.32 and 0.17 e-) make 
these geometry features very similar to those found for the transition structure of concerted 
pathways in related reactions102 and are good evidence for a synchronous pericyclic 
reaction. An HAD-type cyclized compound, characterized by the presence of a localized 
C3=N2 double bond in the ring, originates from the transition state. The strong 
exothermicity of the cyclization reaction provides the driving force for this process. No 
transition state suggestive of a stepwise reaction was found. All attempts to form a 
zwitterionic aldol-type structure starting from the s-cis or s-trans azadiene form resulted 
either in the formation of TS1 or in separation to the reactants. 
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Scheme 5.3: Uncatalyzed cyclization  
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5.3  Lewis acid catalyzed cyclization 
 
The addition of a Lewis acid such as BF3 can lead to different reactions pathways 
depending on where the LA coordinates. In such reactions BF3 is generally regarded as 
coordinating the aldehyde oxygen,3 although it is known that azadiene can coordinate to 
BF3 through the imine nitrogen.60 
Calculations show that BF3 can coordinate to both sites with a length and bond 
order of 1.92 Å, 0.23 e- and 1.70 Å, 0.43 e- respectively. In the isodesmic reaction shown 
in Scheme 5.4 the right-hand part is 5.8 kcal mol-1 more stable, thus showing that the 
azadiene nitrogen must be considered to be preferred coordination site.  
 
N
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Scheme 5.4: Coordination site of BF3  
As a consequence, cyclization would occur between the complexed azadiene and 
the free aldehyde. On the other hand, and according to frontier molecular orbital (FMO) 
theory, the cycloaddition of carbonyl dienophiles with 2-aza-1,3-dienes has been shown to 
be a LUMOdienophile- HOMOdiene controlled process.19,49 In order to analyze the effect of the 
coordination of BF3 on such orbitals, we reported in Table 5.2 the calculated energies for 
uncomplexed and complexed formaldehyde and azadiene. 
 
  HOMO LUMO 
Formaldehyde - -1,15 
Formaldehyde BF3 - -2,67 
   
Azadiene -6,19 - 
Azadiene BF3 -7,35 - 
 
Table 5.2: B3LYP/6-31G* energies [eV] of FMO orbitals 
 
An analysis of the values shows thar the strong electron-withdrawing effect exerted 
on the substrate by BF3 causes  alowering in energy of the orbitals of both substrates. 
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Upon comparing the energies of the involved interacting orbitals it becomes clear that the 
cyclization via formaldehyde complexation should be strongly favored with respect to that 
via azadiene complexation (ΔE=3.52 and 6.20 eV, respectively), whilst the uncatalyzed 
cyclization (ΔE=5.04 eV) would be just in the middle. As the acid-base equilibrium in 
Scheme 5.4 would favor the O-complexed cyclization path, calculations were performed 
for both cases. 
 
 
- N-Complexation 
 
The complexation of the azadiene with BF3 does not change the geometry of the 
azadiene skeleton60 subsequentially and consequently, the behavior of the system is very 
similar to that of the uncatalyzed cyclization. The calculations show the preliminary 
formation of a stabilizing electrostatic complex EC2 (Scheme 5.5) with a mean distance of 
3 Å between the two molecules. A transition state TS2 was located with an energy 16.4 
kcal mol-1 higher than that of the electrostatic complex. 
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Scheme 5.5: Energies transition state values for N-complexation  
 
The transition state TS2, which has the same configuration as TS1, is characterized 
by a minor twisting of the azadiene skeleton (19°) with respect to that in EC2 (47°), a neat 
pyramidalization of C1, C4 and C5 (150-160°) and by the presence of two incipient bonds 
(C4-C5 and C1-O6). 
The coordination with BF3 increases the electrophilic character of C1 and favors the 
bonding to the aldehyde oxygen, as shown by the lenghts and bond orders of the two 
forming bonds (2.35 Å, 0.28 e- and 1.89 Å, 0.41 e- respectively). However, these lenghts 
and the overall geometry of the transition state allow us to consider this reaction as an 
HAD concerted reaction with a certain degree of asynchronicity. No transition state 
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accountable for a step-wise reaction was found. All the attemps to form a zwitterionic 
aldol-type structure starting from the s-cis or s-trans azadiene form resulted either in the 
formation of TS2 or in a separation to the reactants. 
 
 
- O-Complexation 
 
BF3-complexed formaldehyde can approach the s-cis azadiene skeleton in an endo  
or exo fashion. In the endo approach no formation of a zwitterionic or HDA-type transition 
state is observed due to the steric hindrance between the BF3 and the azdiene imine bond. 
In the exo approach a preliminary formation of a tight, stabilizing electrostatic complex 
EC3, very close in distance (2.5 Å).  
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Scheme 5.6: Energies transition state values for O-complexation, azadiene s-cis, exo approach  
 
A transition state originate from this electrostatic complex TS3 has an energy of 0.4 
kcalmol-1 higher than that of the corrisponding electrostatic complex. The azadiene 
skeleton is more twisted than in the previously observed transition states (18°) and, due to 
the coordination to the BF3, which increases the electrophilic character of the aldehyde 
carbon, the transition state is characterized by the presence of only one incipient bond 
between C4 and C5, as shown by the values of the bonds lenghts and bond orders (2.25 
Å, 0.29 e-), by the neat pyramidalization of C4 and C5 (150-160°) and by the long distance 
between C1 and O6 (3.2 Å). TS3, which has the geometry apt to directly form a ring, close 
to CY3 even though the incipient bond between C1 and O6 is failing in the transition 
states. All the attempts to find an acyclic intermediate failed, and a separation of the 
reactants or a cyclization to CY3 occurred. Therefore, even if only one incipient bond is 
formed in the transition state and the presence of a single transition state, the reaction 
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describe in Scheme 5.6 can be considered as one-step HDA-type reaction characterized 
by a high level of asynchronicity. 
In contrast to what is observed in the previous cases, the attack of the complexed 
formaldehyde on the s-trans form of the azadiene is now possible. In this case a 
preliminary formation of a stabilizing electrostatic complex (EC4) with a mean distance of 3 
Å between the two molecules also takes place, followed by bond formation between C4 
and C5. As many orientations of the two molecules are possible in the formation of the 
new bond, all the relevant geometries in discrete staggered conformations were examined, 
with BF3 endo or exo to the azadiene skeleton (dihedral angles B-O6-C5-C4 of +90° or –
90°, respectively). The results are shown in Scheme 5.7. 
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b
 
 
 Only two transition states were found (TS4a and TS5) with an energy 2.9 and 1.1 
kcalmol-1 higher than that of the electrostatic complex and showing only one net incipient 
bond between C4 and C5  (2.22 Å, 0.34 e- for TS4a and 2.21 Å, 0.32 e- for TS5). They are 
characterized by a different geometry around the incipient bond, with TS4a having the C-O 
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bond eclipsed to the C3-C4 bond (0.1°) and BF3 exo to the azdiene skeleton and TS5 
having the C-O bond in a gauche conformation with the C3-C4 bond (-69.5°) and BF3 endo 
to the azadiene skeleton. In both cases an acyclic aldol-like structure is formed (LI4 and 
LI5 in Scheme 5.7) due to the stabilization effect of the LA catalyst, which neutralizes the 
negative charge on the oxygen through the formation of a neat O-B single bond (2.21 Å, 
0.65 e-). The two structures present a different geometry that strongly affects their 
reactivity. In LI5 the BF3 and the SiH3 groups are on the same side of the molecule, with a 
stabilizing interaction between the silicon atom and one of the fluorine atoms (Si•••F 2.20 
Å). This geometry forces the C=N bond onto the other side of the C-O bond, with the 
consequence that the long distance between C1 and O6 (4.50 Å) prevent a further 
cyclization to CY3. In LI4, however, the BF3 and the SiH3 groups are on opposite side of 
the molecule and C1 and O6 are enough close (3.41 Å) and have the right geometry to 
allow cyclization to CY3. This happen to the transition state TS4b which is characterized 
by an incipient bond between C1 and O6 (2.50 Å, 0.11 e-). The presence of two transition 
states and an acyclic intermediate in path a of Scheme 5.7 allows us to consider this path 
as that of an aldolic two-step cyclization, which is competitive with the reaction paths 
describe in Scheme 5.6. the latter, however, is favored by the very low activation energy of 
its unique transition state.  
 
 
 A plot of the relative energy reation coordinates for the LA-catalyzed reaction paths 
(Fig. 5.1) shows that the N-complexation path is characterized by the highest activation 
energy. As a consequence, even if N-complexation is favored over O-complexation path 3 
and 4 (Fig. 5.1) are neatly favored. 
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Fig. 5.1: Path profile for LA_catalyzed reactions. 
  
 
At this point we should draw attention to the activation energy values that we found 
for the BF3 O-complexed, uncatalyzed, and BF3 N-complexed HDA reactions (0.4-0.8, 12.6 
and 16.4 kcal mol-19, which have the same trend of the LUMOdienophile-HOMOdiene energy 
difference (ΔE= 3.52, 5.04 and 6.20 eV, Table 5.2), thus confirming the effectiveness of 
FMO theory in predicting the reactivity of such systems. The different observed need for 
the presence of a Lewis acid catalyst to perform a cyclization8,19,61,62 can therefore be 
ascribe to the effect exerted on the frontier orbitals by the substituents. Accordingly, 
electron-donor substituents present on the azadiene substrate,61,62 which increase the 
azadiene HOMO energy,39 have the effect of decreasing the LUMOdienophile-HOMOdiene 
energy difference and the reaction proceeds without acid catalyst. The same effect may be 
observed when strong electrophilic aldehydes are used.62 In this case the decrease of the 
aldehyde LUMO energy39 allows the reaction to take place without a catalyst. Finally, with 
electron-withdrawing or neutral substituents present on the azadiene substrate8,19 the gap 
energy is higher and an LA catalyst is necessary in order for a reaction between the 
azadiene and the aldehyde moieties to take place. Under such conditions, in the absence 
of an acid catalyst, an electrocyclic conrotatory closure of the azadiene moiety is preferred, 
leading to a four-membered cyclic azetidinone.7,103 
 
Summarizing the results obtained we can conclude that the uncatalyzed cyclization 
is a classic hetero Diels-Alder reaction that occurs through a synchronous mechanism, as 
shown by the structure of the transition state. In the LA-catalyzed reaction BF3 can 
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coordinate to either the azadiene or the aldehyde moiety. In the first case, the reduced 
nucleophilicity of the azadiene strongly increases the energy activation of the HAD-type 
cyclization and makes this reaction path the less probable one, whereas in the second 
case the enhanced electrophilicity of the aldehyde leads to an easier cyclization, which 
can take place through an HAD asynchronous concerted mechanism or an aldolic two-
step one. The presence of substituents with a different stereoelectronic character can shift 
the reaction toward one or the other of these possible ways. 
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Chapter 6                                                      
 
 
 
Experimental 
 
 
 
6.1  General 
 
Melting points are uncorrected. 1H and 13C NMR spectra were recorded in CDCl3 on 
Varian VXR-200 or on Varian-Mercury 400 MHz spectrometers. Chemical shifts are 
reported in   scale and coupling constants (J) are reported in Hertz. Infrared spectra were 
recorded on a Perkin–Elmer Spectrum BX spectrophotometer in CHCl3. Mass spectra 
were recorded on Finnigan MAT GCQ instrument. Optical rotation measurements were 
carried out on a Perkin-Elmer 343 Polarimeter and specific rotation [ ]D20 was reported in 
deg per dm at the specified temperature and with the concentration [c] given in g per 100 
mL in CHCl3. Microwave mediated synthesis have been performed in a Prolabo 
Sinthewave 400 Microwave System and on  
Solvents were distilled according to standard procedures before use and were stored on 
molecular sieves (4 Angstrom) and they have been checked at Karl-Fisher apparatus 
showing the presence of less then 20 ppm of water. 
 
 
6.2 5-Halol-1,3-oxazinan-4-ones preparations 
 
General procedure for the preparation of azadiene (47). GP1 
1 mL of benzaldehyde 44 (1 mmol) was added to a solution of LiHMDS (1.1 mL of 1 M sol 
in THF) and heptane (5 mL) at 0°C under inert atmosphere. The reaction mixture was 
stirred at 0°C for 1 h. IR analysis confirmed the formation of silylimine 45 ( CN=1655 cm-1). 
TMSCl (0.14 mL, 1 mmol) was added in one portion and after stirring for 10 min at 0°C the 
mixture was allowed to stir for 1 h at rt. A white precipitate formed. The mixture was cooled 
at 0°C, triethylamine (0.3 mL, 2 mmol) was added in one portion and after 5 min a solution 
of halo-acid halide 46 (1 mmol) in 5 mL of heptane was added. Stirring was maintained for 
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2 h and precipitate appeared. The mixture was filtered through Celite under argon and the 
solvent was removed in vacuo to afford 47 as an oil, which was analyzed by 1H NMR and 
13C NMR spectroscopy. 
 
1-Chloro-2-trimethylsilyloxy-3-aza-4-phenylbutan-1,3-diene 47a. Prepared according 
GP1 starting from benzaldehyde and chloro acetylchloride. 1H NMR (400 MHz, CDCl3): 
8.39 (s, 1H), 7.81 (m, 2H), 7.45 (m, 3H), 6.00 (s, 1H), 0.35 (s, 9H); 13C NMR (100 MHz, 
CDCl3): 155.1, 153.5, 135.7, 131.3, 128.7, 101.3, 0.6.  
 
1-Bromo-2-trimethylsilyloxy-3-aza-4-phenylbutan-1,3-diene 47b. Prepared according 
GP1 starting from benzaldehyde and bromo acetylbromide. 1H NMR (400 MHz, CDCl3): 
8.40 (s, 1H), 7.80 (m, 2H), 7.44 (m, 3H), 5.93 (s, 1H), 0.37 (s, 9H); 13C NMR (100 MHz, 
CDCl3): 160.4, 155.6, 135.5, 131.3, 128.8,128.6, 88.0, 0.9. 
 
1-Iodo-2-trimethylsilyloxy-3-aza-4-phenyl-butan-1,3-diene 47c. Prepared according 
GP1 starting from benzaldehyde and iodo acetyl chloride. 1H NMR (400 MHz, CDCl3): 8.37 
(s, 1H), 7.78 (m, 2H), 7.44 (m, 3H), 5.56 (s, 1H), 0.37 (s, 9H); 13C NMR (100 MHz, CDCl3): 
159.2, 156.8, 135.1, 131.6, 128.9,128.7, 92.6, 1.1. 
 
General procedure for the preparation of perhydrooxazin-4-ones 49 and 50. GP2 
Azadiene 47 (1 mmol), prepared as reported above, was dissolved in anhydrous CH2Cl2 
(20 mL) and cooled at -78°C. Aldehyde 48 (1 mmol) dissolved in CH2Cl2 (2 mL) was added 
followed by a very slow addition of BF3 etherate (0.12 mL, 1 mmol) in hexane (10 mL). The 
solution was stirred overnight while the temperature was allowed to reach rt. The mixture 
was poured into saturated aqueous NaHCO3 and extracted with CH2Cl2. The organic 
layers were dried and the solvent was removed in vacuo. The reaction mixture was 
purified by flash chromatography on silica gel, eluting with cyclohexane/ethyl acetate 
70/30. Yields and diastereomeric ratio are reported in Tab. 3.2. 
 
(2R*,5R*,6S*)-5-Chloro-6-methyl-2-phenyl-[1,3]-oxazinan-4-one (49a). Prepared acco- 
rding GP2 starting from azadiene 47a and acetaldehyde. 1H NMR (400 MHz, CDCl3): 7.48 
(m, 2H), 7.41 (m, 3H), 6.67 (bs, 1H), 5.77 (s, 1H), 5.27 (dq,1H, J=6.0, 2.4 Hz), 4.16 (d, 1H, 
J=2.4 Hz), 1.45 (d, 3H,J=6.0 Hz); 13C NMR (100 MHz, CDCl3): 165.7, 137.0,130.1, 128.8, 
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126.9, 85.9, 72.9, 57.1, 17.8; IR (cm-1): 3395,1686; MS m/z: 226, 224, 148, 146, 105, 83. 
Anal. calcd for C11H12ClNO2: C 58.54; H 5.36. Found: C 58.44; H 5.37. 
 
(2R*,5R*,6S*)-5-Bromo-6-methyl-2-phenyl-[1,3]-oxazinan-4-one (49b). Prepared acco-
rding GP2 starting from azadiene 47b and acetaldehyde. Mp=156–157 °C; 1H NMR(400 
MHz, CDCl3): 7.50 (m, 2H), 7.43 (m, 3H), 6.29 (bs,1H), 5.84 (s, 1H), 4.29 (d, 1H, J=2.0 Hz), 
4.04 (dq, 1H, J=2.0, 6.0 Hz), 1.43 (d, 3H, J=6.0 Hz); 13C NMR (100 MHz,CDCl3): 166.4, 
137.2, 130.3, 129.0, 127.1, 86.0, 72.4, 48.8,19.6; IR (cm-1) 3395, 1685; MS m/z: 270, 268, 
149, 122, 105, 77. Anal. calcd for C11H12BrNO2: C 48.91; H 4.48.Found: C 48.98; H 4.50. 
 
(2R*,5R*,6S*)-5-Iodo-6-methyl-2-phenyl-[1,3]oxazinan-4-one (49c). Prepared according 
GP2 starting from azadiene 47c and acetaldehyde. 1H NMR (400 MHz, CDCl3): 7.51 
(m,2H), 7.40 (m, 3H), 6.54 (bs, 1H), 5.93 (s, 1H), 4.49 (d, 1H,J=2.4 Hz), 3.12 (dq, 1H, 
J=6.0, 2.4 Hz), 1.35 (d, 3H, J=6.0 Hz); 13C NMR (100 MHz, CDCl3): 168.1, 137.3, 
129.9,128.7, 126.9, 85.9, 71.9, 30.1, 23.5; IR (cm-1): 3395, 1677; MS m/z: 316, 189, 174, 
168, 147, 105, 77. Anal. calcd forC11H12INO2: C 41.66; H 3.81. Found: C 41.75; H 3.84.  
 
(2S*,5R*,6S*)-5-Iodo-6-methyl-2-phenyl-[1,3]oxazinan-4-one (50c). Prepared according 
GP2 starting from azadiene 47c and acetaldehyde. 1H NMR (400 MHz, CDCl3): 7.43 (m, 
6H), 6.10 (s, 1H), 4.51 (d, 1H, J=2.4 Hz), 3.09 (dq, 1H, J=6.0, 2.4 Hz), 1.23 (d, 3H, J=6.0 
Hz); 13C NMR (100 MHz, CDCl3): 168.5, 138.5, 129.2, 128.7, 126.4, 82.2, 65.7, 30.1,22.9; 
IR (cm-1): 3395, 1677; MS m/z: 316, 189, 174, 168,147, 105, 77. Anal. calcd for 
C11H12INO2: C 41.66; H 3.81.Found: C 41.80; H 3.84. 
 
(2R*,5R*,6S*)-5-Bromo-6-propyl-2-phenyl-[1,3]-oxazinan-4-one (49d). Prepared acco-
rding GP2 starting from azadiene 47b and butyraldehyde. 1H NMR (400 MHz, CDCl3): 7.70 
(bs, 1H), 7.48 (m, 2H), 7.38 (m, 3H), 5.77 (s, 1H), 4.19 (d,1H, J=2.0 Hz), 3.74 (m, 1H), 1.42 
(m, 1H), 1.29 (m, 1H),1.20 (m, 2H), 0.95 (t, 3H, J=7.2 Hz); 13C NMR (100 MHz, CDCl3): 
167.0, 137.4, 129.8, 128.7, 126.9, 85.7, 75.8, 47.4,35.2, 17.9, 13.7; IR (cm-1) 3395, 1682; 
MS m/z: 298, 296, 254, 252, 218, 175, 146, 122, 105, 77. Anal. calcd for C13H16BrNO2: C 
52.36; H 5.41. Found: C 52.48; H 5.44.  
 
(2S*,5R*,6S*)-5-Bromo-6-propyl-2-phenyl-[1,3]-oxazinan-4-one (50d). Prepared acco-
rding GP2 starting from azadiene 47b and butyraldehyde.1H NMR (400 MHz, CDCl3): 8.15 
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(bs, 1H), 7.42 (m, 5H), 6.12 (s, 1H), 4.23 (d, 1H, J=2.4 Hz), 3.65 (m, 1H), 1.75 (m, 1H), 
1.46 (m, 1H), 1.32 (m, 1H), 1.19 (m, 1H), 0.78 (t, 3H, J=7.2 Hz); 13C NMR (100 MHz 
,CDCl3): 167.2, 138.0, 129.1, 128.6, 126.4, 82.2, 69.1, 50.0, 35.1, 18.0, 13.7; IR (cm-1) 
3399, 1682; MS m/z: 298, 296,254, 252, 146, 105, 77. Anal. calcd for C13H16BrNO2: 
C52.36; H 5.41. Found: C 52.56; H 5.44. 
 
(2R*,5R*,6S*)-5-Bromo-6-heptyl-2-phenyl-[1,3]-oxazinan-4-one (49e). Prepared acco-
rding GP2 starting from azadiene 47b and octaldehyde.1H NMR (400 MHz, CDCl3): 7.50 
(m, 2H), 7.40 (m, 3H), 7.11 (bs, 1H), 5.79 (s, 1H), 4.22 (d, 1H, J=1.6 Hz), 3.74 (m, 1H), 
1.83 (m, 1H), 1.63 (m, 1H),1.28 (m, 10H), 0.87 (t, 3H, J=7.2 Hz); 13C NMR (100 MHz, 
CDCl3): 166.8, 137.4, 129.9, 128.8, 127.0, 85.9, 76.2, 47.5, 33.2, 31.6, 29.2, 29.0, 24.6, 
22.5, 14.0; IR(cm-1); 3396, 1682; MS m/z: 355, 353, 293, 291, 273. Anal.calcd for 
C17H24BrNO2: C 57.63; H 6.83. Found: C 57.73; H 6.88.  
 
(2R*,5R*,6S*)-5-Bromo-6-isopropyl-2-phenyl-[1,3]oxazinan-4-one (49g). Prepared 
according GP2 starting from azadiene 47b and isopropylaldehyde.1H NMR (400 MHz, 
CDCl3):7.50 (m, 2H), 7.43 (m, 3H), 6.58 (bs, 1H), 5.79 (s, 1H), 4.37(d, 1H, J=2.0 Hz), 3.27 
(dd, 1H, J=2.0, 9.2 Hz), 2.06 (m,1H), 1.07 (d, 3H, J=6.8 Hz), 0.92 (d, 3H, J=6.4 Hz); 
13CNMR (100 MHz, CDCl3): 166.6, 137.4, 130.1, 128.9, 127.0, 86.2, 82.2, 46.0, 30.9, 18.9, 
17.1; IR (cm-1): 3401, 1681; MS m/z: 299, 298, 297, 296, 256, 254, 228, 226, 216, 146,132, 
107. Anal. calcd for C13H16BrNO2: C 52.36; H 5.41.Found: C 52.18; H 5.43. 
 
(2S*,5R*,6S*)-5-Bromo-6-isopropyl-2-phenyl-[1,3]oxazinan-4-one (50g). Prepared 
according GP2 starting from azadiene 47b and isopropylaldehyde. 1H NMR (400 MHz, 
CDCl3):7.40 (m, 6H), 6.14 (s, 1H), 4.28 (d, 1H, J=2.0 Hz), 3.05 (dd, 1H, J=2.0, 9.2 Hz), 1.99 
(m, 1H), 0.85 (d, 3H, J=6.4 Hz), 0.76 (d, 3H, J=6.6 Hz); 13C NMR (100 MHz, CDCl3): 167.4, 
137.9, 129.0, 128.4, 126.6, 82.3, 74.6, 46.7,31.0, 19.0, 17.1; IR (cm-1): 3401, 1681; MS 
m/z: 299, 298, 297, 296, 256, 254, 228, 226, 216, 146, 132, 107. Anal.calcd for 
C13H16BrNO2: C 52.36; H 5.41. Found: C 52.46; H5.45.  
 
(2R*,5R*,6S*)-5-Bromo-6-tert-butyl-2-phenyl-[1,3]oxazinan-4-one (49h). Prepared 
according GP2 starting from azadiene 47b and pivalaldehyde. 1H NMR (400 MHz, 
CDCl3):7.53 (m, 2H), 7.42 (m, 3H), 6.69 (bs, 1H), 5.77 (s, 1H), 4.37 (d, 1H, J=0.8 Hz), 3.53 
(d, 1H, J=0.8 Hz), 1.09 (s, 9H); 13C NMR (100 MHz, CDCl3): 167.1, 137.7, 129.9, 128.8, 
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126.9, 86.3, 82.5, 43.9, 34.9, 26.4; IR (cm-1): 3401, 1686; MS m/z: 313, 311, 257, 255, 177. 
Anal. calcd for C14H18BrNO2: C 53.86; H 5.81. Found: C 53.98; H 5.85. 
 
(2S*,5R*,6S*)-5-Bromo-6-tert-butyl-2-phenyl-[1,3]oxazinan-4-one (50h). Prepared 
according GP2 starting from azadiene 47b and pivalaldehyde. 1H NMR (400 MHz, CDCl3): 
7.42 (m, 5H), 7.16 (bs, 1H), 6.23 (s, 1H), 4.34 (d, 1H, J=1.6 Hz), 3.45 (d, 1H, J=1.6 Hz), 
0.90 (s, 9H); 13C NMR (100 MHz, CDCl3): 167.7, 137.6, 129.4, 128.6, 126.9, 82.4, 75.4, 
44.3, 34.6, 26.3; IR (cm-1): 3401, 1686; MS m/z: 313,311, 257, 255, 177. Anal. calcd for 
C14H18BrNO2: C 53.86;H 5.81. Found: C 53.98; H 5.87.   
 
(2R*,5R*,6S*)-5-Bromo-2,6-diphenyl-[1,3]oxazinan-4-one (49i). Prepared according GP2 
starting from azadiene 47b and benzaldehyde. Mp: 173–175 °C; 1H NMR (400 
MHz,CDCl3): 7.62–7.34 (m, 10H), 6.65 (bs, 1H), 6.02 (s, 1H), 5.17 (d, 1H, J=2.0 Hz), 4.54 
(d, 1H, J=2.0 Hz); 13C NMR(100 MHz, CDCl3): 166.4, 137.2, 136.5, 130.3, 128.9, 128.3, 
127.2, 125.5, 86.1, 77.1, 47.9; IR (cm-1): 3396, 1682; MS m/z: 332, 330, 252, 227, 225, 
211, 109, 184, 182,146, 118, 77. Anal. calcd for C16H14BrNO2: C 57.85; H4.25. Found: C 
57.71; H 4.23.  
 
(2S*,5R*,6S*)-5-Bromo-2,6-diphenyl-[1,3]oxazinan-4-one (50i).  
Prepared according GP2 starting from azadiene 47b and benzaldehyde. Mp: 127–129 °C; 
1H NMR (400 MHz,CDCl3): 8.20 (bs, 1H), 7.52–7.33 (m, 10H), 6.33 (s, 1H), 5.07 (d, 1H, 
J=2.0 Hz), 4.56 (d, 1H, J=2.0 Hz); 13C NMR(100 MHz, CDCl3): 167.1, 137.7, 136.5, 129.5, 
128.9, 128.3, 128.2, 126.6, 125.7, 82.4, 71.3, 47.7; IR (cm-1): 3396, 1682; MS m/z: 332, 
330, 252, 227, 225, 211, 209, 146,131, 118, 77. Anal. calcd for C16H14BrNO2: C 57.85; 
H4.25. Found: C 57.98; H 4.27. 
 
(2R*,5R*,6S*)-5-Bromo-6-p-nitrophenyl-2-phenyl-[1,3]oxazinan-4-one (49j). Prepared 
according GP2 starting from azadiene 47b and p-NO2-benzaldehyde. 1H NMR (400 MHz, 
CDCl3): 8.23 (d, 2H, J=6.7 Hz), 7.59 (m, 2H), 7.52 (d, 2H, J=6.7 Hz), 7.48 (m, 3H), 6.83 (bs, 
1H), 6.04 (s, 1H), 5.28 (d,1H, J=2.0 Hz), 4.57 (d, 1H, J=2.0 Hz); 13C NMR(100 MHz, 
CDCl3): 165.7, 147.8, 143.5, 136.7, 130.5,129.0, 127.2, 126.6, 123.6, 86.2, 76.5, 46.6; IR 
(cm-1): 3395, 1682; MS m/z: 377, 375, 297, 256, 254, 176, 146, 105,78. Anal. calcd for 
C16H13BrN2O4: C 50.95; H 3.47. Found:C 51.15; H 3.50. 
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(2S*,5R*,6S*)-5-Bromo-6-p-nitrophenyl-2-phenyl-[1,3]oxazinan-4-one (50j). Prepared 
according GP2 starting from azadiene 47b and p-NO2-benzaldehyde. 1H NMR (400 MHz, 
CDCl3):8.24 (d, 2H, J=6.6 Hz), 7.50 (d, 2H, J=6.6 Hz), 7.43 (m,5H), 7.22 (bs, 1H), 6.37 (s, 
1H), 5.17 (d, 1H, J=2.4 Hz),4.54 (d, 1H, J=2.4 Hz); 13C NMR (100 MHz, CDCl3):165.9, 
147.8, 143.7, 137.2, 129.8, 129.1, 126.7, 126.5, 123.6, 82.6, 70.9, 46.5; IR (cm-1): 3395, 
1682; MS m/z: 377, 375, 297, 256, 254, 176, 146, 105, 78. Anal. calcd forC16H13BrN2O4: C 
50.95; H 3.47. Found: C 51.08; H 3.49.  
 
 
6.3  α ,β  Epoxy acids preparations 
 
General procedure for the preparation of N-t-Boc-oxazinan-4-ones 106 and 107. GP3  
Perhydroxazinones 49 and 50 prepared as reported above (1 mmol), were dissolved in 
CH2Cl2 (10 mL); Et3N (1.2 mmol), DMAP (cat) and di-tert-butyldicarbonate (2 mmol) were 
added. The mixture was stirred at rt until the starting material disappeared (3 h) then it was 
poured into saturated aqueous NH4Cl and extracted with CH2Cl2.The organic layers were 
dried and the solvent was removed in vacuo. The residue was purified by flash 
chromatography on silica gel, eluting with cyclohexane/ethyl acetate 90/10.  
 
(2R*,5R*,6S*)-5-Bromo-6-methyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid tert-
butyl ester (106b). Prepared according GP3 starting from oxazinan-2-one 49b. Y= 80%; 
Mp=174–176 °C; 1H NMR (400 MHz, CDCl3): 7.50 (m,2H), 7.40 (m, 3H), 6.13 (s, 1H), 4.37 
(d, 1H, J=2.0 Hz), 4.03 (dq, 1H, J=6.0, 2.0 Hz), 1.40 (d, 3H, J=6.0 Hz), 1.14(s, 9H); 13C 
NMR (100 MHz, CDCl3): 164.4, 149.9, 137.6,129.8, 128.6, 127.5, 90.2, 84.4, 71.3, 49.7, 
27.2, 19.1; IR(cm-1): 1776, 1735; MS m/z: 370, 368, 316, 314, 298, 296, 270, 268, 190, 
122, 105, 77. Anal. calcd for C16H20BrNO4:C 51.90; H 5.44. Found: C 52.07; H 5.46. 
 
(2R*,5R*,6S*)-5-Bromo-6-propyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid tert-
butyl ester (106d). Prepared according GP3 starting from oxazinan-2-one 49d. Y= 90%; 
1H NMR (400 MHz, CDCl3): 7.48 (m, 2H), 7.37 (m, 3H),6.09 (s, 1H), 4.38 (d, 1H, J=1.2 Hz), 
3.80 (m, 1H), 1.83–1.32 (m, 4H), 1.11 (s, 9H), 0.92 (t, 3H, J=7.2 Hz); 13CNMR (100 MHz, 
CDCl3): 164.4, 149.8, 137.6, 129.7, 128.5, 127.4, 90.3, 85.1, 75.0, 48.3, 34.8, 27.4, 17.8, 
13.7; IR(cm-1): 1776, 1734; MS m/z: 344, 342, 326, 324, 298, 296, 218, 122, 105, 77. Anal. 
calcd for C18H24BrNO4: C 54.28; H6.07. Found: C 54.48; H 6.10.  
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(2R*,5R*,6S*)-5-Bromo-6-hepthyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid 
tert-butyl ester (106e). Prepared according GP3 starting from oxazinan-2-one 49e. Y= 
98%; 1HNMR (400 MHz, CDCl3): 7.49 (m, 2H), 7.39 (m, 3H), 6.11(s, 1H), 4.40 (d, 1H, J=1.6 
Hz), 3.79 (m, 1H), 1.81 (m, 1H), 1.61 (m, 1H), 1.26 (m, 10H), 1.13 (s, 9H), 0.86 (t, 3H, 
J=6.8 Hz); 13C NMR (100 MHz, CDCl3): 164.5, 149.7, 137.7, 129.5, 128.6, 127.4, 90.3, 
84.3, 75.3, 48.3, 32.7, 31.6, 29.1, 28.9, 27.1, 24.5, 22.5, 14.0; IR (cm-1): 1777, 1738; 
MSm/z: 400, 398, 382, 380, 354, 352, 274, 105. Anal. calcd forC22H32BrNO4: C 58.15; H 
7.10. Found: C 58.10; H 7.08.  
 
(2R*,5R*,6S*)-5-Bromo-6-isopropyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid 
tert-butyl ester(106g). Prepared according GP3 starting from oxazinan-2-one 49g. Y= 
98%; 1H NMR (400 MHz, CDCl3): 7.50 (m, 2H), 7.40 (m,3H), 6.09 (s, 1H), 4.49 (d, 1H, 
J=1.6 Hz), 3.29 (dd, 1H, J=1.6, 9.2 Hz), 2.03 (m, 1H), 1.14 (s, 9H), 1.05 (d, 3H, J=6.8 Hz), 
0.90 (d, 3H, J=6.8 Hz); 13C NMR (100 MHz, CDCl3): 164.6, 149.7, 137.8, 129.8, 128.6, 
127.4, 90.5, 84.3, 81.1, 46.9, 30.6, 27.2, 18.7, 17.1; IR (cm-1): 1776, 1726; MS m/z: 326, 
324, 298, 296, 218, 176, 132, 122, 105. Anal.calcd for C18H24BrNO4: C 54.28; H 6.07. 
Found: C 54.48; H 6.09.  
 
(2S*,5R*,6S*)-5-Bromo-6-isopropyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid 
tert-butyl ester(107g). Prepared according GP3 starting from oxazinan-2-one 50g. Y= 
97%; Mp: 155–156 °C; 1H NMR (400 MHz, CDCl3): 7.38 (m, 3H), 7.30 (m, 2H), 6.68 (s, 
1H), 4.31 (d, 1H, J=2.0 Hz), 3.02 (dd, 1H, J=2.0, 9.2 Hz), 1.97 (m, 1H), 1.40 (s, 9H), 0.82 
(d, 3H, J=6.4 Hz), 0.74 (d, 3H, J=6.4 Hz); 13C NMR(100 MHz, CDCl3): 165.5, 150.1, 137.6, 
129.1, 128.6, 126.5, 86.1, 84.2, 74.9, 48.6, 30.9, 27.7, 18.6, 16.7; IR(cm-1): 1776, 1726; MS 
m/z: 398, 344, 342, 326, 324, 298, 296, 218, 176, 132, 122, 105. Anal. calcd for 
C18H24BrNO4:C 54.28; H 6.07. Found: C 54.39; H 6.09. 
 
(2R*,5R*,6S*)-5-Bromo-6-tert-butyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid 
tert-butyl ester(106h). Prepared according GP3 starting from oxazinan-2-one 49h. Y= 
80%; 1H NMR (400 MHz, CDCl3): 7.53 (m, 2H), 7.40 (m,3H), 6.06 (s, 1H), 4.50 (d, 1H, 
J=2.0 Hz), 3.52 (d, 1H, J=2.0 Hz), 1.14 (s, 9H), 1.05 (s, 9H); 13C NMR (100 MHz, CDCl3): 
164.8, 149.9, 137.8, 129.6, 128.4, 127.7, 90.8, 84.2, 81.4, 44.8, 34.9, 27.2, 26.5; IR (cm-1): 
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1774, 1726; MSm/z: 413, 411, 358, 356, 340, 338, 314, 312, 311, 310, 256, 254, 232, 146, 
132, 106. Anal. calcd for C19H26BrNO4: C55.35; H 6.36. Found: C 55.55; H 6.38. 
 
(2S*,5R*,6S*)-5-Bromo-6-tert-butyl-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic acid 
tert-butyl ester(107h). Prepared according GP3 starting from oxazinan-2-one 50h. Y= 
85%; Mp: 162–165 °C; 1H NMR (400 MHz, CDCl3): 7.36(m, 3H), 7.32 (m, 2H), 6.69 (s, 1H), 
4.36 (d, 1H, J=2.0 Hz), 3.32 (d, 1H, J=2.0 Hz), 1.37 (s, 9H), 0.86 (s, 9H); 13CNMR (100 
MHz, CDCl3): 165.7, 150.0, 137.3, 129.1, 128.5, 126.6, 86.2, 83.1, 74.8, 46.6, 34.6, 27.7, 
26.3; IR (cm-1):1774, 1726; MS m/z: 413, 411, 358, 356, 340, 338, 314, 312, 311, 310, 256, 
254, 232, 146, 132, 106. Anal. calcd for C19H26BrNO4: C 55.35; H 6.36. Found: C 55.45; H 
6.39. 
 
(2R*,5R*,6S*)-5-Bromo-4-oxo-2,6-diphenyl-[1,3]-oxazinane-3-carboxylic acid tert-butyl 
ester (106i). Prepared according GP3 starting from oxazinan-2-one 49i. Y= 67%; Mp:167–
170 °C; 1H NMR (400 MHz, CDCl3): 7.58 (m, 2H), 7.44 (m, 3H), 7.32 (m, 5H), 6.30 (s, 1H), 
5.15 (d, 1H, J=2.0 Hz), 4.62 (d, 1H, J=2.0 Hz), 1.18 (s, 9H); 13C NMR(100 MHz, CDCl3): 
164.4, 149.9, 137.5, 135.8, 129.9, 128.5, 128.4, 128.3, 127.7, 125.5, 90.3, 84.5, 76.0, 48.9, 
27.2; IR (cm-1): 1777, 1735; MS m/z: 332, 330, 252, 146, 31, 105, 77. Anal. calcd for 
C21H22BrNO4: C 58.34; H5.13. Found: C 58.44; H 5.15.  
 
(2S*,5R*,6S*)-5-Bromo-4-oxo-2,6-diphenyl-[1,3]oxazinane-3-carboxylic acid tert-butyl 
ester (107i). Prepared according GP3 starting from oxazinan-2-one 50i. Y= 69%; Mp: 180–
182 °C; 1H NMR (400 MHz, CDCl3): 7.38–7.25(m, 10H), 6.89 (s, 1H), 4.92 (d, 1H, J=2.0 
Hz), 4.53 (d, 1H,J=2.0 Hz), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3):165.3, 150.1, 137.2, 
136.3, 129.3, 128.9, 128.3, 128.2, 126.5, 125.4, 86.1, 84.5, 70.7, 49.9, 27.7; IR (cm-1): 
1777, 1735; MS m/z: 332, 330, 252, 227, 225, 146, 131, 105, 77.Anal. calcd for 
C21H22BrNO4: C 58.34; H 5.13. Found: C58.45; H 5.15.  
 
(2R*,5R*,6S*)-5-Bromo-6-(4-nitro-phenyl)-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic 
acid tert-butylester (106j). Prepared according GP3 starting from oxazinan-2-one 49j. Y= 
35%; 1H NMR (400 MHz, CDCl3): 8.22 (d, 2H, J=6.7 Hz), 7.69 (m, 3H), 7.47 (m, 4H), 6.33 
(s, 1H), 5.29 (d,1H, J=2.0 Hz), 4.65 (d, 1H, J=2.0 Hz), 1.18 (s, 9H); 13CNMR (100 MHz, 
CDCl3): 163.6, 149.6, 147.9, 142.7, 137.0, 130.2, 128.7, 127.7, 126.5, 123.6, 90.3, 84.9, 
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75.4, 47.7, 27.2; IR (cm-1): 1778, 1735; MS m/z: 477, 475, 377, 375,297, 256, 254. Anal. 
calcd for C21H21BrN2O6: C 52.84; H4.43. Found: C 52.80; H 4.41.  
 
(2S*,5R*,6S*)-5-Bromo-6-(4-nitro-phenyl)-4-oxo-2-phenyl-[1,3]oxazinane-3-carboxylic 
acid tert-butylester (107j). Prepared according GP3 starting from oxazinan-2-one 50j. Y= 
40%; 1H NMR (400 MHz, CDCl3): 8.23 (d, 2H, J=6.6 Hz), 7.71 (d, 2H, J=6.6 Hz), 7.53–7.40 
(m, 5H), 6.91 (s,1H), 5.12 (d, 1H, J=2.0 Hz), 4.58 (d, 1H, J=2.0 Hz), 1.43 (s, 9H); 13C NMR 
(100 MHz, CDCl3): 163.7, 149.9, 147.6, 142.8, 136.5, 130.0, 128.7, 127.6, 126.4, 123.5, 
86.4, 84.78, 69.9, 48.6, 27.7; IR (cm-1): 1778, 1735; MS m/z: 477, 475, 377, 375, 297, 256, 
254. Anal. calcd for C21H21BrN2O6: C52.84; H 4.43. Found: C 52.94; H 4.44.  
 
 
General procedure for the preparation of epoxide 108 and 109. GP4  
Method A. N-t-Boc-perhydroxazinone 106 and/or 107 (1 mmol) were dissolved in THF (10 
mL) and LiOH 1 M (3 mmol) was added. The mixture was stirred at rt until TLC showed the 
disappearance of the starting material. The crude mixture was concentrated to half of the 
starting volume, water (5 mL) was added and the mixture was extracted with ether. The 
aqueous layers were made acidic by HCl 1 N at 0°C. Extraction with ethyl acetate and 
removal of the solvent, purification of the crude mixture by short flash chromatography 
(eluted with toluene/CH3COOH 4/1) yielded the epoxy acids 96 and 97. The yields are 
reported in Table 4.1. 
Method B. N-t-Boc-perhydroxazinone 106 or 107 (1 mmol) were dissolved in a solution of 
ethanol/water 5/1 (10 mL). LiOH(5 mmol) and H2O2 30% (5 mmol) were added. The mixture 
was stirred at rt until TLC showed the disappearance of the starting material. The crude 
mixture was concentrated to half of the starting volume, water (5 mL) was added and the 
mixture was extracted with ether. The aqueous layers were made acidic by HCl 1 N at 0°C. 
Extraction with ethylacetate and removal of the solvent, followed by purificationof the crude 
mixture by short flash chromatography (eluted with toluene/CH3COOH 4/1) yielded the 
epoxyacids 108 and 109. The yields are reported in Table 4.1. Analytical data for known 
compounds are in ageement with those reported in literature.  
 
(2S*,3S*)-3-Methyl-oxirane-2-carboxylic acid (108b). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 106b, Method A and B. 1H NMR (400 MHz, CDCl3): 7.38 (bs, 
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1H), 3.56 (d, 1H, J=4.8 Hz), 3.36 (dq, 1H, J=4.8, 5.2 Hz), 1.43 (d, 3H, J=5.2 Hz); 13C NMR 
(100 MHz, CDCl3): 173.30, 54.02, 52.67, 12.89; IR (cm-1): 3580, 1736. 
 
(2S*,3R*)-3-Methyl-oxirane-2-carboxylic acid (109b). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 107b, Method A and B. 1H NMR (400 MHz, CDCl3): 7.40 (bs, 
1H), 3.28 (dq, 1H, J=2.0, 5.2 Hz), 3.22 (d, 1H, J=2.0 Hz), 1.42 (d,3H, J=5.2 Hz); 13C NMR 
(100 MHz, CDCl3): 174.34, 55.08, 53.43, 17.12; IR (cm-1): 3580, 1736. 
 
(2S*,3S*)-3-Propyl-oxirane-2-carboxylic acid (108d). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 106d, Method A. 1H NMR (400 MHz, CDCl3): 3.57 (d, 1H, 
J=4.4 Hz), 3.24(m, 1H,), 1.74–1.42 (m, 4H), 0.97 (t, 3H, J=7.2 Hz); 13CNMR (100 MHz, 
CDCl3): 172.78, 58.06, 52.88, 29.28, 19.46, 13.74.  
 
(2S*,3R*)-3-Propyl-oxirane-2-carboxylic acid (109d). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 107d, Method A. 1H NMR (400 MHz, CDCl3): 6.65 (bs, 1H), 
3.26(d, 1H, J=1.6 Hz), 3.18 (m, 1H), 1.65–1.20 (m, 4H), 0.98 (t,3H, J=7.2 Hz); 13C NMR 
(100 MHz, CDCl3): 174.06, 58.80, 52.95, 29.69, 18.99, 13.73. 
 
(2S*,3S*)-3-Heptyl-oxirane-2-carboxylic acid (108e). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 106e, Method A. 1H NMR (400 MHz, CDCl3): 8.05 (bs, 1H), 
3.57 (d, 1H, J=4.8 Hz), 3.23 (m, 1H), 1.62 (m, 2H), 1.26 (m, 10H), 0.87 (t, 3H, J=7.2 Hz); 
13C NMR (100 MHz, CDCl3): 173.57, 58.25, 52.66, 31.41, 29.16, 28.19, 27.28, 26.11, 
22.57, 14.05.  
 
(2S*,3R*)-3-Heptyl-oxirane-2-carboxylic acid (109e). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 107e, Method A. 1H NMR (400 MHz, CDCl3): 8.10 (bs, 1H), 
3.25(d, 1H, J=2.0 Hz), 3.19 (m, 1H), 1.65 (m, 2H), 1.31 (m,10H), 0.87 (t, 3H, J=7.2 Hz); 13C 
NMR (100 MHz,CDCl3): 174.62, 59.05, 52.66, 31.66, 29.07, 28.16, 27.26, 25.62, 22.58, 
14.05. 
 
(2S*,3S*)-3-Isopropyl-oxirane-2-carboxylic acid (108g). Prepared according GP4 
starting from N-t-Boc-oxazinan-2-one 106g or 107g or 106g+107g, Method A. 1H NMR 
(400 MHz, CDCl3): 3.57 (d, 1H, J=4.4 Hz), 2.90 (dd, 1H, J=4.4, 9.2 Hz), 1.64 (m, 1H), 1.13 
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(d, 3H, J=6.8 Hz), 0.95 (d, 3H, J=6.8 Hz); 13C NMR(100 MHz, CDCl3): 172.58, 63.39, 
53.14, 27.10, 20.09, 18.30. 
 
(2S*,3R*)-3-Isopropyl-oxirane-2-carboxylic acid (109g). Prepared according GP4 
starting from N-t-Boc-oxazinan-2-one 106g or 107g or 106g+107g, Method A.1H NMR (400 
MHz, CDCl3): 3.28 (d, 1H, J=2.0 Hz), 2.30 (dd, 1H, J=2.0, 6.8 Hz), 1.45 (m, 1H), 1.03 (d, 
3H, J=6.8 Hz), 0.99 (d, 3H, J=6.8 Hz); 13C NMR(100 MHz, CDCl3): 173.90, 63.75, 51.79, 
30.06, 18.67, 18.01.  
 
(2S*,3S*)-3-tert-Butyl-oxirane-2-carboxylic acid (108h). Prepared according GP4 
starting from N-t-Boc-oxazinan-2-one 106h+107h, Method B. 1H NMR (400 MHz, CDCl3): 
3.51 (d, 1H, J=4.8 Hz), 3.00 (d, 1H, J=4.8 Hz), 1.02 (s, 9H); 13C NMR(100 MHz, CDCl3): 
172.10, 66.55, 53.69, 31.86, 25.72. 
 
(2S*,3R*)-3-tert-Butyl-oxirane-2-carboxylic acid (109h). Prepared according GP4 
starting from N-t-Boc-oxazinan-2-one 106h+107h, Method B. 1H NMR (400 MHz, CDCl3): 
3.35 (d, 1H, J=2.0 Hz), 3.02 (d, 1H, J=2.0 Hz), 0.96 (s, 9H); 13C NMR(100 MHz, CDCl3): 
174.56, 66.53, 49.98, 31.04, 25.52.  
 
(2S*,3S*)-3-Phenyl-oxirane-2-carboxylic acid (108i). Prepared according GP4 starting 
from N-t-Boc-oxazinan-2-one 106i+107i, Method A. 1H NMR (400 MHz, CDCl3): 7.36 (m, 
5H), 4.32 (d, 1H, J=4.8 Hz), 3.87 (d, 1H, J=4.8 Hz); 13C NMR (100 MHz, CDCl3): 171.51, 
132.02, 128.47, 128.12, 126.64, 57.87, 55.38.  
 
(2S*,3S*)-3-p-nitrophenyl-oxirane-2 carboxylic acid (108j). Prepared according GP4 
starting from N-t-Boc-oxazinan-2-one 106j+107j, Method B. 1H NMR (400 MHz, CDCl3): 
8.30 (d, 2H, J=6.7 Hz), 7.62 (d, 2H, J=6.7 Hz), 4.50 (bs, 1H), 4.39 (d, 1H,J=4.8 Hz), 3.94 
(d, 1H, J=4.8 Hz); 13C NMR (100 MHz, CDCl3): 171.3, 141.6, 131.1, 128.4, 123.5, 56.9, 
55.4. -methyl ester 1H NMR (400 MHz, CDCl3):8.22 (d, 2H, J=6.7 Hz), 7.60 (d, 2H, J=6.7 
Hz), 4.34 (d,1H, J=4.8 Hz), 3.91 (d, 1H, J=4.8 Hz), 3.57 (s, 3H); 13CNMR (100 MHz, 
CDCl3): 167.5, 141.9, 130.6, 127.6, 123.8, 56.7, 55.7, 52.4; MS m/z: 223, 207, 192, 166.4.  
 
(2S*,3R*)-3-p-Nitrophenyl-oxirane-2-carboxylicacid (109j). Prepared according GP4 
starting from N-t-Boc-oxazinan-2-one 106j+107j, Method B. 1H NMR (400 MHz, CDCl3): 
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8.20 (d, 2H, J=6.6 Hz), 7.48 (d, 2H, J=6.6 Hz), 4.60 (bs, 1H), 4.24 (d, 1H, J=1.6 Hz), 3.52 
(d, 1H, J=1.6 Hz); 13C NMR (100 MHz, CDCl3): 169.7, 139.4, 127.7, 123.9, 123.2, 57.0, 
56.5. -methyl ester 1H NMR (400 MHz, CDCl3):8.19 (d, 2H, J=6.6 Hz), 7.47 (d, 2H, J=6.6 
Hz), 4.21 (d, 1H, J=2.0 Hz), 3.85 (s, 3H), 3.50 (d, 1H, J=2.0 Hz); 13CNMR (100 MHz, 
CDCl3): 166.0, 139.7, 126.5, 123.4, 123.2, 56.9, 56.8, 52.9; MS m/z: 223, 207, 192, 166. 
 
 
 
6.4  5-Thiophenyl-1,3-oxazinan-4-ones preparations 
 
 
General procedure for the preparation of azadiene (54). GP5 
1 mL of aldehyde 51 (1 mmol) was added to a solution of LiHMDS (1.1 mL of 1 M sol in 
THF) and hexane (5 mL) at 0°C under inert atmosphere. The reaction mixture was stirred 
at 0°C for 1 h. IR analysis confirmed the formation of silylimine 52 ( CN=1655 cm-1). 
TMSCl (0.14 mL, 1 mmol) was added in one portion and after stirring for 10 min at 0°C the 
mixture was allowed to stir for 1 h at rt. A white precipitate formed. The mixture was cooled 
at 0°C, triethylamine (0.3 mL, 2 mmol) was added in one portion and after 5 min a solution 
of thiophenyl acetylchloride 53 (1 mmol) in 5 mL of hexane was added. Stirring was 
maintained for 2 h and precipitate appeared. The mixture was filtered through Celite under 
argon and the solvent was removed in vacuo to afford 54 as an oil, which was used for the 
next step. 
 
General procedure for the preparation of perhydrooxazin-4-ones 56 and 57. GP6 
Azadiene 54 (2 mmol), prepared as reported above, was dissolved in anhydrous CH2Cl2 
(20 mL) and cooled at -78°C. Aldehyde 55 (1 mmol) dissolved in CH2Cl2 (2 mL) was added 
followed by a very slow addition of BF3 etherate (0.12 mL, 1 mmol) in CH2Cl2(10 mL). The 
solution was stirred overnight while the temperature was allowed to reach rt. The mixture 
was poured into saturated aqueous NaHCO3 and extracted with CH2Cl2. The organic 
layers were dried and the solvent was removed in vacuo. The reaction mixture was 
purified by flash chromatography on silica gel, eluting with cyclohexane/ethyl acetate 
70/30. Yields and diastereomeric ratio are reported in Tab. 3.3. 
 
(2S*,5S*,6R*)-2,6-Diphenyl-5-phenylthio-[1,3]oxazinan-4-one 56a. Prepared according 
GP6 starting from azadiene 54 (R= Ph) and benzaldehyde. Mp 173–174 °C; IR: 1674 cm-1; 
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1H NMR (400 MHz, CDCl3): 7.60–7.10 (m, 15H), 6.30 (br s, 1H), 5.92 (s, 1H), 5.41 (d, 
J=2.4 Hz, 1H), 3.82 (d, J=2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3):169.1, 137.5, 136.9, 
134.6, 133.2, 130.0, 128.8, 128.7, 128.1, 127.9, 127.8, 127.1, 125.9, 86.1, 78.6, 55.4; MS 
m/z: 361, 255, 106, 91, 77; E.A. Calcd for C22H19NO2S: C 73.10; H 5.30. Found: C 73.29; 
H 5.33. 
 
(2R*,5S*,6R*)-2,6-diphenyl-5-phenylthio-[1,3]oxazinan-4-one 57a. Prepared according 
GP6 starting from azadiene 54 (R= Ph) and benzaldehyde. IR: 1667 cm-1. 1H NMR (400 
MHz, CDCl3): 7.78–7.00 (m, 15H), 6.53 (br s, 1H), 6.03 (s, 1H), 5.37 (d, J=3.6 Hz,1H), 
4.03 (d, J=3.6 Hz, 1H). 13C NMR (100 MHz,CDCl3): 169.4, 138.0, 136.1, 134.3, 132.9, 
129.4, 128.8, 128.7, 128.3, 128.2, 127.7, 126.7, 126.6, 82.0, 73.6, 53.9. MS m/z: 361, 255, 
106, 91, 77. E.A. Calcd for C22H19NO2S: C 73.10; H 5.30. Found: C 73.32; H 5.31. 
 
(2S*,5S*,6S*)-2-Phenyl-6-(thiophen-2-yl)-5-phenylthio-[1,3]oxazinan-4-one 56b. Pre-
pared according GP6 starting from azadiene 54 (R= Ph) and 2-thiophenecarboxaldehyde. 
IR:1676 cm-1. 1H NMR (400 MHz, CDCl3):7.43 (m, 7H),7.33 (dd, J1=1.0 Hz, J2=5.0 Hz, 
1H), 7.24 (m, 3H), 7.06(m, 1H), 7.01 (dd, J1=3.4 Hz, J2=5.0 Hz, 1H), 6.54 (br s,1H), 5.93 
(s, 1H), 5.60 (dd, J1=0.6 Hz, J2=2.4 Hz, 1H),3.82 (d, J=2.4 Hz, 1H). 13C NMR (100 MHz, 
CDCl3):168.8, 139.3, 137.1, 134.6, 132.9, 130.0, 128.9, 128.8, 127.8, 127.1, 126.37, 
125.9, 125.5, 86.0, 76.3, 55.3. MS m/z: 368 (M+1), 323, 255, 212, 184, 152, 121, 106, 91, 
77. E.A. Calcd for C21H19NOS2: C 69.01; H 5.24. Found: C 70.39; H 5.34. 
 
(2R*,5S*,6S*)-2-phenyl-6-(thiophen-2-yl)-5-phenylthio-[1,3]oxazinan-4-one 57b. Pre-
pared according GP6 starting from azadiene 54 (R= Ph) and 2-thiophenecarboxaldehyde. 
IR (CHCl3):1675 cm-1. 1H NMR (400 MHz, CDCl3):7.50–7.38(m, 8H), 7.33 (br s, 1H), 7.26 
(m, 4H), 7.14 (m, 1H), 7.05 (dd, J1=3.2 Hz, J2=5.2 Hz, 1H), 5.83 (s, 1H), 5.57 (d, J=4.8 Hz, 
1H), 4.23 (dd, J1=3.6 Hz, J2=4.8 Hz, 1H). 13CNMR (100 MHz, CDCl3):168.6, 137.6, 137.5, 
134.4, 133.5, 129.7, 129.0, 128.8, 127.2, 126.8, 126.7, 81.6, 72.1, 53.4. MS m/z: 366 (M+-
1), 322, 255, 212, 186, 152, 121, 106, 77. E.A. Calcd for C21H19NOS2: C, 69.01; H,5.24; N, 
3.83. Found: C, 70.39; H, 5.34. 
 
(2S*,5S*,6R*)-2-(4-Methoxy-phenyl)-6-phenyl-5-phenylthio-[1,3]oxazinan-4-one 56c; 
Prepared according GP6 starting from azadiene 54 (R=p-MeO-Ph) and benzaldehyde. Mp 
181–183 °C. IR (CHCl3): 1672 cm-1. 1H NMR (400 MHz, CDCl3):7.46–7.16 (m, 12H), 6.93 
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(d, J=8.8 Hz, 2H), 6.45 (br s,1H), 5.86 (s, 1H), 5.38 (d, J=2.0 Hz, 1H), 3.83 (s, 3H),3.80 (d, 
J=2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3):169.5, 160.8, 140.3, 136.9, 134.6, 133.2, 
129.2, 128.8,128.6, 128.1, 126.4, 125.9, 114.1, 85.8, 78.4, 55.4. MS m/z: 392 (M++1), 
334, 316, 299, 285, 187, 162, 136, 105,91, 77. E.A. Calcd for C24H23NO2S: C, 74.00; H, 
5.95.Found: C, 75.48; H, 6.07. 
 
(2R*,5S*,6R*)-2-(4-methoxy-phenyl)-6-phenyl-5-phenylthio-[1,3]oxazinan-4-one 57c. 
Prepared according GP6 starting from azadiene 54 (R=p-MeO-Ph) and benzaldehyde. IR 
(CHCl3):1673 cm-1. 1H NMR (400 MHz, CDCl3):7.40–7.20 (m, 12H), 6.90 (d, J=8.6 Hz, 2H), 
6.27 (br s, 1H), 5.96 (s,1H), 5.38 (d, J=3.8 Hz, 1H), 4.08 (d, J=3.8 Hz, 1H), 3.80 (s, 3H); 
13C NMR (100 MHz, CDCl3):169.7, 160.7,1 36.4, 134.6, 133.1, 130.3, 129.1, 128.5, 128.4, 
128.0, 127.9, 127.1, 114.4, 82.1, 73.9, 55.6, 54.1. MS m/z: 392(M++1), 316, 299, 285, 
281, 210, 136, 105, 91, 77. E.A.Calcd for C24H23NO2S: C, 74.00; H, 5.95. Found: C,75.48; 
H, 6.07. 
 
(2S*,5S*,6R*)-2-(2-Triisopropylsilyloxyphenyl)-6-phenyl-5-(phenylthio)-[1,3]oxazinan-
4-one 56d; Prepared according GP6 starting from azadiene 54 (R=o-TIPSO-Ph) and 
benzaldehyde. IR (CHCl3):1674 cm-1. 1H NMR (400 MHz, CDCl3):7.62–6.85 (m, 14H), 6.36 
(s, 1H), 6.22 (br s, 1H), 5.42 (d, J=2.4 Hz,1H), 3.84 (d, J=2.4 Hz, 1H), 1.10 (m, 21H). 13C 
NMR(100 MHz, CDCl3):168.8, 153.0, 137.1, 134.6, 133.2,130.3, 128.7, 128.1, 127.8, 
127.6, 127.5, 127.2, 125.9, 121.5, 118.0, 80.5, 78.5, 55.5, 18.0, 12.9. MS m/z: 534,427, 
385, 279, 234. E.A. Calcd for C32H41NO2SSi: C,72.27; H, 7.77. Found: C, 74.44; H, 8.00. 
 
(2R*,5S*,6R*)-2-(2-triisopropylsilyloxyphenyl)-6-phenyl-5-(phenylthio)-[1,3]oxazinan-
4-one 57d. Prepared according GP6 starting from azadiene 54 (R=o-TIPSO-Ph) and 
benzaldehyde. IR (CHCl3):1672 cm-1. 1H NMR (400 MHz, CDCl3):7.45–7.05 (m, 14H), 6.33 
(br s, 1H), 6.21 (s, 1H), 5.50 (d, J=4.0 Hz,1H), 4.10 (d, J=4.0 Hz, 1H), 1.05 (m, 21H). 13C 
NMR(100 MHz, CDCl3):168.4, 153.4, 135.6, 134.4, 132.9, 130.1, 128.8, 128.5, 128.3, 
127.7, 127.4, 126.6, 121.1, 118.5, 77.6, 75.1, 53.4, 18.0, 13.0. MS m/z: 534, 427,385, 279, 
234. E.A. Calcd for C32H41NO2SSi: C, 72.27; H,7.77. Found: C, 74.44; H, 8.00. 
 
(2S*,5S*,6R*)-6-Methyl-2-phenyl-5-phenylthio-[1,3]oxazinan-4-one 56e. Prepared 
according GP6 starting from azadiene 54 (R=Ph) and acetaldehyde. IR (CHCl3):1672 cm-1. 
1H NMR (400 MHz, CDCl3):7.70 (m, 2H), 7.45–7.23 (m, 8H), 6.69 (br s, 1H), 5.74 (s, 1H), 
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4.34 (dq,J1=6.4 Hz, J2=2.8 Hz, 1H), 3.51 (d, J=2.8 Hz, 1H), 1.57 (d, J=6.4 Hz, 3H). 13C 
NMR (100 MHz, CDCl3):d=169.7, 137.8, 135.1, 133.3, 130.2, 129.3, 129.0, 128.0, 127.3, 
86.2, 74.2, 54.6, 18.6. MS m/z: 299, 255, 122, 106. E.A. Calcd for C17H17NO2S: C, 68.20; 
H, 5.72; N,4.68. Found: C, 68.34; H, 5.73. 
 
(2R*,5S*,6R*)-6-methyl-2-phenyl-5-phenylthio-[1,3]oxazinan-4-one 57e. Prepared 
according GP6 starting from azadiene 54 (R=Ph) and acetaldehyde. Mp 147–148 °C. 
IR(CHCl3): 1677 cm-1. 1H NMR (400 MHz, CDCl3): 7.61 (m, 2H), 7.50–7.15 (m, 8H), 6.67 
(br s, 1H), 5.97(s, 1H), 4.34 (m, 1H), 3.82 (d, J=3.6 Hz, 1H), 1.48 (d, J=6.8 Hz, 3H). 13C 
NMR (100 MHz, CDCl3):169.0, 138.7, 134.4, 132.8, 129.7, 129.3, 129.1, 128.0, 126.8, 
82.0, 69.0, 54.1, 16.8. MS m/z: 299, 255, 122, 105, 91,77. E.A. Calcd for C17H17NO2S: C, 
68.20; H, 5.72; N,4.68. Found: C, 68.30; H, 5.71. 
 
tert-Butyl-3-[(2S*,5S*,6R*)-4-oxo-2-phenyl-5-(phenylthio)-[1,3]oxazinan-6-yl]-1H-
indole-1-carboxylate 56f; Prepared according GP6 starting from azadiene 54 (R=Ph) 
and. tert-butyl-3-formyl-1H-indole-1-carboxylate. IR (CHCl3): 1737, 1673 cm-1. 1H NMR 
(400 MHz, CDCl3): 7.75 (s, 1H), 7.60–7.05 (m, 14H), 6.21 (br s, 1H), 6.00 (s, 1H), 5.63 
(dd,J1=2.0 Hz, J2=0.8 Hz, 1H), 4.04 (d, J=2.0 Hz, 1H), 1.66 (s, 9H). 13C NMR (100 MHz, 
CDCl3):169.2, 149.8, 137.7, 134.5, 133.2, 130.3, 129.1, 128.9, 128.0, 127.9, 127.4, 124.8, 
124.7, 123.0, 119.0, 118.1, 116.9, 115.7, 86.5, 84.2, 74.7, 54.1, 28.4. MS m/z: 399 (M+_t-
Boc), 334, 255, 202, 106, 91, 77. E.A. Calcd for C29H28N2O4S: C, 69.58; H, 5.64; N, 5.60. 
Found: C, 69.75; H, 5.62 
 
tert-butyl-3-[(2R*,5S*,6R*)-4-oxo-2-phenyl-5-(phenylthio)-[1,3]oxazinan-6-yl]-1H-
indole-1-carboxylate 57f. Prepared according GP6 starting from azadiene 54 (R=Ph) 
and. tert-butyl-3-formyl-1H-indole-1-carboxylate Mp 102–104 °C. IR (CHCl3): 1738, 1673 
cm-1. 1H NMR (400 MHz, CDCl3): 7.84 (s, 1H), 7.50–7.15 (m, 14H), 6.83 (br s, 1H), 5.78 
(s, 1H), 5.67 (dd, J1=4.8 Hz, J2=0.8 Hz, 1H), 4.41 (d, J=4.8 Hz, 1H), 1.71 (s, 9H). 13C NMR 
(100 MHz,CDCl3):168.7, 149.4, 137.7, 135.4, 134.2, 132.4, 129.6, 128.9, 128.8, 128.7, 
127.6, 126.8, 125.2, 124.9, 122.9, 119.1, 115.4, 114.4, 84.3, 81.7, 70.0, 52.4, 28.1. 
MS(m/z): 456, 422, 399, 334, 255, 202, 186, 131, 107, 91, 77. E.A. Calcd for 
C29H28N2O4S: C, 69.58; H, 5.64; N, 5.60.Found: C, 69.77; H, 5.62. 
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Procedure for the preparation of azadiene (60).  
1 mL of lactic aldehyde 58 (1 mmol) was added to a solution of LiHMDS (1.1 mL of 1 M sol 
in THF) and hexane (5 mL) at 0°C under inert atmosphere. The reaction mixture was 
stirred at 0°C for 1 h. IR analysis confirmed the formation of silylimine 52 ( CN=1655 cm-1). 
TMSCl (0.14 mL, 1 mmol) was added in one portion and after stirring for 10 min at 0°C the 
mixture was allowed to stir for 1 h at rt. A white precipitate formed. The mixture was cooled 
at 0°C, triethylamine (0.3 mL, 2 mmol) was added in one portion and after 5 min a solution 
of thiophenyl acetylchloride 53 (1 mmol) in 5 mL of hexane was added. Stirring was 
maintained for 2 h and precipitate appeared. The mixture was filtered through Celite under 
argon and the solvent was removed in vacuo to afford 59 as an oil, which was used for the 
next step. 
 
General procedure for the preparation of perhydrooxazin-4-ones 62 and 63. GP7 
Azadiene 60 (2 mmol), prepared as reported above, was dissolved in anhydrous CH2Cl2 
(20 mL) and cooled at -78°C. Aldehyde 61 (1 mmol) dissolved in CH2Cl2 (2 mL) was added 
followed by a very slow addition of BF3 etherate (0.12 mL, 1 mmol) in CH2Cl2 (10 mL). The 
solution was stirred overnight while the temperature was allowed to reach rt. The mixture 
was poured into saturated aqueous NaHCO3 and extracted with CH2Cl2. The organic 
layers were dried and the solvent was removed in vacuo. The reaction mixture was 
purified by flash chromatography on silica gel, eluting with cyclohexane/ethyl acetate 
70/30. Yields and diastereomeric ratio are reported in Tab. 3.4. 
 
(2R,5R,6S)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-phenyl-5-(phenylthio)-[1,3]oxazinan-
4-one 62a; Prepared according GP7 starting from azadiene 60 and benzaldehyde. [α]D20 
13.0 (c 0.7,CHCl3); IR (CHCl3): 1677 cm-1; 1H NMR (400 MHz,CDCl3):7.45–7.05 (m, 10H), 
6.22 (br s, 1H), 5.25 (d,J=2.0 Hz, 1H), 5.08 (d, J=2.8 Hz, 1H), 4.23 (m, 1H), 3.69 (d, J=2.8 
Hz, 1H), 1.31 (d, J=7.2 Hz, 3H), 1.05 (s, 21H);13C NMR (100 MHz, CDCl3):169.1, 136.7, 
135.0, 132.8, 128.7, 128.0, 127.9, 127.6, 126.0, 85.3, 77.8, 68.8, 56.3, 18.0, 17.9, 15.9, 
12.1. MS m/z: 486, 442, 399, 379, 336, 239, 211, 188, 135, 77. E.A. Calcd for 
C27H39NO3SSi:C 66.76, H 8.09; Found: C 66.86, H 8.11. 
 
(2S,5S,6R)-2-[(S)-1-triisopropylsilyloxyethyl]-6-phenyl-5-(phenylthio)-[1,3]oxazinan-
4-one 63a. Prepared according GP7 starting from azadiene 60 and benzaldehyde. [α]D20   
-41.5 (c 2.0,CHCl3). IR (CHCl3): 1676 cm-1. 1H NMR (400 MHz,CDCl3):7.40–7.07 (m, 10H), 
6.35 (br s, 1H), 5.22 (d,J=2 .4 Hz, 1H), 4.58 (d, J=8.0 Hz, 1H), 3.77 (m, 1H), 3.76 (d, J=2.4 
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Hz, 1H), 1.35 (d, J=5.6 Hz, 3H), 1.05 (s, 21H);13C NMR (100 MHz, CDCl3):168.2, 145.4, 
137.0, 133.7, 128.9, 128.6, 128.2, 127.8, 125.7, 87.6, 78.0, 71.5,55.2, 19.5, 18.1, 18.0, 
12.6. MS m/z: 486, 442, 379, 336, 284, 239, 211, 188, 135, 77. E.A. Calcd for 
C27H39NO3SSi:C 66.76, H 8.09; Found: C 66.82, H8.10. 
 
(2R,5R,6R)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-5-(phenylthio)-
[1,3]oxazinan-4-one 62b; Prepared according GP7 starting from azadiene 60 and 2-
thiophenecarboxaldehyde [α]D20 +33.5 (c 2.9,CHCl3). IR (CHCl3): 1672 cm-1. 1H NMR (400 
MHz, CDCl3): 7.36 (m, 3H), 7.20 (m, 3H), 7.01 (m, 2H), 6.20(br s, 1H, NH), 5.46 (d, J=2.0 
Hz, 1H), 5.09 (d, J=3.6 Hz,1H), 4.19 (dq, J1=3.6 Hz, J2=6.0 Hz, 1H), 3.71 (d, J=2.0 Hz, 
1H), 1.26 (d, J=6.0 Hz, 3H), 1.07 (m, 21H).13C NMR (100 MHz, CDCl3):168.80, 139.61, 
135.80, 132.32, 128.84, 127.60, 126.28, 126.03, 125.52, 85.51, 75.69, 68.72, 56.16, 
18.02, 15.88, 12.14. MS m/z: 492,448, 379, 336, 187. Anal. Calcd for C25H37NO3S2Si: 
C,61.06; H, 7.58. Found: C, 61.20; H, 7.63 
 
(2S,5S,6S)-2-[(S)-1-triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-5-(phenylthio)-
[1,3]oxazinan-4-one 63b. Prepared according GP7 starting from azadiene 60 and 2-
thiophenecarboxaldehyde [α]D20 -58.6 (c 2.5, CHCl3). IR (CHCl3): 1685 cm-1. 1H NMR (400 
MHz, CDCl3): 7.42–7.20 (m, 6H), 7.02–6.98 (m, 2H), 6.33 (br s, 1H, NH), 5.41 (dd, J1=1.2 
Hz, J2=2.4 Hz, 1H), 4.60 (d, J=8.0 Hz, 1H), 3.77 (d, J=2.4 Hz, 1H), 3.68 (m, 1H),1.31 (d, 
J=6.4 Hz, 3H), 1.08 (m, 21H). 13C NMR(100 MHz, CDCl3): 167.68, 139.66, 134.16, 133.56, 
128.71, 127.96, 126.51, 125.54, 124.75, 87.66, 76.07, 71.35, 55.16, 19.43, 18.12, 12.58. 
MS m/z: 491, 446, 379, 336, 217, 186. Anal. Calcd for C25H37NO3S2Si: C,61.06; H, 7.58. 
Found: C, 61.18; H, 7.60 
 
(2R,5R,6S)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-methyl-5-(phenylthio)-[1,3]oxazinan-
4-one 62c; Prepared according GP7 starting from azadiene 60 and acetaldehyde. [α]D20 
+40.0 (c 2.1, CHCl3). IR (CHCl3): 1670 cm-1. 1H NMR (400 MHz, CDCl3): 7.65 (m, 2H), 
7.40–7.18 (m, 3H), 6.10 (br s,1H), 4.90 (d, J=3.2 Hz, 1H), 4.20 (dq, J1=6.0 Hz, J2=1.8 Hz, 
1H), 4.06 (dq, J1=6.4 Hz, J2=3.2 Hz, 1H), 3.46 (d, J=1.8 Hz, 1H), 1.50 (d, J=6.0 Hz, 3H), 
1.11 (d,J=6.4 Hz, 3H), 1.05 (s, 21H). 13C NMR (100 MHz, CDCl3):169.4, 135.6, 132.4, 
129.0, 127.5, 85.4, 73.2, 68.8, 55.1, 18.0, 17.9, 15.7, 12.1. MS m/z: 423, 408, 380, 362, 
336, 223, 187, 149, 77. E.A. Calcd for C22H37NO3SSi: C, 62.37; H, 8.80; N, 3.31. Found: 
C, 62.40; H, 8.83. 
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(2S,5S,6R)-2-[(S)-1-triisopropylsilyloxyethyl]-6-methyl-5-(phenylthio)-[1,3]oxazinan-
4-one 63c. Prepared according GP7 starting from azadiene 60 and acetaldehyde. 
[α]D20 -40.7 (c 1.35, CHCl3). IR (CHCl3): 1667 cm-1. 1H NMR(400 MHz, CDCl3):7.65 (m, 
2H), 7.25 (m, 3H), 6.25 (bs, 1H), 4.39 (d, J=7.2 Hz, 1H), 4.14 (dq, J1=6.4, J2=2.4, 1H), 3.50 
(m, 1H), 3.45 (d, J=2.4, 1H), 1.50 (d, J=6.4, 3H), 1.05 (s, 21H); 13C NMR (400 MHz, 
CDCl3): 138.3, 134.5, 133.4, 128.8, 127.7, 87.5, 73.4, 71.3, 54.5, 19.3, 18.1, 18.0, 12.6; 
MS m/z: 423, 408, 380, 362, 336, 222, 186, 149, 77. E.A. Calcd for C22H37NO3SSi:C, 
62.37; H, 8.80;. Found: C, 62.42; H, 8.84. 
 
(2R,5R,6S)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-(naphthalen-2-yl)-5-(phenylthio)-
[1,3]oxazinan-4-one 62d; Prepared according GP7 starting from azadiene 60 and 2-
naphthaldehyde. [α]D20 -39.7(c 1.40, CHCl3). IR (CHCl3): 1678 cm-1. 1H NMR (400 MHz, 
CDCl3): 7.82 (m, 5H), 7.50 (m, 2H), 7.38 (m, 1H), 7.05 (m, 5H), 6.26 (br s, 1H), 5.41 (d, 
J=2.6 Hz, 1H), 5.15 (d, J=3.6 Hz, 1H), 4.29 (dq, J1=6.4 Hz, J2=3.6 Hz, 1H), 3.83 (d, J=2.6 
Hz, 1H), 1.36 (d, J=6.4 Hz, 3H), 1.08 (s, 21H). 13C NMR (100 MHz, CDCl3):169.1, 134.8, 
134.1, 132.9, 132.8, 132.7, 128.6, 128.1, 127.8, 127.7, 127.6, 126.2, 126.1, 125.2, 123.4, 
85.5, 78.0, 68.8, 56.0, 18.1, 18.0, 16.0, 12.1. MS m/z: 535, 379, 336, 289, 261, 187. E.A. 
Calcd for C31H41NO3SSi:C, 69.49; H, 7.71; N, 2.61. Found: C, 69.63; H, 7.73. 
 
(2S,5S,6R)-2-[(S)-1-triisopropylsilyloxyethyl]-6-(naphthalen-2-yl)-5-(phenylthio)-
[1,3]oxazinan-4-one 63d. Prepared according GP7 starting from azadiene 60 and 2-
naphthaldehyde.[α]D20 -14.2(c 1.70, CHCl3). IR (CHCl3): 1677 cm-1. 1H NMR(400 MHz, 
CDCl3):7.85 (m, 5H), 7.55 (m, 2H), 7.38 (m, 1H), 7.22–7.05 (m, 5H), 6.42 (br s, 1H), 5.37 
(d, J=2.2 Hz, 1H), 4.65 (d, J=7.6 Hz, 1H), 3.90 (d, J=2.2 Hz, 1H), 3.85 (m, 1H), 1.43 (d, 
J=6.4 Hz, 3H), 1.12 (s, 21H).13C NMR (100 MHz, CDCl3):168.1, 134.3, 134.1,133.7, 132.9, 
132.8, 128.5, 128.1, 127.9, 127.8, 127.7,127.6, 126.2, 126.1, 124.9, 123.2, 87.6, 78.2, 
71.5, 55.0, 19.6, 18.1, 18.0, 12.6. MS m/z: 535, 379, 336, 289, 261,187. E.A. Calcd for 
C31H41NO3SSi: C, 69.49; H, 7.71; N,2.61. Found: C, 69.62; H, 7.71. 
 
tert-Butyl-3-[(2R,5R,6S)-2-[(S)-1-triisopropylsilyloxyethyl]-4-oxo-5-(phenylthio)-
[1,3]oxazin an-6-yl]-1Hindole-1-carboxylate 62e; Prepared according GP7 starting from 
azadiene 60 and tert-butyl-3-formyl-1H-indole-1-carboxylate. [α]D20 +24 (c 0.5, CHCl3). IR 
(CHCl3): 1738, 1674 cm-1. 1H NMR(400 MHz, CDCl3):7.70 (s, 1H), 7.42–6.98 (m, 9H), 6.23 
 101 
(br s, 1H), 5.46 (dd, J1=2.2 Hz, J2=1.2 Hz, 1H), 5.14 (d, J=3.2 Hz, 1H), 4.23 (dq, J1=3.2 Hz, 
J2=6.4 Hz, 1H), 3.92 (d, J=2.2 Hz, 1H), 1.68 (s, 9H), 1.30 (d, J=6.4 Hz, 3H), 1.08 (s, 21H). 
13C NMR (100 MHz, CDCl3): 168.7, 149.5, 135.2, 134.4, 132.4, 128.5, 127.4, 124.6, 122.6, 
118.6, 116.5, 115.4, 85.6, 83.9, 73.7, 68.8, 54.5,28.1, 18.0, 17.9, 15.9, 12.1. MS m/z: 567 
(M+_t-Bu), 525, 473, 379, 336, 230, 188, 77. E.A. Calcd forC34H50N2O5SSi: C, 65.14; H, 
8.04; N, 4.47. Found: C,65.41; H, 8.07 
 
tert-butyl-3-[(2S,5S,6R)-2-[(S)-1-triisopropylsilyloxyethyl]-4-oxo-5-(phenylthio)-
[1,3]oxazinan-6-yl]-1H-indole-1-carboxylate 63e. Prepared according GP7 starting from 
azadiene 60 and tert-butyl-3-formyl-1H-indole-1-carboxylate. [α]D20 -42.8(c 1.12, CHCl3). 
IR (CHCl3): 1737, 1671 cm-1. 1H NMR(400 MHz, CDCl3): 7.65 (s, 1H), 7.40–7.00 (m, 9H), 
6.38 (br s, 1H), 5.41 (dd, J1=2.4 Hz, J2=1.2 Hz, 1H), 4.66 (d, J=7.2 Hz, 1H), 3.97 (d, J=2.4 
Hz, 1H), 3.76 (m, 1H),1.68 (s, 9H), 1.35 (d, J=6.4 Hz, 1H), 1.11 (s, 21H). 13CNMR (100 
MHz, CDCl3):167.8, 149.6, 135.3, 133.8, 133.5, 132.5, 128.5, 127.8, 127.7, 124.6, 124.1, 
122.7, 118.7, 116.8, 115.4, 87.8, 83.9, 74.1, 71.4, 53.6, 28.2, 19.5, 18.1, 18.0, 12.6. MS 
m/z: 567 (M+_t-Bu), 379, 336, 230, 188, 77. E.A. Calcd for C34H50N2O5SSi: C,65.14; H, 
8.04; N, 4.47. Found: C, 65.41; H, 8.07 
 
 
6.5 (R)- and (S)-Fluoxetine preparation 
 
(2R,5R,6S)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-phenyl-5-(phenylthio)-[1,3]oxazinan-
4-one 61a; (2S,5S,6R)-2-[(S)-1-triisopropylsilyloxyethyl]-6-phenyl-5-(phenylthio)-
[1,3]oxazinan-4-one 62a. The product have been prepared according GP7 as reported 
above. 
 
(2R,6R)-2-((S)-1-Triisopropylsilyloxyethyl)-6-phenyl-1,3-oxazinan-4-one 110; (2S,6S)-
2-((S)-1-Triisopropylsilyloxyethyl)-6-phenyl-1,3-oxazinan-4-one 111. MW-mediated de-
sulfurization reaction: 5-Phenylsulfanyl-perhydrooxazinone 62a (or 63a) (0.24 mmol), 
Nickel-Raney (0.6 g), and EtOH (6 mL) were mixed in a 30 mL reaction tube. The tube 
was sealed and positioned in the reaction cavity. The sealed reaction was irradiated at 150 
W for 2 min. The reaction mixture was filtered on Celite, and the solvent evaporated. The 
crude reaction mixture was purified by flash chromatography (3:7 EtOAc/cyclohexane) to 
give the desired product 110 in 98% yield (or 111 in 90% yield). 
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Compound 110: IR (neat, cm-1): 3201, 2942, 2866, 1675, 1463; 1H NMR (400MHz, CDCl3): 
7.30 (m, 5H),6.37 (br s, 1H), 5.07 (d, 1H, J = 3.6 Hz), 4.86 (dd, 1H,J1 = 4.4, J2 = 10.8 Hz), 
4.19 (dq, 1H, J1 = 3.6, J2 = 6.0Hz), 2.68 (dd, 1H, J1 = 4.4, J2 = 17.6 Hz), 2.61 (dd, 1H, J1 = 
10.8, J2 = 17.6 Hz), 1.24 (d, 3H, J= 6.0Hz), 1.06 (m, 21H); 13C NMR (100MHz, CDCl3): 
168.73, 139.61, 128.72, 128.39, 125.56,84.88, 76.09, 68.64, 39.75, 17.95, 15.74, 12.08; 
MS(m/z): 378, 334, 316, 202, 188, 131. 
 
Compound 111: oil. [α]D = -37.3 (c = 0.82, CHCl3); IR (neat, cm-1): 3201, 2942, 2866, 
1675, 1463; 1H NMR(400MHz, CDCl3): 7.36 (m, 5H), 6.53 (br s, 1H), 4.83 (dd, 1H, J1 = 
3.6, J2 = 12.0 Hz), 4.61 (d, 1H, J = 6.8 Hz), 3.90 (m, 1H), 2.71 (dd, 1H, J1 = 3.6, J2 = 
17.2Hz), 2.59 (dd, 1H, J1 = 12.0, J2 =17.2 Hz),1.33 (d, 3H, J = 6.4 Hz), 1.09 (m, 21H). 13C 
NMR(100MHz, CDCl3): 168.10, 139.86, 128.63, 128.17,125.44, 87.51, 76.04, 71.45, 
39.29, 19.72, 18.11, 12.65; MS (m/z): 334, 202, 187, 131. Anal. Calcd forC21H35NO3Si: C 
66.80; H 9.34. Found: C 66.92 H 9.38. 
 
(2R,6R)-2-((S)-1-triisopropylsilyloxyethyl)-3-methyl-6-phenyl-1,3-oxazinan-4-one 112; 
(2S, 6S)-2-((S)-1-triisopropylsilyloxyethyl)-3-methyl-6-phenyl-1,3-oxazinan-4-one 113. 
To a solution of 110 (or 111) (1 mmol) in THF (10 mL) at 0°C was added HMDSLi (1M in 
THF,1.0 eq, 1.0mL). The reaction was stirred for 20 min, MeI (8 eq, 0.498mL) added and 
the solution warmed to room temperature. Stirring was then maintained for 2h at the same 
temperature. A saturated solution of NH4Cl was added, the organic solvent removed in 
vacuo and the obtained aqueous solution extracted with AcOEt. The organic phases were 
collected, dried over Na2SO4 and concentrated in vacuo. The crude reaction mixture was 
controlled by 1H NMR analysis and used without purification for the next step. Yields 
>98%. 
 
Compound 113: oil. [α]D = -62.5 (c = 0.92 CHCl3); IR (neat, cm-1): 3201, 2944, 2871, 1675, 
1463; 1H NMR(200 MHz, CDCl3): 7.30 (m, 5H), 4.82 (d, 1H, J = 2.5 Hz), 4.78 (dd, 1H, J1 = 
2.2, J2 = 11.4 Hz), 4.22 (m, 1H), 2.88 (s, 3H), 2.80–2.42 (m, 2H), 1.16 (d, 3H, J = 6.2 Hz), 
1.00 (m, 21H); 13C NMR (50 MHz, CDCl3): 168.51, 139.87, 128.60, 127.85, 125.43, 90.75, 
73.59, 68.84, 40.17, 29.57, 18.21, 16.54, 12.60; MS (m/z): 338(M+-43), 216, 190, 131. 
Anal. Calcd for C22H37NO3Si:C, 67.47; H, 9.52. Found: C, 67.35; H, 9.50. 
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(2R,6R)-2-((S)-1-Triisopropylsilyloxyethyl)-3-methyl-6-phenyl-1,3-oxazinane 114; 
(2S,6S)-2-((S)-1-Triisopropylsilyloxyethyl)-3-methyl-6-phenyl-1,3-oxazinane 115. 
Ph2SiH2 (2.5 equiv, 0.461 mL) and RhH(CO)(PPh3)3(1%) were added to a solution of 112 
(or 113) (1.0 mmol) in THF (10 mL) at room temperature and the stirring maintained for 
15h. THF was removed in vacuo, HCl (1M) added and the reaction extracted with 
Et2O.The aqueous phase was neutralized with NaOH 5M (pH = 10–12) and then extracted 
with Et2O. The organic phases were dried over Na2SO4 and the solvent evaporated. The 
crude reaction mixture obtained was used without purification for the last step of the 
synthesis. 
 
(R)-3-(Methylamino)-1-phenylpropan-1-ol 116; (S)-3-(Methylamino)-1-phenylpropan-
1-ol 117. To a solution of 114 (or 115) in MeOH (10mL) was added HCl 1M (5mL/mmol) 
and the mixture heated at 90°C for 1.5 h. The solution was cooled at room temperature, 
after which MeOH was removed in vacuo and the aqueous solution extracted with Et2O. 
The aqueous solution was neutralized with NaOH 5M and extracted with CH2Cl2. The 
organic phases were collected, dried over Na2SO4 and the solvent removed in vacuo to 
give product 116  (or 117) as a pure enantiomer.  
 
Compound 116: Yield: 60% calculated from 112, [α]D = +37.5 (c = 1.2, CHCl3). IR (neat, 
cm-1): 3303, 3061, 2938, 2854, 1492. 1H NMR (300 MHz, CDCl3): 7.30 (m, 5H), 4.95 (dd, 
1H, J1 = 3.3, J2 = 8.7 Hz),4.20 (br s, 2H), 2.88 (m, 2H), 2.46 (s, 3H), 1.85 (m,2H). 13C NMR 
(75 MHz, CDCl3): 145.02, 128.14, 126.86, 125.54, 75.27, 50.21, 36.75, 35.82. 
Compound 117: Yield: 67% calculated from 113, [α]D = -36.0 (c = 1.0, CHCl3); IR (neat, 
cm-1): 3303, 3061, 2938, 2854, 1492; 1H NMR(300MHz, CDCl3): 7.30 (m, 5H), 4.95 (dd, 
1H, J1 = 3.3, J2 = 8.7 Hz), 4.20 (br s, 2H), 2.88 (m, 2H), 2.46 (s, 3H), 1.85 (m, 2H); 13C 
NMR (75 MHz, CDCl3):145.02, 128.14, 126.86, 125.54, 75.27, 50.21, 36.75, 35.82. 
 
 
 
6.6  (R)- and (S)-Duloxetine preparation 
 
(2R,5R,6R)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-5-(phenylthio)-
[1,3]oxazinan-4-one 62b; (2S,5S,6S)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-(thiophen-2-
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yl)-5-(phenylthio)-[1,3]oxazinan-4-one 63b. The product have been prepared according 
GP7 as reported above. 
 
(2R,6R)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-[1,3]oxazinan-4-one 118. 
(2S,6S)-2-[(S)-1-Triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-[1,3]oxazinan-4-one 119. 
Aluminum (4.0 g) and 50 mL of a solution of HgCl2 (1% in H2O) were stirred for 1 min, the 
mixture was decanted and the residue was washed with water. The amalgam so prepared 
was added to a solution of compound 62b (or 63b) (0.9 mmol) in i-PrOH (50 ml) under 
inert atmosphere. The reaction was stirred overnight until the disappearance of starting 
materials (TLC test). The mixture was filtered through Celite and the solvent was removed 
in vacuo. Product 118 (or 119)so obtained was used for the next step without any 
purification. An aliquot of the crude reaction mixture was utilized for identification of 118 (or 
119) after purification by a short flash chromatography on silica gel (8:2 
cyclohexane/EtOAc). 
 
Compound 118: [α]D20 +1.9 (c 1.3, CHCl3).IR (CHCl3): 1666 cm-1. 1H NMR (400 MHz, 
CDCl3): 7.33 (d, J=5.2 Hz, 1H), 7.05 (d, J=3.6 Hz, 1H), 7.00 (dd, J1=3.6 Hz, J2=5.2 Hz, 
1H), 6.38 (br s, 1H, NH), 5.11 (dd, J1=6.0 Hz, J2=9.6 Hz, 1H), 5.07 (d, J =3.6 Hz, 1H),4.19 
(dq, J1=3.6 Hz, J2=6.4 Hz, 1H), 2.77 (m, 2H), 1.19 (d, J=6.4 Hz, 3H), 1.07 (m, 21H). 13C 
NMR (100 MHz, CDCl3):168.18, 142.26, 126.77, 125.88, 124.88, 84.91, 72.13, 68.61, 
39.66, 18.01, 15.69, 12.14. MS m/z: 384, 340, 322, 202, 187. Anal. Calcd for 
C19H33NO3SSi: C,59.49; H, 8.67. Found: C, 60.68; H, 8.84. 
 
Compound 119: [α]D20 -1.3 (c 2.1, CHCl3). IR (CHCl3): 1666 cm-1. 1H NMR (400 MHz, 
CDCl3): 7.32 (dd, J1=1.6 Hz, J2=4.8 Hz, 1H), 6.99 (m, 2H), 6.53 (br s, NH), 5.05 (dd, J1=6.4 
Hz, J2=8.4 Hz, 1H), 4.62 (d, J=6.4 Hz, 1H), 3.87 (m, 1H), 2.78 (m, 2H), 1.32 (d, J=6.0 Hz, 
3H), 1.07 (m, 21H). 13C NMR (100 MHz,CDCl3):167.52, 142.48, 126.70, 125.72, 124.36, 
87.33, 72.32, 71.20, 38.95, 19.61, 18.06, 12.59. MS m/z: 384, 340, 322, 202, 187. Anal. 
Calcd for C19H33NO3SSi: C,59.49; H, 8.67. Found: C, 60.68; H, 8.84. 
 
(2R,6R)-N-Methyl-2-[(S)-1-triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-[1,3]oxazinan-4-
one 120. (2S,6S)-N-Methyl-2-[(S)-1-triisopropylsilyloxyethyl]-6-(thiophen-2-yl)-
[1,3]oxazinan-4-one 121. To a solution of 118 (or 119) (1 mmol) in THF (10mL) at 0°C 
was added HMDSLi (1M in THF,1.0 eq, 1.0mL). The reaction was stirred for 20 min, MeI 
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(8 eq, 0.498mL) added and the solution warmed to room temperature. Stirring was then 
maintained for 2h at the same temperature. A saturated solution of NH4Cl was added, the 
organic solvent removed in vacuo and the obtained aqueous solution extracted with 
AcOEt. The organic phases were collected, dried over Na2SO4 and concentrated in vacuo. 
The reaction mixture was purified by flash chromatography on silica gel, eluting with 
cyclohexane/EtOAc 70/30. 
 
Compound 120: Y=65% calculated on product 62b. [α]D20 +36.3 (c 2.7, CHCl3). R (CHCl3): 
1644 cm-1. 1H NMR (400 MHz, CDCl3):d=7.31 (dd, J1=1.6 Hz, J2=4.8 Hz, 1H), 7.00 (m, 
2H), 5.03 (dd, J1=5.6 Hz, J2=8.4 Hz, 1H), 4.96 (d, J=0.8 Hz,1H), 4.16 (dq, J1=0.8 Hz, 
J2=6.4 Hz, 1H), 3.06 (s, 3H), 2.76 (m, 2H), 1.17 (d, J=6.4 Hz, 3H), 1.06 (m, 21H). 13CNMR 
(100 MHz, CDCl3):167.45, 142.42, 126.66, 125.63, 124.53, 90.83, 71.14, 70.44, 40.26, 
29.65, 18.03, 16.70, 12.19. MS m/z: 397, 354, 216, 137. Anal. Calcd for C20H35NO3SSi: C, 
60.41; H, 8.87. Found: C, 62.22; H,9.14. 
 
Compound 121: Y=54% calculated on product 63b. [α]D20 -67.4 (c 2.2, CHCl3). IR (CHCl3): 
1646 cm-1. 1H NMR (400 MHz, CDCl3): 7.29 (dd, J1=2.4 Hz, J2=3.6 Hz, 1H), 6.98 (m, 2H), 
5.02 (dd, J1=3.6 Hz, J2=10.0 Hz, 1H), 4.87 (d, J=2.4 Hz,1H), 4.25 (dq, J1=2.4 Hz, J2=6.4 
Hz, 1H), 2.94 (s, 3H), 2.81 (m, 2H), 1.19 (d, J=6.4 Hz, 3H), 1.08 (m, 21H). 13CNMR (100 
MHz, CDCl3): 167.32, 142.87, 126.60, 25.48, 123.93, 90.84, 70.56, 68.87, 39.90, 29.43, 
18.05, 16.57, 12.46. MS m/z: 397, 354, 216, 137. Anal. Calcd forC23H41NO3SSi: C, 62.82; 
H, 9.40. Found: C, 62.70; H, 9.38. 
 
(2R,6R)-[(S)-1-(triisopropylsilyloxy)ethyl]-3-methyl-6-(thiophen-2-yl)-1,3-oxazinane 
122 (2S,6S)-[(S)-1-(triisopropylsilyloxy)ethyl]-3-methyl-6-(thiophen-2-yl)-1,3-
oxazinane 123. Ph2SiH2 (0.46 mL, 2.5 mmol) and RhH(CO)(PPh3)3 (1%)were added to a 
solution of 120 (or 121) (1.0 mmol) in THF (10 mL) at room temperature and the stirring 
maintained for 15 h. Disappearance of starting material was verified by TLC 
(CH2Cl2/cyclohexane/ethylacetate 50/30/20). An aliquot of the solution was utilized for 
identification of the reduction product 122 (or 123) after removing the solvent and fast 
purification by a short flash chromatography eluting with cyclohexane/ethyl acetate 90:10 
(saturated with NH3(g)). 
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Compound 122: [α]D20 +35.7 (c 1.0, CHCl3).IR (CHCl3): 2944, 2865, 1463 cm-1. 1H NMR 
(400 MHz, CDCl3):7.23 (dd, J1=1.6 Hz, J2=4.8 Hz, 1H), 6.96 (m,2H), 4.75 (dd, J1=2.0 Hz, 
J2=11.2 Hz, 1H), 3.99 (m, 1H), 3.92 (d, J=5.2 Hz, 1H), 3.06 (ddd, J1=2.0 Hz, J2=4.4 Hz, 
J3=12.8 Hz, 1H), 2.88 (dt, J1=2.8 Hz, J2=12.8 Hz, 1H),2.40 (s, 3H), 2.13 (m, 1H), 1.64 (m, 
1H), 1.28 (d, J=6.8 Hz, 3H), 1.06 (m, 21H). 13C NMR (100 MHz, CDCl3):145.80, 126.12, 
124.35, 123.43, 97.06, 75.38, 70.46, 54.80, 36.62, 30.51, 18.78, 18.12, 12.27. MS m/z: 
383, 340, 235, 182, 123. Anal. Calcd for C20H37NO2SSi:C, 62.61; H, 9.72. Found: C, 64.49; 
H, 9.99. 
 
Compound 123: [α]D20 -17.8 (c 2.3,CHCl3). IR (CHCl3): 2944, 2865, 1463 cm-1. 1H 
NMR(400 MHz, CDCl3): 7.23 (dd, J1=2.8 Hz, J2=3.6 Hz,1H), 6.96 (m, 2H), 4.73 (dd, J1=2.8 
Hz, J2=11.6 Hz, 1H), 4.15 (m, 1H), 3.92 (d, J=4.0 Hz, 1H), 3.07 (ddd, J1=1.6 Hz, J2=4.4 
Hz, J3=14.4 Hz, 1H), 2.88 (dt, J1=3.2 Hz, J2=13.2 Hz, 1H), 2.37 (s, 3H), 2.13 (m, 1H), 1.71 
(m, 1H), 1.28 (d, J=6.0 Hz, 3H), 1.06 (m, 21H). 13CNMR (100 MHz, CDCl3): 146.17, 
126.24, 124.31,122.89, 96.83, 75.32, 68.14, 54.65, 37.22, 29.81, 18.77, 18.17, 12.60. MS 
m/z: 383, 340, 235, 182, 123. Anal. Calcdfor C20H37NO2SSi: C, 62.61; H, 9.72. Found: C, 
64.49; H,9.99. 
 
(R)-3-(methylamino)-1-(thiophen-2-yl)propan-1-ol 124; (S)-3-(methylamino)-1-
(thiophen-2-yl)propan-1-ol 125. Aqueous HCl (1 M, 2.5 mL) was added to the crude THF 
solution of 122 (or 123) and the stirring maintained at the same temperature for 4 h. The 
organic solvent was removed in vacuo and the obtained aqueous solution extracted with 
Et2O. The aqueous phase was basified with NH4OH (pH=10) and then extracted with 
CH2Cl2.The organic phases were dried over Na2SO4 and the solvent evaporated. The 
crude reaction mixture was subjected to column chromatography (ethyl 
acetate/MeOH/NH4OH 80/19/1) to give 124 (or 125). 
 
Compound 124: Y=68% calculated on product 120. [α]D20 +13.7 (c 2.5, EtOH) [lit. [ ]D 
+13.3 (c 1.05, MeOH)]. IR (CHCl3): 3302, 3103, 2939, 2853, 2793, 1473, 1315 cm-1. 1H 
NMR (400 MHz, CDCl3): 7.20 (dd, J1=1.2 Hz, J2=4.8 Hz, 1H), 6.96 (dd, J1=4.0 Hz, J2=5.2 
Hz, 1H), 6.91 (d, J=1.2 Hz, 1H), 5.19 (dd, J1=2.8 Hz, J2=8.4 Hz, 1H), 2.94 (m, 1H), 2.89 
(m, 1H), 2.44 (s, 3H), 1.95 (m, 2H). 13CNMR (100 MHz, CDCl3): 149.64, 126.53, 123.70, 
122.31, 71.92, 50.12, 36.73, 35.88. MS m/z: 170, 153, 138, 127, 110, 97, 88. Anal. Calcd 
for C8H13NOS: C,56.11; H, 7.65. Found: C, 56.21; H, 7.66. 
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Compound 125: Y=60% calculated on product 121. [α]D20 -12.0 (c 3.0, EtOH). IR (CHCl3): 
3302, 3103, 2939, 2853, 2793, 1473, 1315 cm-1. 1H NMR (400 MHz, CDCl3): 7.20 (dd, 
J1=1.2 Hz,J2=4.8 Hz, 1H), 6.96 (dd, J1=4.0 Hz, J2=5.2 Hz, 1H), 6.91 (d, J=1.2 Hz, 1H), 
5.19 (dd, J1=2.8 Hz, J2=8.4 Hz,1H), 2.94 (m, 1H), 2.89 (m, 1H), 2.44 (s, 3H), 1.95 (m, 2H). 
13C NMR (100 MHz, CDCl3): 149.64, 126.53, 123.70, 122.31, 71.92, 50.12, 36.73, 35.88. 
MS m/z: 170, 153, 138, 127, 110, 97, 88. Anal. Calcd for C8H13NOS: C,56.11; H, 7.65. 
Found: C, 57.23; H, 7.88. 
 
 
 
6.7  (R/S)-Venlafaxine preparation 
 
4-(4-methoxy-phenyl)-3-trimethylsilyloxy-2-aza-1-phenylbutan-1,3-diene 127. 1 mL of 
benzaldehyde 44 (1 mmol) was added to a solution of LiHMDS (1.1 mL of 1 M sol in THF) 
and hexane (5 mL) at 0°C under inert atmosphere. The reaction mixture was stirred at 0°C 
for 1 h. IR analysis confirmed the formation of silylimine 45 ( CN=1655 cm-1). TMSCl (0.14 
mL, 1 mmol) was added in one portion and after stirring for 10 min at 0°C the mixture was 
allowed to stir for 1 h at rt. A white precipitate formed. The mixture was cooled at 0°C, 
triethylamine (0.3 mL, 2 mmol) was added in one portion and after 5 min a solution of (4-
methoxy-phenyl)acetyl chloride 126 (1 mmol) in 5 mL of hexane was added. Stirring was 
maintained for 2 h and a precipitate appeared. The mixture was filtered through Celite 
under argon and the solvent was removed in vacuo to afford 127 as an oil, which was 
analyzed. 1H NMR  (400 MHz CDCl3): 8.45 (s, 1H), 7.83 (m, 2H), 7.57 (d, 2H, J = 8.8), 
7.45 (m, 3H), 6.88 (d, 2H, J = 8.8), 5.92 (s, 1H), 3.82 (s, 3H), 0.21 (s, 9H).  
 
5-(4-methoxy-phenyl)-2-phenyl-1-oxa-3-aza-spiro[5.5]undecan-4-one 128. Azadiene 
127 (1 mmol), prepared as reported above, was dissolved in anhydrous CH2Cl2 (20 mL) 
and cooled at -78°C. Cyclohexanone (1 mmol) dissolved in CH2Cl2 (2 mL) was added 
followed by a very slow addition of BF3 etherate (0.12 mL, 1 mmol) in CH2Cl2 (10 mL). The 
solution was stirred at –78°C for 8 h. The mixture was poured into saturated aqueous 
NaHCO3 and extracted with CH2Cl2. The organic layers were dried and the solvent was 
removed in vacuo. The reaction mixture was purified by flash chromatography on silica 
gel, eluting with cyclohexane/ethyl acetate 40/60. Product 128 was obtained with 62% 
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yield. White solid, mp 186-188 °C; 1H NMR  (400 MHz, CDCl3): 7.56 (m, 2H), 7.42-7.46 (m, 
3H), 7.34 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.75 (bs, 1H), 5.92 (s, 1H), 3.78 (s, 
3H), 3.35 (s, 1H), 2.27 (d, J = 9.2 Hz, 1H), 1.52-1.65 (m, 5H), 1.26-1.39 (m, 3H), 1.08-1.16 
(m, 1H). 13C NMR (100 MHz, CDCl3):171.12, 158.84, 138.30, 130.47, 129.61, 128.98, 
126.63, 113.80, 79.52, 56.65, 55.21, 34.92, 33.28, 25.45, 22.08, 21.27. 
 
3-Hydroxymethyl-5-(4-methoxy-phenyl)-1-oxa-3-aza-spiro[5.5]undecan-4-one 130. 
Cycloadduct 128 (0.3 mmol) was mixed with HCOOH (2.0 mL) and HCHO (4 mL) and put 
in a flask for microwave oven synthesis (Prolabo). The mixture was submitted to microwave 
irradiation for 3’ at 150 Watt power. The formic acid was removed in vacuo and the mixture 
was neutralized with NaHCO3 aq. The residue was extracted with ethylacetate, the solvent 
owas removed in vacuo end the crude reaction mixture was purified by flash 
chromatography on silica gel, eluting with cyclohexane/ethyl acetate 40/60 to give product 
130 in 58% yield.  
 
3-Hydroxymethyl-5-(4-methoxy-phenyl)-2-phenyl–1-oxa-3-aza-spiro[5.5]undecan-4-
one 118. If we stopped the transchetalization after 1min, it’s possible to isolate and 
recognize the intermediate 129. 1H NMR  (400 MHz, CDCl3): 7.55-7.58 (m, 2H), 7.47-7.50 
(m, 3H), 7.44 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.03 (s, 1H), 5.19 (dd, J1 = 3.2 
Hz, J2 = 10.4 Hz, 1H), 4.16 (pt, J = 10.4 Hz, 1H), 3.94 (bs, 1H), 3.78 (s, 3H), 3.42 (s, 1H), 
2.27 (d, J = 11.6 Hz, 1H), 1.46-1.68 (m, 6H), 1.25-1.34 (m, 3H), 1.08-1.16 (m, 1H). 13C 
NMR (100MHz, CDCl3):172.18, 158.87, 137.12, 130.54, 129.78, 129.06, 128.64, 127.95, 
113.83, 83.83, 76.61, 68.42, 56.88, 55.20, 34.58, 32.00, 25.39, 22.12, 21.14.  
 
Compound 130: 1H NMR  (400 MHz, CDCl3): 7.17 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 
2H), 5.04 (dd, J1 = 8.0 Hz, J2 = 12.8 Hz, 2H), 4.89 (dd, J1 = 3.6 Hz, J2 = 11.6 Hz, 1H), 4.67 
(dd, J1 = 6.0 Hz, J2 = 10.4 Hz 1H), 4.00 (bs, 1H), 3.77 (s, 3H), 3.31 (s, 1H), 1.95 (d, J = 
13.6 Hz, 1H), 1.53-1.58 (m, 3H), 1.33-1.48 (m, 3H), 1.17-1.22 (m, 2H), 1.05-1.12 (m, 1H). 
13C NMR (100MHz, CDCl3) ppm:170.34, 158.86, 130.66, 128.47, 113.73, 76.54, 72.86, 
68.37, 57.10, 55.21, 33.16, 32.77, 25.29, 21.68, 21.11.  
 
(R/S)-Venlafaxine 131. Compound 130 (0.3 mmol) was dissolved in THF (3 mL) at 0°C 
and 2 eq of LiAlH4 were added. After 30’ at 0°C the mixture was warmed at 40°C for 2 h. 
After the disappearance of the starting material, controlled by tlc, the rection was 
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hydrolyzed with HCl 0.1 M at 0°C. THF was removed in vacuo and the residue was 
extracted twice with ether. The aqueous solution was basified (pH 10) with NH4OH  and ri- 
extracted with dichloromethane. Compoun 131 was obtained in 66% yield. Spectral data 
are superimposable with literature data94. 
 
 
6.8  5-Unsubstitued-1,3-oxazinan-4-ones preparations 
 
General procedure for the preparation of azadiene 65 and 69. GP8.  
1 mL of aldehyde 51 (1 mmol) was added to a solution of LiHMDS (1.1 mL of 1 M sol in 
THF) and hexane (5 mL) at 0°C under inert atmosphere. The reaction mixture was stirred 
at 0°C for 1 h. IR analysis confirmed the formation of silylimine 52 ( CN=1655 cm-1). 
TMSCl (0.14 mL, 1 mmol) was added in one portion and after stirring for 10 min at 0°C the 
mixture was allowed to stir for 1 h at rt. A white precipitate formed. The mixture was cooled 
at 0°C, triethylamine (0.3 mL, 2 mmol) was added in one portion and after 5 min a solution 
of acetylchloride 64 (1 mmol) in 5 mL of hexane was added. Stirring was maintained for 2 
h and precipitate appeared. The mixture was filtered through Celite under argon and the 
solvent was removed in vacuo to afford azadiene as an oil, which was used for the next 
step. 
 
Procedure for the preparation of perhydrooxazin-4-ones 67, 68, 71 and 72. GP9. 
Azadiene 69 (2 mmol), prepared as reported above, was dissolved in anhydrous 
chlorobenzene (5 mL) and put in a flask for microwave oven synthesis (Prolabo). Aldehyde 
(1 mmol) with catalyst (5%) 70 were added and the mixture was submitted to microwave 
irradiation for the time indicate in Table 3.5 at 300 Watt power. The solvent was evaporated 
and the mixture was purified by flash chromatography on silica gel, eluting with 
cyclohexane/ethyl acetate 70/30. Yields and diastereomeric ratio are reported in Tab. 3.6. 
 
(2S*,6S*)-2,6-Diphenyl-[1,3]oxazinan-4-one 67; (2R*,6S*)-2,6-Diphenyl-[1,3]oxazinan-
4-one 68. Prepared according GP9 using azadiene 65 and activated benzaldehyde 66. 
 
Compound 67: IR: 1653 cm-1; 1H NMR (400 MHz, CDCl3): 7.51 (m, 2H), 7.43–7.30 (m, 
8H), 6.57 (br s, 1H), 5.92 (s, 1H), 5.02 (m 1H), 2.75 (m, 2H); 13C NMR (100 MHz, 
CDCl3):168.8, 139.6, 137.7, 129.9, 128.8, 128.7, 128.3, 126.9, 125.6, 85.7, 76.6, 39.1; MS 
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m/z: 253, 175, 147, 131, 118, 104, 78; E.A. Calcd for C16H15NO2: C 75.87; H 5.97. Found: 
C 75.96; H 5.98. 
 
Compound 68: IR: 1653 cm-1; 1H NMR (400 MHz, CDCl3): 7.60–7.30 (m, 10H), 6.54 (br s, 
1H), 5.95 (s, 1H), 5.05 (dd, 1H, J1=7.2, J2=5.8), 2.86 (m, 2H); 13C NMR (100 MHz, 
CDCl3):169.6, 139.2, 138.4, 129.2, 128.7, 128.6, 128.3, 126.7, 126.1, 81.8, 70.2, 37.6; MS 
m/z: 253, 175, 147, 131, 118, 104, 78; E.A. Calcd for C16H15NO2: C 75.87; H 5.97. Found: 
C 75.99; H 5.60. 
 
(2S*,6S*)-6-Phenyl-2-(2-triisopropylsilanyloxy-phenyl)-[1,3]oxazinan-4-one 71a. 
(2R*,6S*)-6-Phenyl-2-(2-triisopropylsilanyloxy-phenyl)-[1,3]oxazinan-4-one 72a. 
Prepared according GP9 using azadiene 69a and activated benzaldehyde 66. 
 
Compound 71a: : IR: 1663 cm-1; 1H NMR (200 MHz, CDCl3): 7.32 (m, 1H), 7.22 (m, 5H), 
7.12 (m, 1H), 7.06 (m, 1H), 6.93 (m, 1H), 6.20 (bs, 1H), 6.17 (s, 1H), 5.02 (dd, 1H, J1=5.4 
Hz, J2=9.6 Hz), 2.76 (m, 2H), 1.15 (s, 3H), 1.12 (s, 9H); 1.08 (s, 3H). 13C NMR (50 MHz, 
CDCl3):168.44, 153.04, 139.90, 130.15, 128.57, 128.15, 127.78, 126.88, 125.55, 121.30, 
118.15, 80.31, 76.53, 39.29, 17.99, 12.89. 
 
Compound 72a: IR: 1663 cm-1; 1H NMR (200 MHz, CDCl3): 7.50 (m, 1H), 7.17 (m, 5H), 
7.11 (m, 1H), 6.98 (m, 1H), 6.80 (m, 1H), 6.40 (bs, 1H), 6.19 (s, 1H), 5.20 (dd, 1H, J1=5.4 
Hz, J2=6.6 Hz), 2.93 (dd, 1H, J1=5.4 Hz, J2=17.2 Hz), 2.79 (dd, 1H, J1=6.8 Hz, J2=17.2 Hz), 
1.01 (s, 3H), 0.98 (s, 9H), 0.80 (s, 3H); 13C NMR (50 MHz, CDCl3): 168.84, 153.48, 138.90, 
131.00, 131.62, 128.54, 128.24, 127.90, 127.21, 126.60, 120.89, 118.47, 76.81, 71.26, 
37.14, 17.89, 12.82. 
 
(2S*,6S*)-2-(2-Methoxy-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 71b; (2R*,6S*)-2-(2-
Methoxy-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 72b; Prepared according GP9 using 
azadiene 69b and activated benzaldehyde. 
 
Compound 71b: IR: 1661 cm-1; 1H NMR (200 MHz, CDCl3): 7.7 (m, 1H), 7.4 (m, 6H), 6.90 
(m,2H), 6.58 (bs, 1H), 6.25 (s, 1H), 5.04 (dd, 1H, J1=5.6 Hz, J2=9.4 Hz), 3.87 (s, 3H), 2.76 
(m, 2H); 13C NMR (50 MHz, CDCl3):168.43, 155.89, 139.99, 130.23, 130.17, 128.67, 
128.23, 126.24, 126.0, 120.86, 110.32, 80.13, 71.41, 55.38, 39.32. 
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Compound 72b: IR: 1661 cm-1; 1H NMR (200 MHz, CDCl3): 7.2-7.5 (m, 7H), 7.0 (m, 2H), 
6.758 (bs, 1H), 6.19 (s, 1H), 5.21 (t, 1H, J=6.4 Hz), 3.83 (s, 3H), 2.84 (m, 2H); 13C NMR 
(50 MHz, CDCl3):169.10, 156.41, 139.51, 130.11, 128.69, 127.08, 126.36, 126.33, 125.94, 
120.63, 110.18, 80.07, 71.36, 55.26, 39.12. 
 
(2S*,6S*)-2-(4-Methoxy-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 71c; (2R*,6S*)-2-(4-
Methoxy-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 72c; Prepared according GP9 using 
azadiene 69c and activated benzaldehyde. 
 
Compound 71c mp: 138-142°C;  IR: 1653, cm-1;1H NMR (300 MHz, CDCl3): 7.43-7.31 (m, 
7H), 6.89 (d, J=8.8 Hz, 2H), 5.91 (s, 1H), 4.99 (dd, J1=9.9Hz, J2=5.1Hz, 1H), 3.80 (s, 3H), 
2.75(m, 2H); 13C NMR (75 MHz, CDCl3): 169.0, 159.6, 137.7, 131.7, 129.9, 128.9, 127.2, 
126.9, 114.0, 85.7, 76.4, 55.3, 39.0, 1.1; Ms (m/z): 283, 176, 161, 147, 118, 104, 91, 77, 
65. 
 
Compound 72c: mp: 138-142°C ; IR: 1653, cm-1; 1H NMR (200 MHz, CDCl3): 7.54-7.28 
(m, 7H), 6.91 (d, J = 8.8 Hz, 2H), 6.55 (s, 1H), 5.87 (s, 1H), 4.99 (t, J=6.6Hz, 1H), 3.81 (s, 
1H), 2.85 (m, 2H); 13C NMR (50 MHz, CDCl3): 169.2, 159.9, 138.3, 130.8, 129.5, 128.8, 
127.9, 126.8, 114.1, 81.4, 70.6, 55.3, 37.1, 1.01; Ms (m/z): 283, 176, 161, 147, 118, 104, 
91, 77, 65. 
 
 
(2S*,6S*)-6-(4-Methoxy-phenyl)-2-Phenyl-[1,3]oxazinan-4-one 71d; (2R*,6S*)-6-(4-
Methoxy-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 71d; Prepared according GP9 using 
azadiene 69d and activated 4-Methoxy-benzaldehyde. 
 
Compound 71d: 1H NMR (400 MHz CDCl3): 7.41 (m, 7H) 6.89(m, 2H), 6.46 (bs, 1H), 5.91 
(s , 1H), 4.89 (dd J1=4.8 J2=10.4 Hz, 1H) 3.79 (s, 3H) 2.75 (m, 2H).13C NMR (100 MHz 
CDCl3): 168.9, 159.6, 137.8, 131.8, 129.9, 128.8, 127.2, 126.9, 114.1, 85.7, 76.4, 55.3, 
39.0. 
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Compound 72d: 1H NMR (400 MHz CDCl3): 7.43 (m, 7H) 6.90 (m, 2H), 6.73 (bs, 1H), 
5.85 (s, 1H), 4.99 (m, 1H) 3.81 (s, 3H) 2.83 (m, 2H).13C NMR (100MHz CDCl3): 168.9, 
159.6, 137.8, 131.8, 129.9, 128.8, 127.2, 126.9, 114.1, 85.7, 76.4, 55.3, 39.0. 
 
(2S*,6S*)-2,6-Di-(2-Methoxy-phenyl)-[1,3]oxazinan-4-one 71e; (2R*,6S*)-2,6-Di-(2-
Methoxy-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 72e; Prepared according GP9 using 
azadiene 69e and activated 2-Methoxy-benzaldehyde. 
Compound 71e: IR: 1661 cm-1; 1H NMR (400 MHz, CDCl3): 7.70 (m, 2H), 7.32 (m, 2H), 
7.03 (m, 2H), 6.90 (m, 2H), 6.48 (bs, 1H), 6.25 (s, 1H), 5.40 (dd, 1H, J1=3.4 Hz, J2=11.4 
Hz), 3.89 (s, 3H), 3.84 (s, 3H), 2.90 (dd, 1H, J1=3.4 Hz, J2=17.4 Hz), 2.51 (dd, 1H, J1=11.4 
Hz, J2=17.4 Hz); 13C NMR (100 MHz, CDCl3):169.10, 155.85, 155.37, 130.06, 129.54, 
129.12, 128.72, 126.27, 125.54, 120.87, 120.80, 110.26, 110.14, 80.00, 71.34, 55.30, 
55.20, 38.32. 
  
Compound 72e:IR: 1661 cm-1; 1H NMR (400 MHz, CDCl3): 7.50 (, 2H), 7.29 (m, 2H), 7.10-
6.90 (m, 4H), 6.65 (bs, 1H), 6.35 (s, 1H), 5.45 (dd, 1H), 3.83 (s, 3H), 3.85 (s, 3H), 2.90 (m, 
H), 2.60 (m, 1H); 13C NMR (100 MHz, CDCl3): 169.95, 156.64, 156.14, 134.15, 129.80, 
128.71, 128.53, 126.44, 126.39, 120.80, 110.19, 78.15, 66.50, 55.14, 37.65. 
 
(2S*,6S*)-2-(4-Nitro-phenyl)-6-Phenyl-[1,3]oxazinan-4-one 71g; (2R*,6S*)-2-(4-Nitro-
phenyl)-6-Phenyl-[1,3]oxazinan-4-one 72g; Prepared according GP9 using azadiene 
69g and activated 2-Methoxy-benzaldehyde. 
 
Compound 71g: 1H NMR (200 MHz, CDCl3): 8.30 (d, 2H), 7.73 (d, 2H), 7.48 (m, 5H), 7.34 
(bs, 1H), 6.07 (s, 1H), 5.07 (t, 1H, J=3.4 Hz), 2.79 (d, 2H, J=3.4 Hz); 13C NMR (100 MHz, 
CDCl3):169.04, 148.43, 144.07, 139.06, 128.40, 127.92, 126.55, 125.61, 124.13, 84.39, 
76.89, 39.11. 
 
Compound 72g:1H NMR (200 MHz, CDCl3): 8.13 (d, 2H), 7.68 (d, 2H), 7.35 (m, 5H), 7.10 
(bs, 1H), 6.03 (s, 1H), 4.97 (t, 1H, J=6.6 Hz), 2.85 (d, 2H, J=6.6 Hz); 13C NMR (100 MHz, 
CDCl3): 168.46, 148.62, 144.72, 138.35, 129.63, 128.89, 127.82, 126.55, 126.19,124.21, 
122.61, 81.42, 71.15, 37.56. 
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6.9  Piperidinones preparation 
 
General procedure for the preparation of 5-sulfonyl-piperidinones GP8. 
Azadiene (1 mmol) was dissolved in 5 mL of anhydrous chlorobenzene (or solvent 
indicates in Par.3.3) and put in a flask for microwave oven synthesis (Prolabo). Phenyl 
vinylsulphone 73 (1 mmol) was added and the mixture was submitted to microwave 
irradiation for 30’ at 300 Watt power. The solvent was evaporated and the mixture was 
purified by flash chromatography on silica gel, eluting with dichloromethane/ethylacetate 
70/30.  
 
(5R*,6R*)-5-Benzenesulfonylmethyl-6-phenyl-piperidin-2-one 74. Prepared according 
GP8 using azadiene 65. Yields are reported in Tab. 3.7. IR: 1668 cm-1; 1H NMR (400 MHz, 
CDCl3): 7.81 (m, 2H), 7.62 (m, 1H), 7.16 (m, 2H), 7.27 (m, 3H), 7.12 (m, 2H), 5.73 (bs, 1H), 
(dd, 1H, J1=3.2 Hz, J2=4.4 Hz), 3.42 (m, 1H), 2.79 (m, 1H), 2.48 (m, 1H), 2.22 (m, 2H); 13C 
NMR (100 MHz, CDCl3): 170.54, 139.77, 137.62, 134.09, 129.41, 129.11, 126.87, 128.53, 
126.44, 63.76, 55.20, 28.05, 18.47; MS m/z: 316, 173, 172, 158, 144, 130, 118, 104, 91, 
77. 
 
(3S*,5R*,6R*)-5-Benzenesulfonylmethyl-3-chloro-6-phenyl-piperidin-2-one 75. Prepa-
red according GP8 using azadiene 47a. 1H NMR (400 MHz, CDCl3): 7.69 (m, 2H), 7.57 (m, 
1h), 7.43 (m, 2H), 7.25 (m, 3H), 7.16 (m, 2H), 5.98 (bs, 1H), 5.03 (dd, 1H, J1=1.6 Hz, J2=7.2 
Hz), 4.71(t, 1H, J=5.2 Hz), 3.87 (dd, 1H, J1=4.4 Hz, J2=7.2 Hz, J3= 8.8Hz), 2.67 (m,2H); 13C 
NMR (100 MHz, CDCl3): 166.03, 138.39, 137.42, 134.14, 129.34, 129.11, 129.05, 128.33, 
127.13, 61.05, 56.42, 51.16, 29.43. 
 
(5R,6R)-6-[(S)-1-Triisopropylsilyloxyethyl]-5-benzenesulfonyl-piperidin-2-one 78; 
(5S,6S)-6-[(S)-1-Triisopropylsilyloxyethyl]-5-benzenesulfonyl-piperidin-2-one 79. 
Prepared accordino GP8 using azadiene 77. Yields and diastereomeric ratio are reported in 
Table 3.8. 
 
Compound 78:[α]D20 –19.2 (c 0.90, CHCl3). IR: 1669 cm-1; 1H NMR (400 MHz, CDCl3): 7.88 
(m, 2H), 7.69 (m, 1H), 7.29 (m, 2H), 6.51 (bs, 1H), 3.96 (dq, 1H, J1=3.2 Hz, J2=6.0 Hz), 
3.82 (ddd, 1H, J1=2.8 Hz, J2=3.2 Hz, J3=5.2 Hz), 3.82 (ddd, 1H, J1=5.2 Hz, J2=5.6 Hz, 
J3=8.8 Hz), 2.43 (m, 1H), 2.21 (m, 1H), 2.01 (m, 2H), 1.13 (d, 3H, J=6.0 Hz), 0.84 (s, 9H), 
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0.06 (s, 3H), 0.5 (s, 3H); 13C NMR (100 MHz, CDCl3): 172.51, 137.00, 134.28, 129.49, 
128.80, 70.47, 59.20, 55.44, 28.77, 25.73, 21.10, 20.15, 17.84, -4.30, -4.63; MS m/z: 398, 
382, 340, 212, 198, 180, 93, 75. 
 
Compound 79: [α]D20 –13.2 (c 1.06, CHCl3); IR: 1664 cm-1; 1H NMR (400 MHz, CDCl3): 
7.89 (m, 2H), 7.72 (m, 1H), 7.61 (m, 2H), 6.25 (bs, 1H), 4.21 (dq, 1H, J1=4.0 Hz, J2=6.0 
Hz), 3.88 (ddd, 1H, J1=2.0 Hz, J2=4.0 Hz, J3=5.2 Hz), 3.17 (ddd, 1H, J1=5.2 Hz, J2=5.2 Hz, 
J3=6.8 Hz), 2.56 (m, 1H), 2.25 (m, 1H), 2.06 (m, 2H), 1.10 (d, 3H, J=6.0 Hz), 0.86 (s, 9H), 
0.073 (s, 3H), 0.069 (s, 3H); 13C NMR (100 MHz, CDCl3):170.89, 136.88, 134.42, 129.56, 
128.88, 69.48, 58.57, 56.08, 28.68, 25.71, 21.11, 17.86, 17.12, -4.65, -4.90; MS m/z: 398, 
382, 340, 240, 212, 198, 168, 93, 75. 
 
General procedure for the preparation of 5-bis-sulfonyl-piperidinones GP9. 
Azadiene (1 mmol) was dissolved in 5 mL of anhydrous toluene and put in a flask for 
microwave oven synthesis Microsynth-Milestone. 1,1-Bis(phenylsulfonyl)ethylene 82 (1 
mmol) was added and the mixture was submitted to microwave irradiation for 30’ at 500 
Watt power. The solvent was evaporated and the mixture was purified by flash 
chromatography on silica gel, eluting with dichloromethane/ethylacetate 90/10.  
 
(R*)-6-Phenyl-5,5-bis(phenylsulfonyl)piperidin-2-one 83. Prepared according GP9 using 
azadiene 65. Y=65%; 1H NMR (400 MHz CDCl3): 8.20 (m, 2H) 7.75 (m, 1H), 7.66 (m, 2H), 
7.54 (m, 1H), 7.48 (m, 2H), 7.30 (m, 7H), 6.23 (bs, 1H), 5.27 (s , 1H), 2.91 (m, 4H).13C 
NMR (100 MHz CDCl3): 169.5, 138.4, 137.1, 136.2, 135.2, 134.1, 131.3, 130.7, 130.2, 
129.3, 129.2, 128.5, 128.3, 90.3, 58.6, 27.8, 23.5. 
 
(3S*,6R*)-3-Chloro-6-phenyl-5,5-bis(phenylsulfonyl)piperidin-2-one 84. Prepared 
according GP9 using azadiene 47a. Y=70%; IR: 1687 cm-1; 1H NMR (400 MHz CDCl3): 
8.20 (m, 2H) 7.80 (m, 1H), 7.64 (m, 2H), 7.58 (m, 2H), 7.50 (m, 2H), 7.40 (m, 2H),7.32 (m, 
2H), 7.22 (,2H) 6.68 (bs, 1H), 5.14 (dd, 1H, J1=1.2 Hz, J2=3.6 Hz), 4.99 (dd, 1H, J1=8.0 Hz, 
J2=10.4 Hz),3.50 (ddd, 1H, J1=1.2 Hz, J2=8.0 Hz, J3=14.8 Hz), 3.30 (dd, 1H, J1=10.4 Hz, 
J2=14.8 Hz),.13C NMR (100 MHz CDCl3):166.30,137.91, 135.61, 135.13, 134.45,131.34, 
130.64, 130.15, 129.38, 128.64, 128.53 
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(6R)-6-[(S)-1-(Triisopropylsilyloxy)ethyl]-5,5-bis(phenylsulfonyl)piperidin-2-one 85; 
(6S)-6-[(S)-1-(Triisopropylsilyloxy)ethyl]-5,5-bis(phenylsulfonyl)piperidin-2-one 86. 
Prepared according GP9 using azadiene 77. Y=82% diastereomeric ratio 60/40 
respectively. 
 
Compound 85: IR (CHCl3): 1668 cm-1; 1H NMR   (400 MHz CDCl3) ppm: 8.05 (m, 4H), 7.75 
(m, 2H), 7.58(m, 4H), 5.93 (bs, 1H), 4.75 (dq, J1=6 J2=2 Hz, 1H), 3.73 (d J=2 Hz, 1H), 3.05 
(m, 1H), 2.76 (m, 2H), 2.57 ( m, 1H), 1.22 (d J=6 Hz, 3H), 0.75 (s, 9H), -0.03 (s, 3H) –0.09 
(s, 3H).13C NMR (100MHz CDCl3) ppm: 170.5, 138.6, 135.4, 135.1, 134.7, 130.9, 130.7, 
129.0, 128.5, 88.6, 69.6, 59.7, 27.0, 25.5, 22.1, 18.1, -4.9, -5.5. 
 
Compound 86: IR (CHCl3): 1668 cm-1; 1H NMR   (400 MHz CDCl3) ppm: 8.83 (bs, 1H) 8.05 
(m, 4H), 7.77 (m, 2H), 7.60(m, 4H), 5.01 (q, J=6.4, 1H), 3.47 (s , 1H), 3.33 (m, 1H), 2.62 
(m, 3H), 1.15 (d J=6.4 Hz, 3H), 0.83 (s, 9H), 0.14 (s, 3H) 0.05 (s, 3H).13C NMR (100MHz 
CDCl3) ppm: 173.9, 139.6, 135.3, 135.2, 134.3, 131.1, 130.8, 129.2, 128.4, 89.8, 68.1, 
58.5, 28.3, 26.0, 22.8, 18.1, -3.9, -5.7. 
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